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Director’s introduction
In 2005, the United Nations Office on Drugs and Crime (2005) valued the global market for 
ATS at US$44 billion, approximately 13.8 percent of the global illicit drug market (at retail 
level). It has been estimated that Oceania accounts for about 9–10 percent of the global  
ATS market; a market share that is disproportionately large in relation to the small population 
of the region. 
As a result, Oceania, particularly Australia and New Zealand, has emerged as the region  
with the highest rate of consumption of amphetamine-type stimulants (ATS), including 
ecstasy, in the world. In Australia and New Zealand, with the exception of cannabis, ATS 
appears to have become the drug of choice among illicit drug users. This study examines 
the market for ATS in Oceania (Australia, New Zealand and the Pacific Islands) and the 
involvement of criminal organisations in that market. It explores patterns of ATS production, 
trafficking and demand in the region and reviews current legislative frameworks to penalise 
activities in the illicit ATS market. The report does not attempt to discuss individual criminal 
justice responses to the ATS market. These are documented elsewhere and readily available 
from other sources.
The global illicit ATS production in 2005 is estimated to have been between 360 and  
880 tonnes, with approximately half of the global illicit production taking place in east  
and southeast Asia (UNODC 2007). Approximately 9,286 kg of ATS (excluding ecstasy)  
were available in the illicit ATS market in Oceania with 88 percent (8,151 kg) being  
sourced or produced in the region itself. Highly concentrated substances, such as  
crystal methylamphetamine are more readily available in Asia than in Oceania.
With evidence of high levels of ATS consumption, trafficking, and production in the region, 
there is concern that the economic incentives for the involvement of criminal organisations  
in this market are growing, and exceed those for traditional narcotic drugs such as heroin, 
cannabis, and cocaine.
The combination of high levels of supply and demand, stable retail prices, and significant 
expenditure on illicit drugs provide a profitable setting for ATS sales and explain the 
significant and growing involvement of criminal elements in this market. High profitability 
(even of small quantities) and great flexibility in the production process and in the ingredients 
used make illicit ATS production particularly attractive to criminal elements. Organised crime 
is more active in the large scale production of ATS, the importation of precursors, and the 
manufacture of ecstasy and ATS of high purity, but even local producers of small quantities 
of ATS can sell their substances profitably. This explains the significant number of so called 
boxed labs that have been found in Australia and New Zealand. 
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The lack of comprehensive precursor control is often seen as the main factor contributing to 
the spread of ATS in the region. However, because of their widespread use for licit purposes, 
many precursor chemicals are not controlled or only rudimentarily, particularly in the Pacific 
Islands. While more comprehensive control of precursor substances in Australia and New 
Zealand has led to the seizure of greater quantities of ATS precursors, it is hard to gauge  
the impact on levels of ATS production. Patterns of production may change; for example, 
chemicals placed under control can be simply substituted by new ingredients, with no 
significant decline in illicit ATS production. However, data from the Australian Institute of 
Criminology’s (AIC) Drug Use Monitoring in Australia (DUMA) program indicates that 
methylamphetamine use, at least in Australia, may have stabilised in the past few years.
The 1971 Convention on Psychotropic Substances and the 1988 Convention on Illicit  
Traffic in Narcotic Drugs and Psychotropic Substances provide a range of criminal offences 
for activities associated with ATS production, trafficking, importation, and consumption, 
including specific provisions directed against the involvement of criminal organisations in  
this trade and the laundering of proceeds of such crime. However, the effectiveness of these 
conventions is dependent on more countries in Oceania signing up to this body of law and 
bringing their domestic laws into line with international obligations. While Australia, Fiji, New 
Zealand, Niue and the US and French territories in Oceania have very comprehensive and 
up-to-date legislation, the laws in Papua New Guinea, Solomon Islands and Vanuatu are 
particularly out-of-date and ill-suited to deal with large scale operations of transnational 
criminal enterprises. Model laws were recently developed by members of the Pacific Islands 
Forum, including an illicit drugs control Bill. The model laws, however, are best practice 
guidelines and countries cannot be forced to adopt them.
Toni Makkai 
Director 
Australian Institute of Criminology
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Chapter 1: 
Introduction
2This study examines the market for amphetamine-type stimulants (ATS) in Oceania  
including Australia, New Zealand, and the Pacific Islands, and the involvement of criminal 
organisations in that market. The study explores contemporary patterns of ATS production, 
trafficking, and demand in the region, analyses the involvement of organised crime, and 
reviews current legislative frameworks – domestic and international – to penalise activities  
in the illicit ATS market, especially those relating to organised crime activities.
Although ATS are under rigid international and domestic control systems, the illicit 
production, traffic and use of ATS are prevalent throughout the world. In 2005, the United 
Nations Office on Drugs and Crime (UNODC) valued the global market for ATS at US$44 
billion, approximately 13.8 percent of the global illicit drug market (at retail level; UNODC 
2005: 139). It has been estimated that Oceania accounts for about 9–10 percent of the 
global ATS market; a market share that is disproportionately large in relation to the small 
population of the region. 
The illicit ATS trade in Oceania is of great concern to contemporary criminal justice  
and poses an imminent challenge to law enforcement agencies, governments, and the 
international community. The production, trafficking, sale, and consumption of ATS present  
a significant and growing illicit market. The size of the ATS market in Oceania creates 
significant economic incentives for organised crime and other criminal elements, especially  
if the risks of detection, arrest, and seizure are outweighed by the possibilities of large profits 
– monetary and otherwise. With evidence of high levels of ATS consumption, trafficking,  
and production in the region, there is growing concern that the economic incentives for  
the involvement of criminal organisations in this market are growing, even exceeding  
those for traditional narcotic drugs such as heroin, cannabis, and cocaine.
Background
Oceania, most notably Australia and New Zealand, has emerged as the region with the 
highest rate of consumption of ATS, including ecstasy. UNODC’s 2007 World drug report 
again confirmed that ‘at the sub-regional level, the highest annual prevalence rates of 
amphetamines use are reported by countries in the Oceania region’ (UNODC 2007: 152). 
Further, ‘the prevalence rates [for ecstasy] are still higher in the Oceania region (3%) and the 
ecstasy use in the Oceania region is reported to be continuing to increase’ (UNODC 2007: 
161). UNODC estimates that 620,000 persons use amphetamine and 627,000 use ecstasy 
annually in Oceania (UNODC 2007: 151, 161).
In Australia and New Zealand, with the exception of cannabis, ATS have become the drug  
of choice among illicit drug users, and levels of ATS consumption exceed the abuse of 
3traditional narcotic drugs such as cocaine, heroin and other opium derivates. The so-called 
war on drugs has increasingly become a war on ATS and their chemical precursors. 
The size of the ATS market is determined simultaneously by supply and demand 
(Pietschmann 1997: 276). The great demand for ATS in the region creates a profitable illicit 
market for organised crime and other criminal elements. Available data suggest that, despite 
increasing attention and intervention by drug enforcement agencies and legislators, the ATS 
market in Oceania continues to grow rapidly. ATS such as ecstasy (MDMA) and ice (crystal 
methylamphetamine) are on the rise, allegedly flooding the drug markets in ever increasing 
quantities, at reduced costs, with demand rapidly growing.
Strategic knowledge about the nature and level of involvement of criminal organisations and 
other operators in the ATS market in Oceania is limited. Some of the available information is 
conflicting, and some trends emerging in the region seem to be at odds with developments 
elsewhere. It is the purpose of this study to collect and review the existing documentation on 
the illicit ATS industry in the region, explore the criminal elements involved in that industry, 
and analyse current legislative frameworks at domestic and international levels.
The aims of this study are to: 
examine the volume and scale of the illicit ATS market in Oceania •	
discuss the level and patterns of organised crime involvement in that market •	
analyse existing mechanisms at international and domestic levels to criminalise the •	
organised illicit trade in ATS in the region 
develop recommendations for law reform and policy change.•	
Scope
The focus of this study is on the production, trafficking, importation, and consumption of 
ATS in Oceania. The study is limited to synthetic drugs that are commonly classified as 
amphetamine-type stimulants (ATS), including amphetamine, methylamphetamine, MDMA, 
MDA, and MDEA (see Terminology below). The study also covers precursor chemicals used 
in the manufacturing of ATS. Other narcotic drugs and psychotropic substances are not 
further explored in this study.
The focus of this study is on only one class of illicit drugs, namely ATS, and explores the  
ATS problem only insofar as it relates to the Oceania region. This scope is further narrowed 
by examining only those aspects of the ATS trade that relate directly or indirectly to the 
involvement of organised crime. In particular, this study does not examine patterns and 
consequences of ATS consumption, treatment of ATS users, or drug-related crime. 
4Moreover, it does not explore proceeds of ATS crime and the phenomenon of money 
laundering, although they are closely related to the ATS problem.
Geographically, the study focuses on the Oceania region, including Australia, New Zealand, 
and the Pacific Islands. Throughout this study the term Pacific Islands includes Cook 
Islands, Fiji, Kiribati, Northern Marianas, Marshall Islands, Federated States of Micronesia 
(FSM), Nauru, Niue, Palau, Papua New Guinea (PNG), Samoa, Solomon Islands, Tokelau, 
Tonga, Tuvalu, Vanuatu, the French Territories of French Polynesia, New Caledonia, Wallis 
and Futuna, and the US territories of American Samoa and Guam.
In reviewing relevant legal frameworks for ATS in Oceania, the scope of the study is limited 
to enforceable mechanisms under international and domestic laws. Non-enforceable and 
otherwise informal frameworks by international organisations, regional forums, and national 
agencies are not discussed in this study.
Structure
The study examines the illicit market for ATS and their precursors in Oceania in four parts: 
production•	
trafficking and importation•	
demand•	
penal legislation.•	
Each part explores specifically the involvement of criminal elements and the specific 
legislative provisions applicable to them.
Part 1 analyses current levels of production of ATS in Australia, New Zealand, and the  
Pacific Islands, the availability of and illicit trade in ATS precursors, the market factors  
of ATS production, and organised crime involvement in ATS production and precursor 
trading. The second part outlines contemporary patterns and levels of ATS trafficking and 
importation in Oceania, market factors, and organised crime involvement. Part 3 identifies 
current prevalence of ATS consumption in the region and examines the retail market and 
retail prices for these substances.
The fourth part analyses existing domestic and international legal frameworks relevant to the 
criminalisation of the illicit, commercial ATS and ATS-precursor trade. This part outlines and 
examines relevant provisions under international legal instruments, their implementation into 
the domestic laws of the countries in the region, and other relevant penal provisions under 
domestic law. 
5The study concludes by highlighting some key indicators of the ATS trade in Oceania and 
developing a set of basic suggestions for policy change and law reform.
Literature and data
Despite significant media attention and public concern, the ATS trade in Oceania and  
the involvement of criminal elements in this illicit industry remain issues that are poorly 
documented and neither well understood nor adequately researched. While the phenomena 
of illicit drug use, production, trafficking, supply etc. are long standing, surprisingly little 
research has been undertaken into the conditions and circumstances of the illicit market  
for ATS and their precursors, particularly in the Oceania context. 
Customs, drug and law enforcement agencies, along with international organisations such 
as UNODC and the International Narcotics Control Board (INCB) have produced a wealth  
of relevant data on this topic, but academic analysis of these statistics is rare and many 
figures remain unexplained. National agencies in Australia and New Zealand, especially the 
Australian Crime Commission (ACC), Australian Customs Service (ACS) and New Zealand 
Customs collect data on ATS seizures and importations. A number of studies have been 
undertaken to uncover and explain the levels of abuse of ATS in Australia and New Zealand 
(for example, AIC 1999–2007; Degenhardt et al. 2004; Hando & Hall 1997; NDARC 2006; 
NDARC 2004; Wilkins et al. 2005; Wilkins et al. 2004a; Wilkins, Bhatta & Casswell 2002), 
but frequently the samples are too small to allow generalisations (for example, NDARC 2004; 
NDARC 2006; Wilkins et al. 2004a). Moreover, the main focus of the existing scholarly 
writing is on the patterns of ATS consumption and there is, to date, no comprehensive 
inquiry into the organisational and operational patterns of the illicit ATS industry. Relevant 
penal provisions, too, have attracted limited scholarly interest and are often misinterpreted, 
and many gaps remain uncovered and unresolved.
To date here has not been any comprehensive study of the market aspects and the level of 
organised crime involvement in the production and trafficking of ATS and their precursors in 
Australia, New Zealand, and the Pacific Islands. Moreover, despite a plethora of international 
drug conventions and domestic drug offences, there is no contemporary research on the 
application and operation of international and domestic law in Oceania in relation to ATS  
and ATS precursors. This study seeks to fill this void.
Limitations and obstacles
Some general statements about the data and information used in this study need to be 
made from the outset. Many statistics about criminal activities and illicit markets are by their 
very nature fragmentary and sometimes contradictory. The illicit and clandestine nature of 
6these operations dictates this. While some generalisations can be made on the basis of the 
information found, there are significant limitations to the evidence. 
The data and information used in this report come from a variety of sources, both national 
and international, and the methodologies used by these sources differ substantially. At 
domestic levels, national agencies involved in drug law enforcement collect different data 
depending on their jurisdiction and mandate; some operate only within national borders, 
other agencies investigate only cross-border operations. As a result, the data these agencies 
collect differ and are not always comparable. The differences that exist between different 
agencies within one country are further augmented if data from agencies from multiple 
countries are used. Their mandates, modi operandi, and resources differ considerably and  
it is difficult to compare the findings and figures from different jurisdictions. Further, statistics 
and other information from the Pacific Islands are notoriously scarce, though there have 
been significant improvements in recent years. Much of the information, however, remains 
anecdotal and frequently does not allow any generalisations. 
Consequently, it is preferential to use figures compiled by international organisations that  
use a consistent methodology in collecting information from a variety of sources and that 
use the same methodology over a period of time. This study relies very heavily on statistics 
published by UNODC and the INCB. Both organisations release annual reports about levels 
and patterns of the global illicit drug market and provide the most comprehensive statistics 
on the levels of production, trafficking, and consumption of drugs in every corner of the 
world. These statistics are, however, not without inaccuracies. The contents and quality  
of UNODC and INCB reports are for the most part dependent on information supplied to 
these organisations by individual countries. Many countries, however, do not provide any 
information. Frequently, the data are not collected annually or at all. Some countries are 
reluctant to disclose and publicise information about the levels of their drug problem.  
Other countries simply do not see the illicit drug trade as a problem worth investigating.  
As a result, the data published by UNODC and the INCB may not, or not always, reflect 
accurate levels of ATS production, trafficking, and consumption. The reports are, however, 
very useful to monitor trends and developments over a period of time. Moreover, by  
using data and other information from a variety of international and national sources, 
methodological differences between those sources may be beneficial to identify and  
validate those trends and highlight contradictions. 
A further difficulty arising from the nature of the topic of this study is the confidentiality of 
much of the information, especially if it relates to ongoing investigations. Although the study 
involved extensive consultation with relevant law enforcement and customs agencies and 
with international organisations in the region, some key contact persons were unable or 
unwilling to reveal information, and some of the information obtained is classified and  
cannot be reproduced here.
7A final point to be noted about the existing research and current scholarship on this topic 
relates to the use of information unique to the Oceania region. In compiling evidence, 
documents, and data for this study, specific emphasis was placed on using research and 
sources from the region itself. The scale, nature, and patterns of the illicit ATS trade in the 
region are unique and many observations made in other parts of the world do not apply in 
Oceania. This study seeks to crystallise the particular characteristics of the illicit ATS trade  
in the region and consequently relies more heavily on local sources of information than on 
findings made elsewhere. The material used included published academic research in books 
and journal articles, reports from research centres, government agencies and international 
organisations, online resources, case studies reported in the news media, and personal 
communication with key officials in Australian Government, state/territory, and international 
drug enforcement agencies. 
Terminology
The terminology for illicit drugs is frequently confusing, highly technical and sometimes 
conflicting, and many expressions used overlap. For consistency and simplicity, the  
study follows the terminology and definitions adopted by UNODC (UNODC 2003b: v; 
UNODCCP 2000).
The umbrella term to describe the synthetic drugs analysed in this study is amphetamine-
type stimulants (ATS). The term covers a large group of synthetic drugs with a powerful 
stimulant action on the central nervous system usually without producing hallucinations. 
Amphetamine and methylamphetamine are closely related and have similar psychomotor, 
cardiovascular, anorexogenic, and hyperthermic properties. ATS can produce a sense of 
confidence, euphoria, and wellbeing. Compared with amphetamine, the stimulatory effects 
of methylamphetamine are stronger and last longer (UNODCCP 2000: 6–7; Bellamy & 
McNab 2003: 3; Topp et al. 2002: 341). Research shows that the euphoric effects created 
by ATS are very similar to (but last longer than) those created by cocaine and that even 
experienced cocaine users are unable to distinguish between them (Hall & Hando 1993: 59; 
Anglin et al. 2000: 137). In this study, ATS refers to substances encountered exclusively on 
the illicit market, although they may have medicinal use.
Perhaps the simplest form of ATS is amphetamine which is synthesised primarily from  
the precursor norephedrine (see further Section 1.2.1 below). The most commonly 
consumed ATS is methylamphetamine, a stimulant usually synthesised from ephedrine  
or pseudoephedrine. Crystalline (or crystal) methylamphetamine, also known as ice, P, 
crystal meth, glass or shabu, is a highly refined, very concentrated (up to 80% purity) form  
of methylamphetamine produced as crystal powder or crystal rocks which are smoked  
or snorted. Crystal methylamphetamine is also produced as a clear liquid for intravenous 
8injection (Bellamy & McNab 2003: 3). Throughout this study the phrase ATS excluding 
ecstasy refers to amphetamine and methylamphetamine without hallucinogenic effect, 
unless otherwise stated.
Substances in the so-called ecstasy group are ATS in their chemical structure, but have 
different precursors and usually have different pharmacological effects. Ecstasy-type 
substances are usually orally ingested, sometimes snorted, and rarely injected. The most 
common type of this group of ATS is methylenedioxymethylamphetamine (MDMA), more 
commonly known as ecstasy. MDMA is an ATS with mild hallucinogenic properties which 
has gained notoriety internationally as a recreational or party drug (UNODCCP 2000: 43–44). 
Methylenedioxyamphetamine (MDA) is similar to MDMA but with strong hallucinogenic 
effects that can last twice as long as those of MDMA (UNODCCP 2000: 42). A third 
substance in this group is methylenedioxyethylamphetamine (MDEA) which is also similar  
to MDMA, but has less desirable effects and consequently is less frequently produced and 
used (UNODCCP 2000: 43). Throughout this study, the term ecstasy is used for MDMA  
and the related substances MDA and MDEA, unless otherwise specified.
Other synthetic stimulants such as methcathinone, phentermine, and fenetylline are not 
covered in this study.
Chapter 2: 
Production of ATS in Oceania
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The first part of this study explores the production of amphetamine-type stimulants (ATS) in 
Oceania and the market factors and organised crime involvement in illicit ATS manufacturing 
in the region. First, the history and methods of ATS production are set out and contemporary 
levels of illicit ATS production in Australia, New Zealand, and the Pacific Islands analysed. 
Second, the key precursor chemicals used in ATS production are identified and the illicit 
trade in these substances is examined. Third, economic and market factors of illicit ATS 
production are explored and some observations about the role of criminal organisations  
in this aspect of the ATS trade are made.
The means and methods used to produce ATS differ between those used for the production 
of amphetamine and methylamphetamine, and those used to manufacture ecstasy. The 
different manufacturing processes and the difference in ingredients used to produce ATS 
and ecstasy have significant consequences on the way in which the illicit production  
is carried out, how precursor chemicals are obtained, and also on the market and sale  
of these substances. Consequently, throughout this part of the study, ecstasy and ATS  
other than ecstasy are examined separately.
The following sections briefly outline the history and key production methods of ATS and 
ecstasy and give a brief overview of global and regional levels of illicit production. This is 
followed by an analysis of patterns and levels of ATS and ecstasy production in Australia, 
New Zealand, and the Pacific Islands.
ATS production (excluding ecstasy)
History
The use of ephedrine, the key ingredient of amphetamine, is said to have been first 
documented in 2760 BC when the Chinese herb ma huang or ephedra was used as a 
natural herbal remedy for asthma and other respiratory illnesses (UNODCCP 2000: 25–26). 
Research into Chinese medicine in the late 19th and early 20th century generated new 
interest in the medical use of ephedrine. As its popularity grew, there was some concern  
that natural supplies of ephedrine could be exhausted and pharmacologists started to 
search for ephedrine substitutes and investigate the creation of synthetic ephedrine 
(Grinspoon & Hedblom 2005: 21; Anglin et al. 2000: 138).
The first substitute for natural ephedrine was found in amphetamine, which was synthesised 
in 1887 by the German pharmacologist Edelano, who named the drug phenylisopropylamine 
or, as it became known commercially, benzedrine. Around the same time, between 1893 
and 1919, methylamphetamine was discovered and synthesised by Japanese researchers. 
Commercial amphetamine production and consumption first emerged during the early 
1930s when the substance was used for its therapeutic effects, especially in the treatment 
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of conditions such as asthma, epilepsy, hyperactivity in children, motion sickness, 
narcolepsy, obesity, and schizophrenia. Benzedrine was initially sold as an inhaler and  
in 1932 the American Medical Association named the substance amphetamine, short for 
alpha-methyl-phenethyl-amine. In 1937, the American Medical Association also approved 
the drug in tablet form recognising its therapeutic effect in the treatment of narcolepsy, 
postencephalitic Parkinsonism and certain depressive psychopathic conditions, and 
acknowledged the drug’s ability to create ‘a sense of increased energy or capacity for  
work, or a feeling of exhilaration’ (Grinspoon & Hedblom 2005: 22; Yamada 1997: 5–6).  
The use of amphetamine was particularly widespread during Word War II and at that time 
was frequently given to soldiers for endurance and as a fatigue fighter. Historical records 
show that amphetamine was distributed to the British, German, and Japanese armies  
during World War II and later to United States (US) armed forces in the Korean War in 
1950–53 and also in Vietnam (Anglin et al. 2000: 137–138; Grinspoon & Hedblom 2005: 26; 
Hall & Hando 1993: 59). Starting in the 1960s amphetamine use became common among 
long distance truck drivers and shift workers in Japan, the US, and later also in Australia 
(Hall & Hando 1993: 59).
The problems associated with amphetamine misuse and dependence were first recognised 
in the late 1940s and early 1950s. A study conducted by Monroe and Drell (1947) found 
high levels of amphetamine abuse by US military personnel. ATS abuse was particularly 
prominent in Japan where, from 1941, methylamphetamine was sold over the counter as 
philopon and sedrin to ‘fight sleepiness and enhance vitality’. After the end of the war large 
surplus stocks of injectable methylamphetamine became available on the licit market. It has 
been estimated that at this time, between 550,000 and 1.5 million Japanese consumed 
methylamphetamine, leading to the first ‘amphetamine epidemic’. As psychiatric disorders 
among heavy users became more evident – some estimates suggest about 10 percent of 
users developed methylamphetamine induced psychoses – the Japanese Government 
introduced stringent controls with the Stimulant Control Law 1951 (Anglin et al. 2000;  
Brill & Hirose 1969). 
Further research showed a link between paranoid psychoses and heavy ATS use,  
especially if ATS are administered by injection. Consequently, the manufacturing and 
availability of ATS were further restricted. In the US, pharmaceutical companies started  
to withdraw amphetamine in the early 1950s and the US Food and Drug Administration 
banned the sale of non-prescription amphetamine inhalers in 1959; methylamphetamine 
inhalers were banned in 1971 (Grinspoon & Hedblom 2005: 25–26; Hall & Hando 1993: 59). 
During the 1960s and 70s ATS abuse changed from being a localised problem in some 
countries to a worldwide phenomenon (Bassiouni & Thony 1996: 908–909). As a result, 
other countries followed with similar laws and ATS were eventually brought under 
international control with their inclusion in the list of controlled psychotropic substances  
in the schedules of the 1971 Convention on Psychotropic Substances (1019 UNTS 175. 
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See chapter 5). In New Zealand, amphetamine production was first criminalised in 1975, 
with Schedule 2, Class B Controlled Drugs of the Misuse of Drugs Act 1975 (NZ), and in 
Australia, with the Psychotropic Substances Act 1976 (Cth).
The control of ATS production under international and domestic laws led to a gradual 
decline of legal ATS production and availability. The prohibition of ATS was followed by  
the emergence of a black market for amphetamine, initially fuelled by leakages from 
pharmaceutical companies, pharmacists, and medical practitioners. While the drugs 
remained easily accessible, profit margins stayed low which ‘retarded the growth of large 
scale, organised trafficking in this area’ (Lessem 1974: 128). As these avenues, too, were 
sealed up by law and law enforcement, criminal organisations increasingly took control of 
ATS production and distribution (Anglin et al. 2000: 138; Grinspoon & Hedblom 2005: 28). 
Illicit manufacturing of ATS started to emerge almost simultaneously with the introduction  
of control mechanisms for the licit ATS market in the early 1960s, manifested in the growing 
number of seizures of illicit laboratories (UNDCP 1996: 35; Grinspoon & Hedblom 2005: 30). 
The first known clandestine ATS laboratories were found in San Francisco and the Bay  
Area in 1962 (Anglin et al. 2000: 138). Initially, illicit production was carried out in small 
laboratories in or close to large metropolitan areas (Lessem 1974: 129), to reduce the 
distance between the places of production and sale, and thus limit exposure to law 
enforcement intervention. The first clandestine ATS laboratory in Australia is said to  
have been detected in Sydney in 1976 (Caldicott et al. 2005: 156), and large scale illicit 
production of ATS in Australia began in Victoria (Vic) in the late 1970s (Wardlaw 1993: 96).
ATS production process
The production process for ATS other than ecstasy is comparatively simple and does not 
require a great deal of skill, training, or sophistication. The chemical process to manufacture 
these substances involves only a few steps, is easily learned, and involves very basic 
equipment; even everyday household items can be used in ATS manufacturing. ATS 
production is further facilitated by the fact that many key ingredients – usually referred  
to as precursors – are easily available through legitimate and illegitimate channels. The  
most common precursors, ephedrine and pseudoephedrine, for instance, can be found  
in many cold and cough tablets, as discussed below. It should be noted, however, that the 
production process can be very dangerous and harmful as it involves highly flammable and 
poisonous substances. There have been a number of reports about injuries and deaths of 
‘cooks’, bystanders, and nearby residents (see, for example, Caldicott et al. 2005; Wilkins  
et al. 2005).
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Four main ATS production methods have been identified, although there is some degree of 
variation in each procedure and recipe (see Allen & Cantrell 1989: 183–199; Caldicott et al. 
2005: 155–157; Cherney, O’Reilly & Grabosky 2005: 8; Ely & McGrath 1990: 720–723; 
Skinner 1990: 48; US National Drug Intelligence Center 2005: 11). 
In the ammonia (‘Birch’ or ‘Nazi’) method, ephedrine or pseudoephedrine is reduced in  •	
a chemical process using anhydrous ammonia (a fertiliser and air conditioner refrigerant) 
and lithium or sodium metal to form d-methylamphetamine. This method is hazardous, 
as any release of ammonia creates a toxic environment and lithium and sodium react 
violently with water, creating the possibility of fire or explosion.
The principal chemicals involved in the hypophosphorous acid method are ephedrine  •	
or pseudoephedrine, iodine, and hypophosphorous acid. A variation of the red 
phosphorous method (see below), this method is often used when hydriodic acid  
is in short supply. This method produces high quality d-methylamphetamine and  
is highly dangerous as a result of the phosphine gas released.
In the phenyl-2-propanone (P2P) method, P2P is reduced in a chemical process using •	
methylamine and mercuric chloride to form a mixture of d- and l-methylamphetamine. 
This method is less common today as the resulting product is not as pure  
and restrictions have been placed on the supply of the necessary chemical,  
phenylacetic acid. 
Red phosphorous method. In this method, ephedrine or pseudoephedrine is reduced in •	
a chemical process using red phosphorus (extracted from match box striker plates) and 
hydriodic acid to form d-methylamphetamine. Red phosphorous is highly unstable and 
slight friction will cause ignition and the release of deadly phosphine gas. 
The flexibility and simplicity of the ATS production process means that production can  
be carried out in close proximity to the consumer market and can easily be relocated 
depending on market shifts and law enforcement activities (UNDCP 1996: 44). The 
comparatively simple synthesis and manufacturing process of ATS, such as 
methylamphetamine, allow small scale productions by amateur producers, and even small 
quantities of ATS can be produced profitably. Hence, clandestine production frequently 
takes place in so called kitchen or boxed laboratories found in private homes, vans, and 
cars (UNDCP 1996: 44). The relative simplicity of the production process also means that 
many unskilled amateurs attempt to manufacture ATS, though the hazardous nature of the 
process means that accidents and even deaths of ATS ‘cooks’ are not uncommon. The 
production can also pose significant health risks to other bystanders, including children,  
and the waste from the ATS production is environmentally hazardous (Bellamy & McNab 
2003: 6; Cherney, O’Reilly & Grabosky 2005: 11).
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Levels of production
UNODC estimates the levels of ATS production by taking an approach ‘of triangulation, 
estimating production based on reported seizures of the end products in combination with 
some assumptions of law enforcement effectiveness, seizure data of precursor chemicals 
and estimates based on the number of consumers and their likely levels of the per capita 
consumption’ (UNODC 2007: 261).The global illicit ATS production in 2005 is estimated  
to have been between 360 and 880 tonnes (UNODC 2007: 124). Some authors predict  
‘that the production of ATS is actually beginning to outstrip the global production of 
cannabis and heroin’ (Cherney, O’Reilly & Grabosky 2005: 7). According to reports by 
UNODC, approximately half of the global illicit production of ATS (not including ecstasy) 
takes place in east and southeast Asia, especially in China and increasingly in Myanmar 
(Chawla & Pietschmann 2005: 171). North America, Europe, Oceania and, more recently, 
South Africa are the other main sources of ATS (UNODC 2007: 124). 
Estimates in 2005 suggested that approximately 9,286 kg of ATS (excluding ecstasy) were 
available in the illicit ATS market in Oceania. The great majority of the ATS available in the 
region (88% or 8,151 kg) are sourced (or produced) in the region itself. Only 12 percent are 
imported from elsewhere, mostly from east and southeast Asia (796 kg or 8.6%), western 
and central Europe (229 kg or 2.5%), and from eastern Europe (28 kg or 0.3%). According 
to the ACC (2005: 11), ATS are usually only imported into Australia if they involve highly 
concentrated substances, such as crystal methylamphetamine which is more readily 
available in Asia than in Oceania.
Figure 1: ATS in Oceania 2005, place of production (percent) 
Source: UNODC 2006
Other 1%
Europe 2%
Asia 9%
Oceania 88%
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Ecstasy production
In contrast to other ATS, ecstasy does not have a significant history of legal production. 
These substances were developed largely within the illegal market (UNDCP 1996: 36). 
MDMA was first discovered in 1913 by the pharmaceutical company Merck as a diet pill  
but it was never manufactured and marketed because of its negative side effects. Although 
not illegal at the time, MDMA production emerged again in clandestine laboratories in the 
late 1960s (Gertz 2005: 67–68; Webb 2003: 84–85). Legal availability resulted in widespread 
use of MDMA, prompting control of the substance in the United Kingdom in 1977 and in  
the United States in 1985. Following a request by the World Health Organization (WHO)  
in 1984, MDMA was brought under international control in 1985 (UNDCP 1996: 37; Webb 
2003: 89–90). New South Wales (NSW) was the first State in Australia to include MDMA  
in its drug laws in 1986, being added to schedule 1 of the Drugs Misuse and Trafficking Act 
1985 (NSW). Domestic control in New Zealand followed in 1987 in First Schedule, Misuse  
of Drugs Amendment Act 1987 (NZ), and national control in Australia in 1990, in Schedule 3, 
Crimes (Traffic in Narcotic Drugs and Psychotropic Substances) Act 1990 (Cth).
The most popular means of illegal MDMA production involves the reductive animation of  
3,4-methylenedioxyphenyl-2-propane. A range of substances can be employed as reducing 
agents, although most frequently platinum oxide (PtO) is used as a catalysing agent or 
reduction is done with sodium burohydride (NaBH4) at a low temperature. Less common 
methods of illicit MDMA production are the Leuckart reaction and the bromination of safrole.
Ecstasy production is more complicated than other ATS. The process requires more 
precision and know-how, and involves precursor chemicals, such as safrole, isosafrole,  
and 3,4-methylenedioxyphenyl-2-propane, which are difficult to obtain and are also more 
heavily controlled. This explains why ecstasy production is generally concentrated in larger, 
sophisticated laboratories which serve greater geographical markets (UNDCP 1996: 44; 
Wilkins 2002: 14; Cherney, O’Reilly & Grabosky 2005: 10).
An additional, unique feature of the production and marketing of ecstasy is the design, 
colouring, and branding of ecstasy tablets. Unlike other illicit drugs that are usually fungible 
in appearance, ecstasy tablets are manufactured in a range of different samples with 
different effects, and users can choose between them. The branding used to market  
ecstasy often reflects contemporary logos and symbols that appeal to young consumers 
(Webb 2003: 78).
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ATS production in Australia
In the absence of any actual records, the extent of illicit ATS production is usually measured 
with reference to seizures of clandestine laboratories. The general view is that the number  
of clandestine laboratories seized reflects, to some degree, the level of illicit production in  
a jurisdiction. As with all data used in this study, the value and validity of production figures 
have significant limitations. While the number of clandestine laboratories seized may give 
some indication about the spread of the problem, there is no systematic data collection on 
the size and production capacities of these illicit laboratories. This is particularly important  
as the size of illicit ATS laboratories is known to vary greatly. Further, it has to be noted that 
investigation and data collection methods have improved significantly in recent years. As  
a result, the total number of seizures increased, even if actual production levels remained 
unchanged. One additional difficulty with production data is that some agencies and 
jurisdictions separate the data between ATS laboratories and ecstasy laboratories  
while others report them together, thus making it difficult to draw comparisons.
ATS other than ecstasy
Illicit production of ATS (not including ecstasy) in Australia can be traced back to 1976  
when the first clandestine ATS laboratory was detected in Sydney (Caldicott et al. 2005: 
156). Large scale illicit production of ATS in Australia began in Victoria in the late 1970s 
(Wardlaw 1993: 96) and illicit production levels grew more significantly in the early 1990s.  
By the mid 1990s it was found that a substantial part of the global clandestine amphetamine 
production was taking place in Australia (UNDCP 1996: 48). It is estimated that 
approximately 90 percent of the ATS on the Australian market are produced domestically; 
only 10 percent are said to be imported (UNODC 2003a: 107–108). These observations 
confirm research findings from other jurisdictions which suggest that ATS are typically 
manufactured in the country of final consumption. 
Domestic ATS production usually involves methylamphetamine of low purity in powder  
form, generally referred to as speed, or in the damp, sticky form of methylamphetamine 
base. Methylamphetamine of high purity, such as ice, is generally imported from Asia, 
although there have been some recent reports about domestic crystal methylamphetamine 
production in Australia, albeit at low levels (NDARC 2006: 47; Pieper 2006: 19).
The available data on illicit ATS production show a significant increase in the number of 
clandestine laboratory seizures in Australia since the mid 1990s. According to data collected 
by the former Australian Bureau of Criminal Intelligence (ABCI) and the ACC (shown in Table 
1 below), the number of clandestine ATS laboratories seized increased almost seven-fold 
between 1996–97 and 2005–06 (see also Figure 4 below). The vast majority of clandestine 
ATS laboratories appear to have been used for the illicit production of methylamphetamine 
(INCB 2006: para 637). 
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Table 1: Clandestine drug laboratories in Australiaa (number)
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Detectedb 58 95 131 150 201 252 314 358 381 390
Seizedc n.a. n.a. n.a. n.a. 201 240 n.a. 314 221 381
a: UNODC reports are based, at least in part, on annual ACC surveys. Differences can often be explained by the fact 
that UNODC reports cover calendar years while ACC reports refer to fiscal years. Moreover, detection of non-ATS 
clan labs is not included in the UNODC data
b: Clandestine drug laboratories detected in Australia. Source: ABCI and ACC 1997–2007
c: Seizures of illicit laboratories, combined amphetamine, methylamphetamine group. Source: UNODC 2004: 259; 
2006: 265; 207: 7
UNODC data, shown in Table 1, although not available for every single year, confirm this 
trend. UNODC also observed that ‘[r]apidly rising laboratory seizures have had no significant 
impact on prices and purities – suggesting that overall production increased in recent years’ 
(UNODC 2005: 101). However, UNODC notes that ‘against this backdrop of stabilising of 
domestic production, it appears that attempts are being made to import methamphetamine, 
including crystal-ice, from South-East Asia, notably from China’ (UNODC 2007: 129).
According to UNODC, there appear to be signs of a levelling off in the scale of ATS 
production in Australia since 2004. UNODC statistics show a decline in clandestine drug 
laboratory seizures between 2003 and 2004 and UNODC noted that the lower figure of 
2004 coincided with ‘slightly falling purity levels, indicating that production was losing 
momentum’ (UNODC 2006: 130). This, however, does not seem to affect the availability of 
ATS in the Australian marketplace as ‘there are increasing imports of methylamphetamine 
produced in southeast Asia, notably China and the Philippines, offsetting some [of] the 
decline in domestic production’ (UNODC 2006: 130). The data released by Australian 
agencies currently do not confirm these observations, however.
Within Australia the illicit production of ATS (not including ecstasy) is, and has been for some 
time, concentrated in Queensland (Qld), especially in the southeastern part of the state near 
the two main cities of Brisbane and the Gold Coast. According to a study published in 2005, 
almost half of all clandestine drug laboratory detections in Australia have been made in 
Queensland, followed by NSW and South Australia (SA).
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Table 2: Clandestine drug laboratories detected in Australia  
by jurisdiction (number)
1999 2000 2001 2002 2003–04
New South Wales 20 20 42 32 56
Victoria 4 18 32 24 22
Queensland 83 79 77 138 162
Western Australia 8 17 22 22 39
South Australia 8 19 31 31 52
Australian Capital Territory 2 1 0 0 0
Northern Territory 2 1 3 1 12
Tasmania 0 0 1 3 3
Total 137 155 208 251 346
Source: Caldicott et al. 2005: 156
Figure 2: Clandestine drug laboratories detected, by jurisdiction,  
2002–03 (percent)
Source: Caldicott et al. 2005: 156
Tasmania 0.8%
Northern Territory 3.5%
Australian Capital Territory 0%
South Australia 15.0%
Western Australia 11.3%
Queensland 46.8%
Victoria 6.4%
New South Wales 16.2%
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UNODC reports confirm that methylamphetamine production ‘is particularly concentrated in 
Queensland (35 per cent of all dismantled amphetamines laboratories in 2004, followed by 
New South Wales (20 per cent), and South Australia (20 per cent)’ (UNODC 2006: 130).  
This geographical distribution does not reflect the size of the population in these states.  
The specific causes for this concentration of clandestine ATS laboratories in southeast 
Queensland are currently not well understood and require further investigation and research. 
As Koch asks, ‘[d]o these statistics mean that Queensland has become the drug capital  
of Australia: that amphetamine manufacture and the consumption of illicit drugs are 
disproportionately high in this state? Or does it mean as [Police Minister] Spence suggests, 
that Queensland police are far more vigilant than their counterparts in all other states?’ 
(Koch 2006: 33).
The number of clandestine laboratories seized each year does not reflect the level of actual 
production, because no information is available publicly about the size of the laboratories 
seized. There have been numerous reports that domestic illicit ATS production in Australia 
usually takes place in small, often mobile laboratories (sometimes referred to as boxed or 
boot labs). Domestic seizures of ATS precursors have been limited in size (not in numbers) 
thus suggesting that production generally does not take place in large scale manufacturing 
sites (UNODC 2003a: 107–108). Small scale manufacturing is harder to detect for law 
enforcement agencies and can more easily be relocated. On the other hand, larger and 
more profitable laboratories are probably more professionally concealed and difficult  
to detect. There are no reliable estimates about the ‘dark figure’ of clandestine ATS 
laboratories, although one report suggested ‘that for every laboratory discovered,  
three are not’ (Skeers 1992: 6–10). 
Ecstasy
In contrast to other ATS, ecstasy in Australia is, for the most part, sourced from overseas. 
As shown in Figure 3 ecstasy sold or seized in Australia is largely produced in Europe (78%) 
and in smaller numbers, in north America (14%), and east and southeast Asia (5%; UNODC 
Regional Centre for East Asia and the Pacific 2004: 9; INCB 2005: para 640; cf Webb 2003: 
109). There are a number of recent reports suggesting that production is being moved away 
from Europe and that east and southeast Asian countries are increasingly becoming a new 
source of ecstasy in Australia (Cherney, O’Reilly & Grabosky 2005: 6).
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Figure 3: Ecstasy in Oceania, place of production (percent)
Source: UNODC 2004: 9
Domestic production of ecstasy in Australia is limited and only a rudimentary fraction of  
the ecstasy sold in Australia is manufactured here. Accordingly, the number of clandestine 
ecstasy laboratories detected in Australia is very limited, especially in comparison to the  
high number of clandestine laboratories used for the production of other ATS. 
There are a growing number of reports and anecdotal evidence suggesting that domestic 
production of ecstasy may be growing, and that this, along with the large quantities that 
continue to be imported from overseas, is further increasing the availability of ecstasy in  
the Australian market (Chawla & Pietschmann 2005: 173). In 2004, 24 laboratories used  
for the production of MDMA were seized in Australia (UNODC 2006: 132, 168; Webb  
2003: 109). UNODC notes that in 2005 ‘some ecstasy labs were dismantled in Australia,  
but were included under the category of ATS laboratories, with no detailed breakdown 
provided’ (UNODC 2007: 132). The INCB reported in 2006 ‘some evidence that  
clandestine laboratories are increasingly being used for the illicit manufacture of both 
methylamphetamine and MDMA (ecstasy)’ (INCB 2005: para 621; Webb 2003: 109).  
New South Police detected ‘several large labs producing high quality ecstasy’ in the  
six months between August 2005 and February 2006, ‘perhaps indicating a new trend’ 
(NSW Police 2006: 2). The Australian Federal Police (AFP), too, has observed ‘a move 
towards the domestic manufacture of MDMA, highlighted by the recent detection of  
MDMA labs, the increased detection rate of [MDMA] precursors and the identification  
of specialist Dutch chemists’ (AFP 2006: 5).
Other 1%
North America 5%
Asia 14%
Europe 80%
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The otherwise low levels of domestic ecstasy production can be explained by the technical 
equipment, sophistication, and ingredients required for the production of ecstasy. Many local 
producers do not possess the know-how for this process and find it very difficult to obtain 
ecstasy precursors. Given the obstacles associated with ecstasy production and the limited 
availability of precursors on the one hand, and the significant demand for ecstasy in Australia 
on the other (see chapter 4), some local entrepreneurs have entered into the production of 
fake MDMA, which visually resembles ecstasy and is sold as ecstasy, but does not contain 
the chemical ingredients of MDMA (UNODC 2003a: 108; Webb 2003: 79).
ATS production in New Zealand
Levels of ATS production in New Zealand are considerably lower than in Australia. ATS was 
predominantly imported into New Zealand, and domestic production has only recently been 
established (see Figure 4). 
Figure 4: Clandestine drug laboratories detected in Australia and  
New Zealand (number)
Source: ABCI and ACC 1997–2007; NZ Parliamentary Library 2003; UNODC 2006
According to New Zealand Police and UNODC reports, annual seizures of clandestine ATS 
laboratories increased from just one in 1998, to 41 in 2001, and 202 in 2003. The number 
decreased slightly, to 182 in 2004 (Wilkins et al. 2005; Wilkins 2002; NZ Parliamentary 
Library 2003; Narcotics trafficking… 2006). 
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Table 3: Seizures of illicit methylamphetamine drug laboratories,  
New Zealand, 1996–2004 (number)
1996 1997 1998 1999 2000 2001 2002 2003 2004
Total 2 2 1 6 9 41 83 201 182
Source: NZ Parliamentary Library 2003; UNODC 2006: 267
ATS labs detected in New Zealand were used solely for the production of 
methylamphetamine. Evidence of ecstasy production in New Zealand is extremely  
limited. Official reports show records of only one clandestine MDMA laboratory, which  
was detected in 2003 (Wilkins 2002; UNODC 2006: 268). 
While the total number of illicit ATS laboratories seized in New Zealand is small in 
comparison with Australia, seizure numbers in New Zealand are greater relative to the  
small population of the country. However, further information about the size and capacities 
of laboratories seized in both countries is currently unavailable.
ATS production in the Pacific Islands
Compared with Australia and New Zealand, the Pacific Island nations are not significant 
producers of illicit drugs. UNODC confirms that ‘none of the islands in the region are 
considered major global drug producers of any drug’ (UNODC Regional Centre for East  
Asia 2003: 8; US Dept of State 2004). Comprehensive data on the levels of production in 
the islands are not available and much of the conventional wisdom on drug manufacturing  
in the islands derives from anecdotal sources and not from academic research. The 
information used in this study derives from international organisations such as UNODC,  
PIF and INCB, from media reports, and from a small number of scholarly articles.
In the past, much of the local production of illicit drugs involved native kava and betelnut 
plants (Crocombe 2001: 84; Devaney, Reid & Baldwin 2006b: 300). Cannabis is cultivated  
in the region especially in the Melanesian islands and there are some reports from 
Micronesia, Tonga, and Samoa (INCB 2002: para 564; Crocombe 2001: 85–86; Devaney, 
Reid & Baldwin 2006b: 82; Halvaksz 2006: 56–58; US Dept of State 2004). There have  
also been some anecdotal reports about coca cultivation in PNG’s Sepik province (UNDCP 
Regional Centre for East Asia 2003: 12), but UNODC stated this ‘has never been proven 
due to lack of evidence’ (UNODC Regional Centre for East Asia 2003: 8).
Recent seizures of amphetamine and methylamphetamine in the region have led to 
suggestions that some illicit production of ATS is occurring in the Pacific Islands. In 2003, 
UNODC remarked that ‘as yet there is no evidence of production. However, with a growing 
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incidence of abuse the establishment of local production facilities is unlikely to lag far behind’ 
(UNODC Regional Centre for East Asia 2003: 7). Gordon (c2003) has suggested that it is 
‘only a relatively small step from using a country like PNG as a conduit for precursors to 
actually manufacturing methylamphetamine there for export purposes, perhaps in some of 
the highland areas where the rule of law is relatively difficult’. In 2002, authorities foiled an 
apparent attempt to import up to 12 tonnes of the precursor chemicals, ephedrine from 
India, and pseudoephedrine from China, into PNG. Although the importation was originally 
authorised by PNG authorities, the INCB expressed concern over the size and purpose of 
the shipment, given that PNG only ever knowingly imported 46.5 kg of pseudoephedrine in 
1998 (Gordon c2003; PIF 2006: 20).
The most significant ATS seizure was made on 9 June 2004 by Fijian authorities in Laucala 
Beach, Suva, where 2.8 kg of crystal methylamphetamine and over 1.5 tonnes of precursor 
chemicals were found (State v Yuen Yei Ha [2005] FJHC 165). This seizure was described  
as one the world’s largest clandestine labs ever detected, having the potential to produce 
500–1000 kg of crystal methylamphetamine a week (State v Yuen Yei Ha [2005] FJHC 165; 
Delaney et al. 2006: 303; Chulov & Harvey 2004). Local authorities suggested the precursors 
used to make the drug had been brought to Fiji from Australia and New Zealand and that 
the end products were destined for markets in Australia, the US, and Europe. 
Following these incidents the Pacific Islands Forum (PIF) Secretariat (2006: 19–20) issued  
a Transnational crime strategic assessment warning about the use of the Pacific Islands for 
illicit ATS production:
There has been, are currently and are likely to continue in the future, efforts to 
develop large methamphetamine production facilities (clandestine laboratories 
or ‘clanlabs’) on the model of the Suva clanlab in 2004. There are continued 
efforts to import large volumes of methamphetamine precursor agents into 
certain Forum Island Countries (FICs). This is a clear notice of intent where  
a country has no pharmaceutical industry that someone wants to produce 
ATS and is trying to either trans-ship the precursors through the FIC or even 
manufacture ATS in the importing country.
The PIF strategic assessment further remarked that ‘[t]he location of another major 
laboratory is assessed to be a matter of time. This remains a very serious issue for  
the present and foreseeable future’ (2006: 22). Other reports also anticipate growing 
methylamphetamine production in the Pacific Islands and suspect that profits deriving  
from illicit cannabis cultivation may be used to set up clandestine ATS laboratories in  
the region (Devaney, Reid & Baldwin 2006b: 303). As later parts of this study show,  
there is growing concern that the Pacific Islands are witnessing a rapidly expanding 
methylamphetamine market at production, trafficking, and retail levels (see chapters  
3 and 4). 
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Precursors
The production of ATS involves a variety of precursor substances such as acids, solvents, 
reagents and other chemicals. The following sections identify the key precursors used to 
manufacture amphetamine, methylamphetamine, and ecstasy, and explore the illicit trade  
in precursor chemicals. 
Precursor substances
In relation to ATS other than ecstasy, it has already been noted that the ingredients and the 
manufacturing process are comparatively simple: ‘it is possible to build amphetamine-type 
stimulants through a relatively simple process, in a few steps, requiring few and easily 
available additional chemicals and relatively simple technology’ (UNDCP 1996: 50). ATS 
production is characterised by great flexibility in the processes and ingredients used:
[O]ne key precursor may have a number of pre-precursor ancestors and  
may serve as starting material for several ATS end-products; conversely, any 
end-product may have several alternate precursors within a broader synthetic 
concept; and finally, synthetic pathways from a given precursor to a given 
end-product are numerous (UNDCP 1996: 50).
The main ATS precursor is ephedrine, a substance which can either be derived from the 
ephedra bush, a plant that is native to northwest China, or manufactured synthetically. 
Throughout the 1990s, China was seen as the most significant source of ephedrine but  
as the Chinese Government began to enforce the ban on precursor production, India 
emerged as a new source of ephedrine (Chawla & Pietschmann 2005: 170).
Amphetamine production involves norephedrine which is also commonly used in the 
manufacture of nasal decongestants and appetite suppressants. Norephedrine is also 
known as phenylpropanolamine and certain isomers occur naturally in the Catha edulis  
(or khat) plant. The key ingredient in methylamphetamine is usually pseudoephedrine  
which is synthesised ephedrine. The substance is usually obtained from over the counter 
cold remedies and can be extracted simply by soaking the tablets in methylated spirits, 
decanting or filtering to remove sediment, and then evaporating the solvent, leaving the 
precursor (Caldicott et al. 2005: 156). 
A further precursor used in ATS production is 1P2P or 1-Phenyl-2-Propanone (P2P) which is 
also used in the pharmaceutical industry (INCB 2005: 73–74). Other ingredients occasionally 
used to manufacture ATS include anhydrous ammonia, a farm fertiliser, and phenylacetic 
acid, which is a cleaning solution. 
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In contrast to other ATS, ecstasy precursors are more difficult to obtain through licit and illicit 
channels. Ecstasy precursors have extremely limited legitimate use (largely in the perfume 
industry) and are therefore placed under more rigid control. Two of the key ingredients  
of ecstasy are safrole and isosafrole (also used in the manufacture of piperonal and as  
a pesticide). Other ecstasy precursors include piperonal, which is sometimes found as  
a component of insect repellents, and 3,4-Methylenedioxyphenyl-2, a substance used  
in piperonal production (INCB 2005). 
Illicit precursor trade
The precursor substances used in illicit ATS production are also used by the chemical 
industry for licit purposes. The control regimes that were instituted for ATS in the 1970s 
initially focused only on the finished substances and not on their precursor ingredients.  
As a result, the trafficking patterns shifted away from the finished ATS to the diversion  
and trafficking of precursor substances which, until recently, were subject to lesser,  
if any, control. 
The lack of comprehensive precursor control is often seen as the main factor that 
contributed to the spread of ATS in the region (Hando & Hall 1997: 81). Given their 
widespread use for licit purposes, many precursor chemicals were not, are still not,  
or are only rudimentarily, controlled. It is widely held that inconsistencies in precursor  
control and in penalties attached to precursor-related offences are actively exploited by 
criminal elements (Wilkins 2002; Gilmore 1996: 10–11). Moreover, some substances can  
be extracted from easily available medicine or can be purchased, diverted, or stolen from 
pharmacies, commercial distributors, or manufacturers. For example, a common pattern  
of obtaining pseudoephedrine (so called ‘pseudo-runs’) is where medication containing 
pseudoephedrine is purchased from multiple pharmacies and then extracted to be used  
in illicit ATS production (Cherney, O’Reilly & Grabosky 2005: 10; Caldicott et al. 2005: 157). 
Other means of precursor diversion include, 
channelling shipments avoiding countries with good or effective control 
systems; product mislabelling, falsification of official authorisations and/or 
shipping documents; misuse of facilities of free ports, free trade zones and 
bonded warehouses; and by the lack of accountability on the part of brokers 
and others who arrange transactions with fictitious names of recipients or 
re-exports to other undisclosed suppliers (Jayasuriya 1998: 273).
International precursor control commenced in the 1980s and 90s in an attempt to prevent 
illicit ATS production by denying access to the chemicals required for the manufacturing 
process (Gilmore 1996: 2; Jayasuriya 1998: 272). As control and enforcement measures for 
precursors were stepped up, a new illicit market for the substances emerged. Research has 
shown that producers of ATS frequently shift between different precursors or substitute 
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precursors in response to availability, control, regulation, enforcement, and price (UNDCP 
1996: 65). Today, precursors are sourced, trafficked, and sold by criminal organisations  
in the same way as ATS and other illicit drugs. The increasing control of precursors has 
triggered illicit precursor production for supply to illicit ATS manufacturers and a new illicit 
trade for pre-precursor substances has emerged (Cherney, O’Reilly & Grabosky 2005: 10; 
Caldicott et al. 2005: 157). There have also been reports about ATS producers ‘assuming 
the roles of specialised brokers of precursor chemicals’ (Cherney, O’Reilly & Grabosky 2005: 
8). Moreover, illicit manufacturers change their manufacturing procedure to include substitute 
precursors that are not, or not equally, criminalised. In some instances, certain herbal 
preparations may be used (Caldicott et al. 2005: 157). 
Recent research into the types and purity of ATS available in the Australian illicit drug market 
has confirmed that the ingredients and purity of ATS are determined by the availability and 
control of relevant precursors. It was noted that throughout the 1980s, for example, 
amphetamine in Australia was usually sold as amphetamine sulphate. The increased 
precursor control in the 1990s necessitated changes to the ingredients and recipes used  
for ATS production. As a result, methylamphetamine began to feature more prominently  
in the Australian illicit drug market as it can be produced from pseudoephedrine which  
is comparatively easy to obtain (Topp et al. 2002: 342). 
An additional difficulty in the control of precursors is the fact that much of the ATS 
production occurs in very small, often mobile laboratories. This means that the small 
amounts of precursors kept for ATS production are easy to disguise and may fall below 
monitoring and record keeping thresholds (UNDCP 1996: 66). To further conceal the illegal 
activities, the manufacturing process is frequently subdivided into several small procedures 
which are carried out in different locations by different persons. Precursors are often  
stored a safe distance from the ATS ‘kitchens’. It has also been observed that the  
people purchasing the precursor substances in pharmacies or elsewhere are often only 
rudimentarily involved with the criminal enterprise, do not have a criminal record, and  
are frequently paid in ATS to create a cashless transaction (Caldicott et al. 2005: 158; 
Cherney, O’Reilly & Grabosky 2005: 11).
Precursor seizures
Levels of illicit ATS production are frequently measured in reference to seizures of 
precursors. Article 12 of the 1988 Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances introduced a requirement that signatory parties must report 
annually on precursor seizures to the INCB (see chapter 5). The data generated this way  
are, however, extremely fragmentary and do not allow generalisations about the illicit trade 
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and use of ATS precursors. As early as 1996, UNDCP highlighted ‘a few salient points’ 
about the precursor data collected by the INCB: 
(a) The relatively small quantities of the different precursors seized do not 
correspond with the widespread availability of the related end-products on 
illicit markets. […] (b) The total number of countries reporting seizures of 
precursor chemicals has decreased steadily […]. (c) The only exception is 
ephedrine […] (UNDCP 1996: 55). 
There is a general correlation between seizures of clandestine ATS laboratories and seizures 
of ATS precursors, which is largely to be expected. Naturally, countries that detect large 
numbers of illicit laboratories also seize greater quantities of ATS precursors. For example,  
in 2004 about 97 percent of all clandestine laboratories were detected in north America, 
which is said to have the greatest illicit methylamphetamine industry in the world. The United 
States has also consistently recorded large seizures of ephedrine and pseudoephedrine, 
which are used in the synthesis of methylamphetamine (UNODC 2006: 126). Similarly, 
Germany, Netherlands, and Poland – three other main source countries of illicit ATS – have 
reported significant seizures of these controlled substances over the past decade. In the 
Asia Pacific region, China, Myanmar, and the Philippines have intercepted large amounts of 
ephedrine, pseudoephedrine, and 1-P-2-P. China and India are also the principal producers 
of ATS precursors, largely because of the size of their licit pharmaceutical and chemical 
industries (Pieper 2006: 20).
Among the countries in Oceania, only Australia reported ATS precursor seizures to the  
INCB in recent years. The Australian data are, however, incomplete as information is only 
available for some years and only for selected precursor substances. Despite repeated 
precursor seizures in these countries, no data have been submitted by New Zealand or 
Pacific Island countries. Some Pacific Island nations, however, are not state parties to the 
1988 convention and thus are not obliged to compile and report that information. Also,  
in some Pacific nations, possession of some ATS precursors is not controlled and not 
criminalised (see chapter 5).
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Australia
Table 4: ATS precursor seizures, Australia, 2000–03 (number)
2000 2001 2002 2003
ATS precursors (excl. MDA/MDMA)
Norephedrine (kg) n.a. 15 3 14
-P-2-P (l) n.a. 4 n.a. n.a.
Phenylacetic acid (kg) n.a. n.a. 5 n.a.
Ephedrine, pseudoephedrine (kg) 124 7,230 n.a. 856
MDMA/MDA precursors
Isosafrole (l) n.a. n.a. n.a. n.a.
-3,4 MDP (l) v n.a. 3 n.a.
Piperonal (g) n.a. 32 16,100 n.a.
Safrole (l) n.a. 1 1 405
Source: INCB 2005: Annexe III
Table 4 shows the size of ATS precursor seizures in Australia between 2000 and 2003 as 
reported to the INCB. The data shown in the table are too fragmentary for any conclusive 
observations to be made or to allow any generalisations on precursor availability and ATS 
production in Australia. There appeared to be an increase in seizures of ephedrine and 
pseudoephedrine between 2000 and 2003, although this increase was possibly more 
reflective of increasing control and law enforcement during that period than of the actual 
levels of precursor trading and ATS production.
More comprehensive figures are released by the Australian Customs Service which collects 
data on ATS precursor seizures at the border. These figures reflect only the level of illegal 
importation of precursor substances, not their availability, circulation, or actual use in 
clandestine ATS production in Australia. ACS data also do not include information on 
diversion of precursors and pharmaceuticals in Australia, which is said to be very significant 
despite tighter regulatory controls (Pieper 2006: 20). The information published by ACS is 
separated between precursors for MDMA (ecstasy) (Table 6), and other ATS precursors 
(Table 5).
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Table 5: ATS (excluding ecstasy) precursor detectionsa by mode  
of importation, Australia, 2002–06 (number of cases) 
2002–03 2003–04 2004–05 2005–06
Air (passengers + crew) 66 56 23 30
Cargo and postalb 1,506 705 235 494
Shipping + aircraftc 1 n.a. n.a. 1
(Total) (1,573) (782) (276) (525)
a: Detection of chemical substances that are prohibited imports/exports which may be used in the manufacture  
of illicit drugs. Precursors for ATS include ephedrine, ma huang/ephedra, phenylpropanolamine/norephne, 
pseudoephedrine
b: Includes detections made from air cargo, sea cargo, and international post
c: Includes detections made from searches of sea passengers and crew, vessels, and aircraft
Source: ACS 2005b; 2006
According to ACS figures, there was a decrease in ATS precursor seizures between 
2002–03 and 2004–05 followed by an increase in 2005–06. As border control measures  
and precursor regulation in Australia and elsewhere have tightened significantly during that 
time, this development may indicate that fewer ATS precursors are, in fact, imported into 
Australia. On the other hand, it was mentioned earlier that the ACC has recorded greater 
levels of ATS production in recent years. Accordingly, precursor seizures increased between 
2004 and 2006. Domestic seizures of ATS, too, increased during that time (see chapter 3), 
suggesting that greater amounts of precursors were imported or diverted. The AFP 
anticipates that following the institution of tighter domestic controls over precursors and 
pharmaceuticals in recent years (see Sections 4.16 and 4.2.1 below) importation of ATS 
precursors will again increase (AFP 2006: 2; Pieper 2006: 19). 
Very limited information is available about the origin of the ATS precursors that are imported 
into Australia. NSW Police has identified China and India as the main sources of ephedrine 
and pseudoephedrine imports (NSW Crime Commission 2006: 3). Piperonal (also referred  
to as PMK, piperonylnmethylketone) seems to originate largely from China which is said to 
have the only factories producing that substance (Cherney, O’Reilly & Grabosky 2005: 10).
There are no separate data available on the size of illegal precursor shipments, although 
seizures of large quantities of ephedrine and pseudoephedrine are not uncommon. For 
example, on 19 June 2006 ACS and the AFP seized over 2 million tablets containing  
120 kg of pseudoephedrine (ACS 2006). In August 2005, the two agencies found over  
400 kg of ephedrine concealed in statues (ACS 2005a).
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Table 6: MDMA (ecstasy) precursor detectionsa by mode of importation, 
Australia, 2002–06 (number of cases) 
2002–03 2003–04 2004–05 2005–06
Air (pass + crew) n.a. n.a. n.a. n.a.
Cargo and postalb 3 1 4 2
Shipping + aircraftc n.a. n.a. n.a. n.a.
(Total) (3) (1) (4) (2)
a: Detection of chemical substances that are prohibited imports/exports which may be used in the manufacture  
of illicit drugs. Precursors for MDMA (ecstasy) may also be precursors to related drugs such as MDA or MDEA,  
and includes piperonal, and safrole, isosafrole, and3,4-MDP-2-P)
b: Includes detections made from air cargo, sea cargo, and international post
c: Includes detections made from searches of sea passengers and crew, vessels, and aircraft
Source: ACS 2005b; 2006
ACS statistics displayed in Table 6 show very small numbers of MDMA precursor 
importation into Australia. All detections were made in cargo and postal shipments.  
NSW Police identified China and the Netherlands as the main sources of MDP2P and 
sassafras oil, the two main ecstasy precursors (NSW Crime Commission 2006: 3). There  
is no suggestion that many cases of importation and attempted importation of ecstasy 
precursors remain undetected. In contrast, these data confirm earlier observations that 
MDMA and other ecstasy-type substances are manufactured overseas and imported into 
Australia as a finished product rather than being produced domestically. 
Tables 5 and 6 demonstrate that most detections of ATS precursor importation are made  
in air cargo, sea cargo, and in international post. Approximately 90 percent of seizures 
involved these types of shipments in recent years. Trafficking routes and patterns are very 
flexible and change frequently, depending on available sources of precursors and control 
and enforcement mechanisms in source and transit points. 
New Zealand
Data produced by New Zealand Customs show a considerable increase in seizures of 
ephedrine and pseudoephedrine in recent years, albeit starting from low levels (see Table 7). 
This supports the view that growing quantities of precursors are being imported into New 
Zealand for local production which, too, is increasing. Figures for other precursors are 
currently not available.
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Table 7: Precursor seizures, New Zealand, 2000–05a 
2000–01 2001–02 2002–03 2003–04 2004–05
Ephedrine/pseudoephedrine 16,600 143,300 570,482 1,329,488 1,436,862
a: tablets or powder equivalent of 50 g tablets
Source: NZ Customs Service 2005: 10
Pacific Islands
The Pacific Islands are not considered sources of any precursors used to produce synthetic 
drugs, largely because of the lack of any significant chemical industry in the region (UNODC 
Regional Centre for East Asia 2003: 10). There are, however, some reports of precursor 
trafficking to and through the island nations. For example, there have been some reports 
about attempts to import up to 12 tonnes of ephedrine and pseudoephedrine into PNG  
from India and China (Gordon c2003). In 2003, almost 2.5 kg of pseudoephedrine was 
found in scuba tanks shipped to Brisbane from Fiji (Feizkah 2004), and the 2004 seizure  
of the ‘megalab’ in Suva, too, involved 1000 kg of liquid methylamphetamine precursors 
(Chulov & Harvey 2004).
Organised crime involvement in ATS production 
The incentives for criminal organisations to engage in the illicit manufacturing of ATS are 
obvious, given that profit margins are high and ongoing demand is virtually certain. 
The involvement of organised crime in the production of ATS dates back to the 1960s  
when amphetamine was first banned from commercial sale. Initially, most of the ATS 
available on the black market were illegally diverted substances from pharmaceutical 
companies, pharmacies, and medical practitioners. When efforts to criminalise all aspects  
of the ATS production and precursor trade were stepped up, criminal organisations became 
increasingly sophisticated in manufacturing ATS domestically, and importing precursors and 
ecstasy from overseas. Research published as early as 1993 confirmed that
[t]here appears to be a well organised system of illicit manufacture and 
distribution which has developed because amphetamines have been easy  
to manufacture in the absence until recently of controls on the supply of 
precursor chemicals (Hall & Hando 1993: 61).
ATS production in Australia involves a large number and changing mix of criminal elements 
ranging from highly sophisticated criminal organisations to small scale entrepreneurs who 
operate within small, local markets or friendship circles (ACC 2005: 14). Naturally, the larger 
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clandestine laboratories are more often associated with sophisticated criminal organisations 
with overseas links. On the other hand, the smaller and ‘boxed’ labs are often run by local 
manufacturers; a phenomenon that appears to be particularly common in southeast 
Queensland (ABCI 2002: 47–50; ACC 2006: 8).
Outlaw motorcycle gangs
In Australia, there appears to be significant involvement of so-called outlaw motorcycle  
(or bikie) gangs in the manufacturing and distribution of ATS (Caldicott et al. 2005: 158;  
ACC 2006b: 8; Barrett 2004). Some reports suggest that outlaw motorcycle gangs were  
in control of the illicit ATS production when it first began in Victoria in the 1970s (Wardlaw 
1993: 96). Similarly, in the US, illicit ATS production, too, was initially limited to ‘motorcycle 
gangs and other independent groups’ (Anglin et al. 2000: 138). 
Research into the structure of motorcycle gangs has shown that they are characterised  
by a hierarchy divided into different regions, each with some autonomy, also referred to as 
chapters. Each chapter is headed by a president, who has absolute rule. Outlaw motorcycle 
gangs are bound together by social bonds and gang members are usually drawn from 
caucasian, working class backgrounds. Gangs are entirely male. Admission to the groups 
was formerly regulated by strict internal procedures, although this has been relaxed to allow 
greater numbers of new members to join. It is estimated that outlaw motorcycle gangs  
have several thousand members in approximately thirty chapters around Australia and are 
involved in a variety of illegal activities. To carry out their operations, the gangs sometimes 
hire specialists such as accountants, chemists, real estate agents, and lawyers. The gangs 
engage in a range of legitimate business activities, such as operating bars or security firms, 
and there is extensive crossover between their licit and illegitimate activities. To conduct their 
criminal activities and increase profits, the gangs frequently resort to violence in order to 
silence witnesses or eliminate rival gangs. It is said that they have no political influence and 
do not usually engage in corruption. The activities of outlaw motorcycle gangs are, for the 
most part, domestic but the gangs do cooperate with other chapters abroad (UNODC 2002: 
19, 21, 36, Appendix B).
Despite frequent media reports on organised motorcycle gangs, little is known about their 
level of involvement in the ATS trade and the degree of sophistication of their operations. 
UNODC described the role of outlaw motorcycle gangs in the manufacturing and supply  
of ATS as ‘prominent’ (UNODC 2002: 36). In 2001, the ACC reported that outlaw 
motorcycle gangs
feature heavily in the domestic production of methylamphetamine. Their 
involvement may be more significant than reported given that these groups 
often employ ‘associates’ to carry out various tasks in the production and 
supply process (ABCI 2002: 47). 
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The ACC suggested links between outlaw motorcycle gangs in Australia and Canada where 
these gangs are involved in ecstasy production (ACC 2004: 5–6). In 2004, Superintendent 
Fred Gere from the WA Police was cited: 
[T]hese groups are very much business [oriented] criminal organisations who 
strategically plan their expanding criminal enterprises that reach far into all 
forms of organised crime and focus on building partnerships with other 
criminal networks such as street-gangs, Southeast Asian organised crime 
syndicates, the Russian mafia and other crime gangs, even rival OMCGs 
(Barrett 2004). 
There have been some reports about collaboration between criminal organisations involved 
in the production of ATS in Australia and those sourcing precursors from overseas. In 2001, 
the ABCI reported links between ethnic-based criminal organisations and outlaw motorcycle 
gangs. It has been suggested that these gangs use specialists from other organisations to 
perform specific tasks and distribute drugs which outlaw motorcycle gangs rarely do 
themselves to avoid police attention (ABCI 2002: 48, 55).
It is unclear just how much of the ATS trade in Australia is controlled by or associated with 
outlaw motorcycle gangs. It seems that, as the methods of ATS production and supply 
become more widely known, a greater variety of criminal elements of different sophistication 
and size are appearing. It has been suggested that ‘[i]t is now doubtful if it is possible to 
identify a small group of manufacturers or distributors whose removal would have a long 
term disruption effect on the market’ (Wardlaw 1993: 100).
A further trend relating to ATS production in Australia noticed by the ACC involves the 
infiltration of chemical and pharmaceutical companies by criminals to divert ATS precursors 
from them (ACC 2005: 14). Statements about a nexus between ATS production in the 
region and terrorist organisations are, however, at best, speculative and are currently not 
supported by evidence (see Caldicott et al. 2005: 158). 
Only limited information is available about organised crime involvement in ATS production  
in NZ. From the very few reports available it appears that there is a close link between 
clandestine ATS laboratories and criminal organisations and that different gangs are 
collaborating in ATS production. There is also some evidence of well-established production 
networks with anecdotal reports about one major gang producing methylamphetamine since 
the 1980s (Bellamy & McNab 2003: 7–8). 
The limited information available on the Pacific Islands suggests that ATS production is 
closely related to organised crime networks from southeast Asia and is usually not under  
the control of local islanders. The crystal methylamphetamine lab seized in Suva in 2004,  
for example, had links to syndicates in Hong Kong and Malaysia (Feizkah 2004).
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Market factors in ATS production
A number of factors determine the income that can be achieved from the production of ATS. 
Among the main factors are the availability and price of ATS precursors, the volume of ATS 
production locally, the volume and availability of ATS produced elsewhere, risks of seizures, 
arrests, and other losses, and the availability of the necessary personnel, skills, and technical 
equipment (Pietschmann 1997: 276, 281). A particular advantage of ATS production (other 
than ecstasy) is flexibility in the use of precursor chemicals which offers a degree of 
independence from the supply of specific substances. Many precursors can easily be 
substituted with alternative ingredients. Furthermore, some substances are available  
on the licit market or are subject to only rudimentary controls.
The relative ease with which ATS production can be carried out means that more people  
or groups of people are likely to engage in the activity and that production levels are likely  
to rise if levels of law enforcement remain unchanged. If production levels are high and if 
substances are widely available, prices are lower.
Seizures of illicit ATS laboratories impact not only on the amounts of ATS available at 
wholesale and retail levels but also on the prices charged for these drugs. Seizures of 
manufacturing sites also influence the way in which ATS production is carried out, on  
the way it is disguised, and ultimately on the level of supply of and demand for these 
substances. In simple terms, the greater the danger of seizures, arrests, and other losses 
associated with ATS production, the more expensive the substances are at the place of 
production, and at the wholesale and retail levels (Pietschmann 1997: 278). Seen this way, 
law enforcement activities that target ATS production contribute to an increase in profit 
margins for criminal organisations. The increased profit has been described as ‘a “risk 
premium”, ie a compensation for the additional risks taken by manufacturers’ (Pietschmann 
1997: 278; Cherney, O’Reilly & Grabosky 2005: 13).
In 2005, UNODC undertook the first study into the profit margins of ATS production in 
Oceania (Table 8). For ATS other than ecstasy, UNODC suggests that most are sourced 
within the region and that great quantities are available for sale. As a result, laboratory prices 
for ATS at origin are relatively low, approximately US$7 per gram or US$7,099 per kilogram. 
UNODC estimates that the total income for ATS producers in Oceania in 2005 amounted to 
approximately US$58 million.
The relatively low price of ATS other than ecstasy is a result of the ease with which 
production can be carried out. This, in turn explains the magnitude of local production.  
For criminal operators, illicit ATS production offers a range of advantages especially when 
compared with other narcotic drugs. Research published in 2005 stated that:
To produce one kilo of cocaine, one has to cultivate nearly one hectare of 
coca, and use nearly 200 kilograms of inputs which include acids, solvents, 
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bases and salts. To produce one kilogram of synthetic drugs requires only five 
kilograms of inputs, an amount that can vary depending on the precursors 
used and the method of manufacture (Cherney, O’Reilly & Grabosky 2005: 7).
In contrast to opium and cocaine, ATS production and profits do not depend on climate, 
harvests, or other environmental factors. Precursors can be sourced very easily, cheaply, 
and often legally. For example, ‘30 tablets containing 60 milligrams each of pseudoephedrine 
[…] available in pharmacies for around $AUD10.00 can produce more than 300 doses of 
methamphetamine which retails between $2000 and $8000 on the illicit drug market’ 
(Cherney, O’Reilly & Grabosky 2005: 7). The manufacturing process, especially for 
substances other than ecstasy, is simple and inexpensive (especially relative to the 
wholesale price for ATS), involves limited skills, and can be completed within one or two 
days. Further, the manufacturing process is highly flexible and can be carried out almost 
anywhere, including household kitchens, garages, hotel rooms, cargo containers, or even 
the boot of a car (Wilkins et al. 2005). This also allows for the process to be disguised  
very easily. 
These observations confirm research findings from other jurisdictions which suggest that 
ATS are typically manufactured in the country of final consumption. This, in turn, means  
that any value-adding of the production process remains in the country of final consumption, 
making ATS production very attractive for local entrepreneurs who work in close proximity  
to consumers. From the available information it appears that it is the ease with which profits 
can be made, and not necessarily the size of those profits, that attracts new competitors. 
This is manifest in the growing number of clandestine laboratories throughout the region 
(Wilkins et al. 2005).
Table 8: Amounts and income of ATS and ecstasy production,  
Oceania, 2005 
ATS (excl. ecstasy) Ecstasy
Production in Oceania 8,151 kg 784 kg
Total available for sale 8,151 kg 784 kg
Laboratory price per kg at origin US$7,099/kg US$47,014/kg
Producer income US$58 million US$37 million
Source: UNODC 2005: 140
In comparison to other ATS, ecstasy production in the region is small, especially relative to 
the levels of ecstasy trafficking and importation into Oceania (see chapter 3). Given the costs 
of and difficulties in obtaining ecstasy precursors in the region and the higher costs and 
greater degree of sophistication required to carry out ecstasy manufacturing, laboratory 
prices at origin for ecstasy are much greater than those for other ATS. Table 8 shows that 
UNODC estimates that the price for ecstasy at origin in Oceania is US$47.00 per gram or 
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US$47,014.00 per kilogram. The total income of ecstasy producers in the region is 
estimated to be US$37 million. The profit margin relative to the small amount of production 
is much greater for ecstasy than it is for other ATS. 
Despite the great profit margins of local ecstasy production, most of the producer income 
for ecstasy is made overseas, not in the region. According to UNODC figures, the amount  
of ecstasy imported into the region is over seven times greater than the local production. 
Other reports suggest that 90 percent of the ecstasy available in Oceania is sourced from 
overseas (see chapter 3). Consequently, and in contrast to other ATS, ecstasy production 
outside the region limits value-adding in the consumer countries to trafficking and retail 
activities. For ecstasy (as well as for crystal methylamphetamine, heroin and cocaine) only 
minor production or modification processes occur in Australia, New Zealand, and the Pacific 
Islands, thus production profits remain offshore and essentially beyond the reach of local 
criminal organisations.
Observations
Although exact figures on the level of illicit ATS production do not exist, the available 
information from domestic and international agencies and from academic research confirms  
a number of trends and allows the following observations about illicit ATS production in 
Oceania:
The beginning of illicit production of ATS in the region coincided with the ban on licit •	
production and on over-the-counter availability of ATS. A market opportunity for 
organised crime was created with the prohibition of ATS.
Of the ATS (excluding ecstasy) available in Oceania, approximately 90 percent are •	
manufactured in the region, particularly in Australia and, in smaller proportions, in New 
Zealand. Manufacturing of ATS, with the exception of high quality methylamphetamine 
and ecstasy, usually takes place in close proximity to the retail market. In Australia, illicit 
ATS production is particularly concentrated in southeast Queensland. There is also  
some isolated, occasional production of ATS in the Pacific Islands.
ATS produced in the region are, for the most part, methylamphetamine of low purity. •	
Methylamphetamine of higher purity, such as crystal methylamphetamine or ice, is largely 
imported into the region from east Asia. Ecstasy, too, is for the most part imported into 
the region from Europe and increasingly from east and southeast Asia. There are some 
reports of small levels of ecstasy production in Australia.
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According to Australian sources, the number of clandestine ATS laboratories and the •	
volume of domestic ATS production have continued to grow in recent years. UNODC 
and New Zealand agencies noticed a slow decrease in the number of detections of 
clandestine laboratories since 2003 but suggest that domestic production may have 
been substituted by greater imports of ATS. 
As a result of more comprehensive control of precursor substances, Australian and New •	
Zealand agencies are interdicting more cases and greater quantities of ATS precursors. 
Precursor seizures, however, do not seem to have impacted on the levels of illicit ATS 
production, although in Australia use of ATS appears to have stabilised. The availability 
and control of precursors does, however, impact on the methods and ingredients used 
for illicit ATS production. Increased precursor control so far seems to be followed by  
a shift in illicit ATS production. Precursor control remains very rudimentary in the Pacific 
Islands and is nonexistent in some island nations.
High profitability (even of small quantities) and great flexibility in the production process •	
and in the ingredients used make illicit ATS production particularly attractive to criminal 
elements. Organised crime features more prominently in the large scale production  
of ATS, the importation of precursors, and the manufacture of ecstasy and ATS of  
high purity.
Organised crime involvement in the illicit ATS trade in the Pacific region is unsurprising •	
given the existence of well-organised, sophisticated criminal networks in the region with 
established networks across borders and around the world.
Of the criminal organisations operating in Australia, outlaw motorcycle gangs have  •	
a long standing association with illicit ATS manufacturing and have controlled much of 
the domestic production. These gangs continue to feature prominently in the domestic 
ATS markets in Australia and New Zealand but their position may be weakening as new 
criminal elements, including entrepreneurial amateurs, enter the market. Other criminal 
organisations have a less visible involvement in illicit ATS production, and seizures made 
in the Pacific islands show links to Asian criminal syndicates.
Current research suggests that illicit ATS production in Oceania will continue. There  •	
are some suggestions that ATS of higher purity and ecstasy, too, will increasingly be 
produced locally. Many reports anticipate that illicit ATS production in the Pacific Islands 
will increase.
Chapter 3: 
Trafficking and importation
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Trafficking and importation of ATS in Oceania
In the absence of exact records of imports and exports of illicit substances, the extent of 
trafficking in ATS is usually measured with reference to the size of ATS seizures made by law 
enforcement and customs agencies. As with all data used in this study, statistics and other 
information are subject to different reporting practices in different countries. The information 
is often incomplete and frequently anecdotal rather than representative of the true extent of 
trafficking and illicit importation activities. The figures for ATS seizures generally only reflect 
the level and intensity of law enforcement activity and do not show the true extent of the  
ATS problem. For example, research from New Zealand has suggested that only about  
eight percent of ecstasy is seized by law enforcement agencies and that seizure rates for 
amphetamine are as low as four percent of the actual supply (Wilkins et al. 2004b: 63). 
Similar suggestions have been made by UNODC, which estimates that during the trafficking 
stage only about 12.6 percent of ecstasy and as little as 6.1 percent of other ATS are seized 
by law enforcement agencies (UNODC 2005: 140).
An additional problem in assessing ATS trafficking arises from the fact that the statistics 
usually do not reflect the quality or purity of the substances seized. To complicate matters 
further, different jurisdictions measure their seizures differently – some in kilograms, some  
in litres, some in units – with no accepted standard of conversion between the three scales.
Global trends
Worldwide, methylamphetamine is the most commonly seized type of ATS, accounting for 
about 62 percent of all seizures between 2000 and 2004 (Figure 5). Ecstasy accounted for 
17 percent of seizures during that time period, although its proportion has grown to 28 
percent in 2004. Amphetamine accounted for 14 percent of all seizures in 2000–04 and 
other ATS make up the remaining seven percent (UNODC 2006: 132).
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Figure 5: Global ATS seizures (including ecstasy) by type, 2000–05 
(percent)
Source: UNODC 2007: 123
The World drug report, published annually by the UNODC, shows a considerable increase  
in the seizures of ATS in recent years. The methodology is described in the report (UNODC 
2007: 261–262). Worldwide seizures increased ten-fold between 1990–91 (4 tonnes) to 
almost 40 tonnes in 2000–01 (UNODC 2003a: 3). After cannabis, ATS are the most 
frequently seized drugs. Global ATS seizures peaked in 2000 and have since decreased 
significantly (see Table 9 and Figure 6). For example, seizures in 2002 and 2004 were only 
about half of the amount seized in 2000. Most ATS are seized in Asia. In 2002, 64 percent, 
and in 2003, 52 percent of worldwide amphetamine seizures (excluding ecstasy) were  
made in east and southeast Asia (UNODC 2005: 103; Chawla & Pietschmann 2005: 170). 
Accordingly, the decrease of worldwide seizures of ATS in recent years has largely been 
attributed to lower seizures in Asia.
Other ATS 7%
Ecstasy 14%
Amphetamine 17%
Methylamphetamine 62%
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Table 9: Global ATS seizures, 2000–05
2000 2001 2002 2003 2004 2005
ATS (excl. ecstasy)
kg 3,659.257 971.103 731.496 2,496.015 3,257.541 2,385.764
lt 229.96 1.00 10.51
u 26,725,520 10,075,500 28,748,890 9,789,583 20,641,080 127,294,300
Ecstasy (MDA, MDEA, MDMA)
kg 1,653.981 1,056.245 3,278.132 1,956.448 5,042.606 2,640.433
lt 3.00 210.00 12.00
u 33,345,990 34,398,240 34,547,290 23,739,870 26,194,790 26,504,540 
Source: UNODC 2007: seizures
Figure 6: Global ATS seizures (excluding ecstasy), 2000–05
Source: UNODC 2007: 64
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Figure 7: Global ecstasy seizures, 2000–05
Source: UNODC 2007: 82
Global seizures for ecstasy seem to be unrelated to seizures of other ATS. The available 
information also shows some conflicting developments, depending on the measurement 
used. Overall, total ecstasy seizures worldwide increased in the 2000–05 period and there 
have been some suggestions that worldwide seizures of ecstasy increased further since 
2004 (INCB 2005: para 640). Measured in weight, ecstasy seizures increased almost 
ten-fold between 2000 and 2005, although decreases were recorded in individual years;  
see Table 9 and Figure 7 above. Seizures of ecstasy in units (u), in contrast, peaked in 2001 
with the seizure of almost 40 million units and have since decreased by about 25 percent to 
approximately 28 million ecstasy units in 2005, mostly due to a decline in ecstasy production 
in Europe.
Oceania
As the following sections show, trafficking trends in Oceania, manifested in the seizure of 
ATS and ecstasy, do not seem to follow global developments. In general, seizures of ATS  
in Oceania, especially methylamphetamine and ecstasy, grew significantly over recent  
years until 2003. Ecstasy seizures continued to increase in 2004 while methylamphetamine 
seizures in Oceania dropped slightly, largely due to reduced methylamphetamine trafficking 
in Australia and lower levels of methylamphetamine importation from southeast Asia 
(UNODC 2006: 134).
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The different developments at global and regional levels are explained by the common and 
long standing observation that trafficking in ATS, with the exception of ecstasy, is conducted 
only within a particular region or within one country (UNDCP 1996: 40). ‘Production and 
consumption of ATS are, in general, less geographically separated than in the case of the 
other illicit drugs’ (Chawla & Pietschmann 2005: 175). Much of the illicit ATS trade (other 
than ecstasy) is carried out within one region or even within one country and is not 
interregional. Thus, the developments in Oceania are not necessarily linked to developments 
elsewhere or to global trends. In contrast to substances such as heroin and cocaine, ATS 
other than ecstasy are not commonly trafficked across great geographical distances. It was 
mentioned in chapter 2 of this study that approximately 90 percent of ATS in Oceania are 
also manufactured in the region. This means, inter alia, that suppression and seizures  
of ATS in one part of the world do not automatically translate into shortages in other parts. 
However, production capacities in Oceania are limited relative to the high demand in the 
region (see chapter 4). As a result, there is also some trafficking of methylamphetamine  
from southeast Asia into the region (UNODC 2006: 132), especially in the form of crystal 
methylamphetamine. Precursor chemicals for ATS production, too, are sourced from outside 
Oceania. Thus ATS availability in Australia is, to some degree, dependent on the availability 
of ATS and ATS precursors elsewhere.
A somewhat different picture emerges for ecstasy, which is trafficked internationally, often 
across very great geographical distances. The global ecstasy market connects different 
regions and countries across the world and thus enforcement measures or fluctuations in 
production on one side of the globe may indeed have flow on effects on the opposite side. 
The trade in ATS precursors, too, is interregional, partly because of the great discrepancies 
in precursor control in different countries (Chawla & Pietschmann 2005: 176).
Australia
ATS and ecstasy seizures
ATS seizures in Australia are relatively high, accounting for approximately six percent of 
global seizures (UNODC 2005: 103). In Australia, seizures of ATS generally and ecstasy 
seizures in particular (including MDA, MDEA, and MDMA) increased greatly between 1998 
and 2003, as illustrated in Table 10 and Figure 8. The greatest quantity of ATS seizures was 
recorded in 2003 when over 707 kg of ATS were seized in Australia. The quantity of ATS 
seizures has since decreased, to less than 250 kg in 2004. In contrast, ecstasy seizures  
are continuing to increase. Over 1.4 tonnes of ecstasy were seized in 2005 alone.
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Table 10: ATS and ecstasy seizures, Australia, 1998–2005
1998 1999 2000 2001 2002 2003 2004 2005
ATS (excl. ecstasy)
kg 182.2 276.8 427.3 537.6 561.1 707.55 248.18 18.59
u 136 8,645 39,449
lt 0.08 10.51
Ecstasy
kg n.a. 55.6 n.a. 338.4 722.0 1,083.1 1,321.63 1,433.43
u 4,885 125,867 22,756
Source: UNODC 2005: 316, 321; UNODC 2006: 339, 344
Figure 8: ATS and ecstasy seizures, Australia, 1998–2005
Source: UNODC 2005: 321; UNODC 2007: 64, 82
The first ecstasy seizure in Australia is believed to have been made in June 1986 at Sydney 
airport (Webb 2003: 91). Ecstasy seizures in Australia have since increased steadily and 
continued to grow rapidly in the 1999–2004 period. As shown in Table 10 and Figure 8, 
seizures nearly doubled between 2001 and 2002 and increased by a further 30 percent 
between 2002 and 2003, and again from 2003 to 2004. According to UNODC, 13 percent 
of global ecstasy seizures between 2001 and 2003 were made in Australia. In 2003 alone, 
24 percent of all ecstasy seizures worldwide were made in Australia, second only to the 
Netherlands (28%). Ecstasy seizures in Australia in 2004 account for about 17 percent  
of all seizures made worldwide, ranking third behind Canada and Belgium (both 19%  
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of global seizures). In 2005, the Oceania region accounted for 27 percent of ecstasy 
seizures worldwide, second only to west and central Europe (38%; UNODC 2007: 145).  
As mentioned before, most of the ecstasy seized in Australia originates from Europe,  
smaller amounts come from Asia, and recently there are reports of some low scale  
domestic ecstasy production in Australia (UNODC 2006: 132, 140; see chapter 2).
Unlike UNODC data, ATS seizures recorded by the ACC shown in Table 11 are not 
separated between ecstasy and other ATS, making is impossible to identify a distinct  
trend for either substance. The ACC statistics do, however, show a steady increase in the 
total number of ATS seizures and also in the quantity (measured in weight) seized annually 
between the 1997–98 and 2005–06 financial years. ACC statistics do not reveal the actual 
size of individual seizures. From the data shown in Table 11 it appears that the average size 
of seizures has increased in recent years, as the total weight of ecstasy seized by state, 
territory, and federal agencies has grown more rapidly than the total number of seizures.  
The number of ATS seizures more than doubled between 1997–98 and 2005–06. This 
reflects the fact that law enforcement and border controls improved significantly during  
that time. During the same period the amount of ATS seized (in weight) increased about 
twelve-fold, which may be explained by the growth of ATS production (see chapter 2 above).
Table 11: ATS (including ecstasy) seizures, Australia, 1998–2006
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Seizures (n) 4,551 6,529 4,861 6,309 6,471 6,179 8,027 8,600 9,987
Weight (kg) 182.22 256.98 381.27 801.50 1,835.98 2,023.02 1,371.94 2,276.15 1,296.62
Source: ABCI and ACC 1997–2007
Seizures by type of substance
The previous section has shown that in recent years, seizures of ecstasy have been  
greater than seizures of other ATS. This trend is also confirmed by reports by the Australian 
Customs Service which collects comprehensive statistics on detections of illicit importations 
of ATS into Australia. These statistics are by their very nature limited to detections that occur 
at the border and do not involve ATS seizures that are made by law enforcement agencies 
domestically. Table 12 shows that in the period between 1999 and 2004 the total number  
of and weight of ecstasy seizures at the border have been far greater than those of other 
ATS. While there has been a slight decrease in the number of ecstasy seizures since the 
2002–03 financial year, the quantity of ecstasy seized in these years has continued to remain 
high, suggesting that ecstasy is increasingly found in very large shipments.
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Table 12: ATS (including ecstasy) detection by type of substance, 
Australia,1999–2006
1999–
2000 2000–01 2001–02 2002–03 2003–04 2004–05 2005–06
ATS (excl. MDMA, ice)
Detections (n) 42 35 173 198 128 186 n.a.
Weight (kg)a 13.02 1.22 273.94 6.15 3.55 27.31
Ice (crystal meth.)
Detections (n) 18 15 30 17 12 18 n.a.
Weight (kg) 8.73 83.47 154.31 233.18 2.37 123.85
Ecstasy (MDMA)
Detections (n) 104 148 285 311 294 169 135
Weight (kg) 142.67 338.42 445.04 556.19 872.95 2,374.95 413.31
a: Weight shown is an estimation only. Unless the exact weight was available, weight is calculated using  
0.29 g per tablet
Source: ACS 2002–06
There have been a number of reports stating that crystal methylamphetamine is increasingly 
popular and more easily available than previously on the Australian illicit drug market. There 
have also been suggestions that crystal methylamphetamine is, for the most part, imported 
into Australia from Asia where the substance is produced in great quantities and is thus 
more easily available (ACC 2005: 11; Pieper 2006: 19). It was mentioned earlier that local 
clandestine laboratories in Australia generally do not produce methylamphetamine of such 
high purity. The data in Table 12 show that ACS seizures of crystal methylamphetamine 
account for approximately 10 to 30 percent of ATS seizures (excluding ecstasy) with great 
variations between individual years. Measured in weight, crystal methylamphetamine 
detections are greater than seizures of other ATS in some years. While Table 12 does not 
show any particular trend in the level of illicit importation of crystal methylamphetamine, the 
data confirm that relatively large quantities of crystal methylamphetamine are imported into 
Australia, while border seizures of other ATS are small relative to local production. In 2004, 
the ACC suggested that ‘[c]rystalline methamphetamine is exclusively imported and the 
market is dominated by a small number of large shipments and a large number of small 
scale imports’ (ACC 2004: 6). Other reports confirm that crystal methylamphetamine is 
almost exclusively imported into Australia, especially from mainland China via Indonesia  
and the Philippines and also increasingly from Myanmar (Pieper 2006: 19). There have been 
suggestions that the increased level of importation, combined with the growing demand for 
high purity crystal methylamphetamine, is impacting on Australian illicit methylamphetamine 
producers who, in order to compete with overseas suppliers, are forced to produce higher 
quality products (Topp et al. 2002: 346).
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Mode of importation
In the absence of any land borders with another country, importation of ATS into Australia 
occurs exclusively by air and sea. Customs classifies ATS detections into three different 
modes of importation:
air (passengers and crew)•	
air and sea cargo and international post•	
shipping vessels and aircraft (including ship crews and passengers).•	
Table 13 illustrates that approximately 90 percent of ATS detections (not including ecstasy) 
are made in cargo and postal shipments. In most years, only a comparatively small number 
of detections are made on passengers and crew, and on board sea vessels and aircraft. 
This leads to the suggestion that most ATS are imported into Australia in air, sea and postal 
shipments and are not commonly brought in by couriers or drug mules. The total weight  
of ATS detections involving cargo and postal shipments is also greater than the quantities 
found in other modes of importation, although in some years, individual large seizures of ATS 
have been made in searches of aircraft and sea vessels. For example, in 2001–02, more 
than 400 kg of ATS were found in (only) three seizures aboard sea vessels and aircraft. This 
demonstrates that the statistics can be heavily influenced by individual seizures and unique 
incidents, making it difficult to form any generalised observations about trafficking patterns. 
From the raw data, it appears that imported ATS, for the most part, arrive in Australia in 
many, relatively small shipments. Further information about the size of seizures is discussed 
in the following section.
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Table 13: ATS (excluding ecstasy) detection by mode of importation, 
Australia, 1999–2006
1999–
2000 2000–01 2001–02 2002–03 2003–04 2004–05 2005–06
Air (passengers + crew)
Detections (n) 20 17 22 13 15 7 13
Weight (kg) 19.52 2.81 1.99 1.06 2.40 8.06 16.32
Cargo and postala
Detections (n) 39 32 178 199 124 196 410
Weight (kg) 2.23 81.88 14.81 238.26 3.51 133.30 73.34
Shipping + aircraftb
Detections (n) 1 1 3 3 1 1 n.a.
Weight (kg) 0.00 0.00 411.45 0.01 0.01 9.81 n.a.
Total
Detections (n) 60 50 203 215 140 204 423
Weight (kg) 21.75 84.69 428.26 239.33 5.92 151.17 89.67
a: Includes detections made from air cargo, sea cargo, and international post
b: Includes detections made from searches of sea passengers and crew, vessels, and aircraft
Source: ACS 2002; 2005b; 2006
As with other ATS, trafficking in ecstasy mostly occurs by way of concealment in sea cargo, 
air cargo, and postal shipments, although some opportunistic trafficking aboard commercial 
flights also occurs. This is shown below in Table 14 and Figure 9. In most years, the number 
of ecstasy detections is higher than the number of detections of other ATS. The total 
quantities of ecstasy seized each year are also far greater than those of other ATS. The 
number and quantity of ecstasy seized from airline passengers and crews has gradually 
decreased in recent years, suggesting that ecstasy is rarely imported by couriers or drug 
mules. This is also confirmed by reports from the ACC (2005: 25).
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Table 14: Ecstasy (MDMA) detection by mode of importation, Australia, 
1999–2006
1999–
2000 2000–01 2001–02 2002–03 2003–04 2004–05 2005–06
Air (passengers + crew)
Detections (n) 49 51 35 20 29 15 9
Weight (kg) 36.27 64.70 123.24 10.30 37.89 42.59 25.62
Cargo and postala 
Detections (n) 54 96 249 291 265 154 125
Weight (kg) 90.61 273.71 320.24 545.89 835.06 2,332 36 387.69
Shipping + aircraftb
Detections (n) 1 1 1 n.a. n.a. n.a. 1
Weight (kg) 15.80 0.00 1.56 n.a.
Total
Detections (n) 104 148 285 311 294 169 135
Weight (kg) 142.67 338.42 445.04 556.19 872.95 2,374.95 413.31
a: Includes detections made from air cargo, sea cargo, and international post
b: Includes detections made from searches of sea passengers and crew, vessels, and aircraft
Source: ACS 2002; 2005b; 2006
Figure 9: Ecstasy (MDMA) detection by mode of importation, Australia, 
1999–2006
Source: ACS 2002; 2005b
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Size of ATS seizures
Seizures of ATS made by ACS are further classified by the size of the detection. ACS 
differentiates between commercial, trafficable, and minor quantities, a terminology also  
used in the former drug offences under the Customs Act 1901 (Cth). The actual quantities 
associated with these terms differ depending on the substance involved. For ATS other than 
ecstasy, commercial quantities are seizures involving 750 grams or more, and trafficable 
quantities involve two or more grams but less than 750 grams of ATS. Quantities that are 
smaller than two grams are classified as minor.
Table 15: ATS (excluding ecstasy) detection, Australia, 1999–2006
1999–
2000 2000–01 2001–02 2002–03 2003–04 2004–05 2005–06
Commercial (≥ 0.75 kg)
Detections (n) 3 1 4 2 1 8 12
Weight (kg) 17.28 79.11 421.17 233.90 2.32 146.78 79.81
Trafficable (≥ 2 g, < 0.75 kg)
Detections (n) 45 33 152 179 117 170 311
Weight (kg) 4.46 5.57 7.06 5.41 3.59 4.37 9.76
Minor (less than trafficable, < 2 g)
Detections (n) 12 15 47 34 22 26 100
Weight (kg) 0.01 0.01 0.02 0.02 0.01 0.02 0.09
Total
Detections (n) 60 50 203 215 140 204 423
Weight (kg) 21.75 84.69 428.26 239.33 5.92 151.17 89.67
Source: ACS 2002; 2005b; 2006
Table 15 shows that most seizures made by ACS involve trafficable quantities of ATS, 
accounting for about 80 percent of all detections made each year. A small number of 
commercial-size shipments are also apprehended each year. The picture that emerges  
is that ATS other than ecstasy are trafficked most frequently in medium sized shipments, 
although individual very large shipments are also detected each year. If seen in context with 
the modes of importation outlined before, it appears that the very large shipments almost 
exclusively arrive by sea cargo, air cargo, or in postal shipments. These observations are 
confirmed by reports of recent ATS seizures. For example, in June 2005, 11 kg of crystal 
methylamphetamine was seized, having been imported on a US Navy vessel (ACS 2005b). 
In February 2006, the AFP and ACS seized 46 kg of crystal methylamphetamine in a 
speedboat from Canada (ACS 2006). It has been suggested that the importation of large 
shipments of ATS into Australia occurs along established routes which are simultaneously 
used for other illicit drugs such as heroin (ACC 2005: 14; ACC 2003: 5–6).
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Ecstasy detections show the same pattern as seizures of other ATS (see Table 16). The  
size of ecstasy seizures is, however, classified differently. Seizures of 500 grams or more  
are called commercial quantity. Trafficable quantities involve 0.5 grams or more but less  
than 500 grams. Seizures of less than 0.5 grams are referred to as minor. The great majority 
of ACS seizures involve trafficable quantities of ecstasy. In contrast to other ATS, ecstasy 
appears to be more frequently trafficked in very large shipments. While the number of 
seizures involving commercial quantities is relatively low, accounting for approximately  
five to 20 percent of all seizures in most years, the total quantity in weight of commercial 
seizures is extremely high. For example, the 21 seizures of commercial-size shipments 
apprehended in 2004–05 involved over 2.3 tonnes of ecstasy. This is confirmed by reports 
of recent large scale seizures of MDMA in Australia. In June 2006, 350 kg of MDMA was 
seized in Melbourne in an ink shipment from Canada. In April 2005, 1 tonne or 5 million 
tablets, the then largest seizure of MDMA, was found in Melbourne in a sea cargo 
consignment of tiles from Italy (SA Police 2006). In November 2004, 161 kg of MDMA  
was detected in Port Botany (NSW) in a sea cargo consignment from Belgium. And  
in October 2004, 818 kg of MDMA was found in Sydney concealed in an air cargo 
consignment from Poland (ACS 2005b).
Table 16: Ecstasy detection, Australia, 1999–2006
1999–
2000 2000–01 2001–02 2002–03 2003–04 2004–05 2005–06
Commercial (≥ 0.5 kg)
Detections (n) 25 39 24 16 32 21 17
Weight (kg) 139.88 333.35 435.79 550.14 861.81 2,369.49 407.19
Trafficable (≥ 0.5 g, < 0.5 kg)
Detections (n) 70 99 244 281 247 146 117
Weight (kg) 2.84 5.06 9.26 6.05 11.13 5.46 6.12
Minor (less than trafficable, < 0.5 g)
Detections (n) 9 10 17 14 15 2 1
Weight (kg) 0.00 0.00 0.00 0.00 0.00 0.00 n.a.
Total
Detections (n) 104 148 285 311 294 169 135
Weight (kg) 142.67 338.42 445.04 556.19 872.95 2374.95 413.31
Source: ACS 2002; 2005b; 2006
In summary, it appears that there is, at present, no significant trend in the level of importation 
of ATS (other than ecstasy) into Australia. While some years have seen very high numbers  
of seizures and the seizure of very large quantities, there is no consistent development over 
time. Ecstasy importations, in contrast, have grown steadily in recent years.
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The growing number of seizures of ATS and ecstasy made by law enforcement agencies in 
Australia has, for the most part, been attributed to greater law enforcement activity, including 
the levels and intensity of investigations, intelligence, etc. Greater seizures may, however, 
also be explained by greater availability of ATS in the illicit market. In this context UNODC 
has described the upsurge in seizures of ATS in Australia, especially ecstasy, over the  
past 15 years as ‘a frightening measure of a growing market’ in Australia, Oceania, and 
worldwide (UNODC 2003a: 3). This is supported by evidence showing an increase in the 
number and size of manufacturing sites in more countries (UNODC 2003a), including 
Australia.
New Zealand
Patterns of ATS trafficking and importation in New Zealand are very similar to developments 
in Australia, although there are some signs of greater levels of ATS importation relative to  
the local illicit ATS production. Until recently, ATS other than ecstasy were, for the most part, 
imported into New Zealand. Before local ATS production in New Zealand reached significant 
levels in 2000, ATS were largely sourced from Australia and the United States (Wilkins 2002). 
At that time, seizures of ATS in New Zealand also rose rapidly from only 1.3 kg in 1998 to 
10.2 kg in 2000 (see Table 17 below). As local production of ATS in New Zealand grew, the 
need for ATS imports declined. Accordingly, ATS seizures decreased between 2000 and 
2003. However, a new high was reached with the seizure of over 30 kg and 934 units of 
ATS in 2004.
Data for seizures of methylamphetamine in New Zealand are not available for all years. 
Seizures increased markedly between 1999 and 2002 and the New Zealand press reported 
elsewhere that seizures of methylamphetamine in the form of crystal methylamphetamine or 
ice alone rose from just one kilogram in 2003 to 17 kg in 2004 (Narcotics trafficking through 
NZ causes UN concern 2006).
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Table 17: Seizures, New Zealand, 1998–2003
1998 1999 2000 2001 2002 2003 2004 2005
ATS (excl. ecstasy)a
kg 1.34 1.10 10.18 4.17 7.44 2.19 30.47 n.a.
u 1,400 103 523 57 934
Methylamphetamineb
kg n.a. 1.8 2.1 3.8 6.4 n.a. n.a. n.a.
Ecstasy (UNODC)a
lt n.a. n.a. 0.07 3.00
u 8,798 u 83,449 256,350 271,799 45,387 25,401
Ecstasy (NZ Customs)c
u 3,000 n.a. 10,000 73,000 167,000 260,000 n.a. n.a.
a: from UNODC 2005: 316, 321; 2006: 339, 344; 2007: 64, 82
b: Bellamy & McNab 2003: 7
c: Wilkins 2002: 14; Wilkins et al. 2005: 142
Table 17 shows that ecstasy seizures in New Zealand have followed similar trends to those 
in Australia, showing rapid increases in the years up to 2003. According to UNODC data, 
seizures of ecstasy grew ten-fold between 2000 and 2001 alone, albeit starting from very 
low levels. Ecstasy seizures in New Zealand peaked in 2003 with seizures totalling over 
270,000 units. A significant decrease in seizures was recorded by UNODC in 2004 and 
2005, although it is unclear at this point whether this drop signalled a new trend.
Figures provided by the New Zealand Customs Service show the total amount of ecstasy 
seized at the border and in imported shipments. Unlike UNODC data, these figures do not 
include purely domestic seizures. The Customs data confirm that the great majority of 
ecstasy is imported into New Zealand. It was noted earlier that there is no evidence of 
ecstasy production in that country. Other reports confirm that ecstasy in New Zealand 
originates for the most part from Western Europe and is trafficked to New Zealand by  
air or through international mail (Wilkins 2002).
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Pacific Islands
The Pacific Islands have been considered vulnerable to trafficking and smuggling activities 
by sea and air for some time. Their geographical location between Asia, Australia, and the 
Americas make the islands important stopover, storage, and transit points for cross-Pacific 
operations and serve to camouflage the origins and routes of illicit consignments (Devaney, 
Reid & Baldwin 2006b: 300, 304; Shibuya & Smith 2002). In 2003, UNODC observed that:
Viewed from a drug-business perspective, the geographic location of the 
Pacific islands lends itself to facilitation of traffic from major drug suppliers in 
East Asia and South America to serving demand in Australia/New Zealand 
and North America. The Pacific islands connect some of the world’s largest 
drug producers with the largest drug markets in the world. It is a strategic,  
if perilous, location with regard to the global illicit drug trade. Adding to this  
is the virtual isolation of many of the islands (security for traffickers) and  
their sheer number (opportunities) including often hundreds, sometimes 
thousands, of smaller islets. A Pacific transit can also enable drug traffickers 
to camouflage the country of origin of their illicit drug consignments 
originating from high-risk countries. It is a fact that the Pacific islands are 
extremely vulnerable to exploitation by drug traffickers (UNODC Regional 
Centre for East Asia 2003: 9; cf McCusker 2006).
The actual level of trafficking in illicit drugs through the Pacific Islands is unknown and,  
unlike Australia and New Zealand, there are no annual reports of drug seizures, and modes 
and sizes of importations. Recent seizures may give some indication about the existence 
and modi operandi of drug traffickers in the region but the available data do not allow any 
generalisations about the true extent of the problem.
Much of the available information on the Pacific Islands relates to illicit trafficking in narcotic 
drugs and not specifically to ATS shipments. For example, during the late 1990s, there  
was some evidence of trafficking in ‘illicit southeast Asian heroin and cannabis products, 
South American cocaine, European ATS and LSD […] at varying scales and intensity using 
Vanuatu, Papua New Guinea, Fiji, Tonga, Tahiti, and New Caledonia as transit points’ 
(UNDCP 2003: 12; cf Crocombe 2001: 370; Gordon c2003). In 2000, police in Suva seized 
357 kg of heroin bound for Australia, New Zealand, and Canada. It is believed that the 
heroin originated in southeast Asia (INCB 2002: para 564). In April 2001, some Chinese 
nationals were arrested in Fiji for shipping 160 kg of heroin from Myanmar to Vanuatu, 
presumably on their way to Australia. A frequently cited case is that of 50 kg of cocaine 
which was found floating in a lagoon in Micronesia. The locals who found it mistook the 
white powder for washing detergent and used it accordingly, before realising that the 
powder was not lathering as expected (Hon P McIlrath, Secretary, Dept of Justice, FSM, 
pers. comm. 6 June 2001). In 2001, the INCB reported that ‘Fiji and Vanuatu are known  
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to be used by drug traffickers as transit points for large consignments of heroin originating  
in southeast Asia and destined for Australia […]. Drug traffickers continue to move cocaine 
from South America to Australia through the Pacific islands’ (INCB 2002: paras 565–567). 
On 10 September 2004 police in Vanuatu found 120 kg of heroin on a beach in the biggest 
such haul in the Pacific nation’s history (Winter 2006).
In recent years, the focus of drug trafficking in the Pacific Islands seems to have shifted  
from heroin and cocaine to ATS especially in the form of methylamphetamine, including 
crystal methylamphetamine (or ice). A 2006 assessment by the Pacific Islands Forum 
Secretariat identified methylamphetamine seizures in three different forms:
namely crystal, liquid and methamphetamine powder. There are three 
possible scenarios that may account for this. The first is that different  
groups are involved in the manufacture of different drug forms. Secondly,  
the importers are changing the modus operandi in an attempt to evade 
detection and thirdly, it is an importer preference (PIF 2006: 21).
Since the late 1980s there have been many reports of crystal methylamphetamine 
importation from the Republic of Korea, Japan, the Philippines, and Taiwan into Hawai’i, 
which was the first US state to be affected by this drug (Lerner 2005: 74–76; Anglin  
et al. 2000: 138; Devaney, Reid & Baldwin 2006b: 305). In 2000, Palau and the Northern 
Marianas also reported their first significant seizures of 332 g and 8.8 kg respectively  
of crystal methylamphetamines from the Philippines (UNDCP Regional Centre for East  
Asia 2003: 13; Shibuya & Smith 2002). A further 700 g of ice was reportedly seized  
in Palau in 2001 (UNODC Regional Centre for East Asia 2003: 10). Seizures of crystal 
methylamphetamine in Palau have averaged 3–7 kg per year for the past several years 
(INCB 2002: paras 565–567). Guam, too, has reported seizures of ice originating from  
the Philippines (INCB 2002: paras 565–567; UNDCP Regional Centre for East Asia 2003: 
13; Devaney, Reid & Baldwin 2006b: 305). One of the most recent cases reported in  
Guam involved a Korean national who was caught in possession of two kilograms of 
methylamphetamines (PIF 2006: 20). In a 2003 study of the illicit drug problem in the  
Pacific region, UNODC argued that:
With a growing ice abuse problem in some of the American Pacific islands  
in recent years, the surrounding Pacific islands could be at risk of becoming 
transshipment points for these drugs that are destined within the region. 
According to some sources, federal and local law enforcement officials now 
consider the heroin and cocaine traffic in Guam and the Northern Marianas to 
be small in comparison with ‘ice’ imports (UNODC Regional Centre for East 
Asia 2003: 10).
In Melanesia, much of the ATS trafficking seems to involve methylamphetamine and its 
precursors. There have been no reported ecstasy seizures in the Pacific Island countries 
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since a single detection in 2003 (PIF 2006: 22). In 2000, 0.333 kg of (unspecified) ATS were 
seized in Fiji (UNODC 2005: 316, 399). In 2002, 74 kg of methylamphetamine was found on 
a ship in Singapore headed for Fiji and Australia (Feizkah 2004). In 2003, UNODC reported 
of evidence of methylamphetamine importation into PNG by Filipino and Asian syndicates 
(UNDCP Regional Centre for East Asia 2003: 13). The seizure of a large scale illicit laboratory 
used for crystal methylamphetamine production in Fiji in June 2004, the seizure in Australia 
of 125 kg of ice from PR China in October 2004, along with significant seizures in New 
Zealand has led to suggestions ‘that Oceania may be emerging as a transit area for 
consignments of crystal methylamphetamine.’ (INCB 2006: paras 522, 638).
Trafficking in illicit drugs through the Pacific Islands occurs by air and sea, frequently using 
common commercial shipping and trading routes. The sea trade involves regular cargo 
vessels as well as small, private vessels that can be used to access shallow bays and 
beaches. The vulnerabilities of the Pacific Islands to trafficking are obvious: archipelagic 
coastlines, sea borders, and vast areas of ocean are difficult, if not impossible, to patrol, 
especially for countries with limited financial, technical, and human resources. This makes  
it easy, especially for small vessels to remain undetected and cross international borders 
clandestinely (Devaney, Reid & Baldwin 2006b: 304; Feizkah 2004). Moreover, the size  
of the seaborne trade across the Pacific is difficult to monitor and control. UNODC  
reports that:
There are about 5,000 vessels transiting the Pacific on any given day.  
Large shipments may be unloaded from a mother ship into a smaller vessel, 
and can subsequently go in hiding at the many small, uninhabited islets and 
atolls, waiting for the next step. Rapidly expanding regional transportation 
links to Asia, North and South America is also a factor and is likely to increase 
the use of islands as a transit area (UNODC Regional Centre for East Asia 
2003: 11).
The small amounts of ATS that are brought into the region for the purpose of local 
consumption are usually carried by couriers or drug mules on commercial flights and 
sometimes by parcel delivery. These two methods seem to be the preferred modi operandi 
for crystal methylamphetamine brought into Micronesian countries (Devaney, Reid & Baldwin 
2006b: 304). Unlike trafficking patterns in Australia and New Zealand there is, to date, no 
evidence of trafficking by way of concealed cargo shipments to Pacific Island destinations. 
The relatively small amounts of ATS consumed in the region perhaps do not warrant this 
type of operation. Bulk consignments of ATS apprehended on boats in the Pacific Islands 
are generally destined for drug markets in Australia, New Zealand, and North America 
(Devaney, Reid & Baldwin 2006b: 304).
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Organised crime involvement in ATS trafficking and importation
Knowledge about actual levels and types of organised crime involvement in the trafficking 
and importation of ATS in the region is very limited and frequently conflicting. In particular, 
there appears to be some disagreement among official reports and scholarly analysis about 
the scale and sophistication of ATS trafficking and importation. On the one hand it has been 
argued that organised crime involvement in the ATS trade in Australia and elsewhere in the 
region is limited because the local nature of ATS production, distribution, and consumption 
does not warrant the involvement of large, international criminal networks. On the other 
hand, there are reports which see the local ATS trade as part of big international enterprises 
with strong links to other parts of the Asia Pacific region and to other parts of the world. In 
reviewing the available evidence, it appears that both views are in fact closely related and 
that the degree of organised crime involvement in the ATS trade in Oceania varies from  
large international criminal syndicates to local amateur operations.
International studies on linkages between organised crime and ATS trafficking have found 
significant differences between different regions in the level and patterns of organised crime 
involvement. Some studies show that in east and southeast Asia the ATS trade is, for the 
most part, controlled by transnational criminal organisations that dominate supply and 
distribution. For example, it was found that the Japanese Yakuza controls much of the  
illegal methylamphetamine importation into Japan. In Myanmar, ethnic based groups who 
traditionally engaged in opium crop growing and opium trafficking are increasingly involved  
in the production and distribution of ATS. In contrast, in Europe, north America, and also in 
Australia and New Zealand, the criminal elements involved in the illicit ATS trade appear to 
be much more diverse, ranging from small amateur operations to global criminal syndicates 
(Chawla & Pietschmann 2005: 176).
Comprehensive research into the presence and magnitude of criminal organisations in 
Australia and in other parts of the region is very scarce and some of the available information 
is out of date. For example, the last major inquiry into organised crime in Australia was 
conducted in 1995 by the then Parliamentary Committee on the National Crime Authority. 
This inquiry focused specifically on Asian organised crime. It found ample evidence of 
Chinese and Vietnamese organised crime involvement in the heroin trade in Australia  
did not address their involvement in ATS trafficking (Australia. Parliament… 1995), possibly 
because of a lack of evidence at that time. In 2002, UNODC studied a number of criminal 
organisations and found that outlaw motorcycle gangs are a dominant group in the ATS 
trade in Australia. Other syndicates such as, for example, the McLean Group or the 
Japanese Yakuza may engage in cannabis and cocaine trafficking, but it was found that  
they are generally not involved in ATS supply and distribution (UNODC 2002: Appendix B).
Trafficking in ‘traditional’ narcotic drugs such as heroin and cocaine differs substantially from 
the ATS trade as the key ingredients of heroin and cocaine – opium and coca – are not 
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grown in Oceania, thus necessitating the creation of global transportation networks and 
wide ranging criminal organisations. In contrast, much of the ATS production (excluding 
ecstasy) is carried out within the region and the production process is simple and  
ingredients are, for the most part, easy to obtain. This frequently removes the need  
to engage in cross-border trafficking and allows for small scale, amateur operations  
(see Section 1 above).
In contrast to purely local, small scale ATS production and distribution, larger operations 
which involve the importation of precursor substances or finished products into the region 
require the involvement of persons in multiple locations and invite for the creation or use of 
transnational criminal networks. It was noted earlier that many precursor chemicals are 
sourced outside the region, that crystal methylamphetamine is usually imported from east 
Asia, and that ecstasy, for the most part, comes from European and some Asian sources. 
Trafficking of these substances to Australia, New Zealand, and the Pacific Islands covers 
long geographical distances and uses complex and often circuitous routes and transport 
systems to disguise operations and avoid border controls. It is therefore not surprising that 
the high end of ATS trafficking frequently involves international criminal syndicates. The AFP 
and NSW Police, for instance, report that trafficking in ecstasy to Australia is largely carried 
out by European organised crime groups from Belgium, Netherlands, the UK, and also Israel 
(AFP 2006: 4; NSW Crime Commission 2006: 2). In recent years, law enforcement agencies 
have reported greater ecstasy precursor seizures in Australia and in Asia and also made 
several arrests in the region of European chemists involved in illicit ecstasy production.  
This has led to suggestions that European syndicates involved in ecstasy production are 
moving some manufacturing to Asia and also Australia, bringing it closer to the place  
of consumption (Pieper 2006: 19–20; Chawla & Pietschmann 2005: 176). There is also 
evidence that criminal organisations engaged in heroin and cocaine trafficking increasingly 
diversify by using their established routes and networks for the distribution of ATS (ACC 
2005: 14; ACC 2003: 5–6; Cherney, O’Reilly & Grabosky 2005: 7). Given the shift of ecstasy 
and ATS trafficking to Asia it can be assumed that Asian syndicates are equally involved in 
the illicit ATS trade in the region, but there is, at present, no published material that identifies 
particular criminal organisation.
Thus, the trafficking in, importation and supply of ATS in Australia involves a variety of 
criminal elements ranging from highly sophisticated criminal organisations to small scale 
entrepreneurs who operate within small, local markets or friendship circles (ACC 2005: 14; 
ACC 2003: 5–6; AFP. ACT Policing 2006: 1). The Queensland Crime and Misconduct 
Commission, for example, has described the organised crime elements involved in the ATS 
trade as
fluid groups of criminals who share a common purpose. […] [T]he description 
of these groupings of criminal as ‘networks’ is for analytical convenience 
rather than an accurate reflection of the criminals’ intention (CMC 2006: 3).
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It seems that the ATS trade in WA, Qld, and SA is dominated by local, sometimes small 
scale networks, and all three states report the continuing involvement of outlaw motorcycle 
gangs in the domestic ATS trade (South Australia Police 2006; Western Australian Police 
2006: 1; CMC 2006: 3; ACC 2006b: 3). In contrast, the general experience of investigations 
made by the AFP and some state police forces seems to suggest that the trafficking and 
importation of ATS in Australia and the Pacific region is dominated by large Asian syndicates 
(pers. comm. AFP Border & International, 30 June 2006; Western Australian Police 2006:1). 
In Queensland, however, ‘there is currently an absence of large-scale ethnic criminal 
syndicates’ (CMC 2006: 8). There is also evidence that ecstasy from European sources is 
trafficked through southeast Asia by Asian criminal networks (Gordon 2001: 21–22).
A similar picture emerges from New Zealand, where ATS trafficking was initially carried  
out by outlaw motorcycle gangs with international connections (Wilkins 2002; Wilkins et al. 
2004b: 57). In a 2003 survey of persons working in drug enforcement and drug treatment  
in New Zealand most respondents confirmed that criminal gangs ‘have a wide influence’  
in methylamphetamine supply (Wilkins et al. 2004a). Recent reports suggest that outlaw 
motorcycle gangs remain dominant suppliers of ATS in New Zealand but no longer hold  
a monopoly position (Wilkins et al. 2004b: 57, 116–118).
The types and size of ATS seizures made in the Pacific Islands seem to suggest that 
transshipments of ATS in the Pacific Islands are part of transnational criminal enterprises  
and are not under the control of people belonging to the local population. The majority of 
reports about ATS trafficking in the Pacific Islands argue that most operations are organised 
by criminal networks operating outside the region, often in China, southeast Asia, Australia, 
or the United States (ACC 2004: 6; Devaney, Reid & Baldwin 2006b: 304, 305; Feizkah 
2004: 54; UNODC, Regional Centre for East Asia and the Pacific 2003). A recent analysis  
of the illicit drug market in the region also found evidence of subgroups of the Japanese 
Yakuza engaging in crystal methylamphetamine trafficking to the Northern Marianas 
(Devaney, Reid & Baldwin 2006b: 305).
Market factors in ATS trafficking and importation
The opportunities and profits of ATS trafficking and importation are determined by a variety 
of factors. These include, inter alia, the volume of domestic ATS production, types and 
quality of domestic production, precursor availability and prices in domestic and international 
markets, levels of law enforcement activities (including seizures and arrests) in production 
and transit points, volume of overseas ATS production, the number of transactions  
and trafficking steps needed between production, wholesale, and distribution points, 
requirements and availability of human resources, skills and know-how, carriers, suppliers, 
technical equipment, etc (Pietschmann 1997: 276).
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The existence and level of law enforcement activities that take place between illicit ATS 
production and retail sale impact significantly on the level of ATS trafficking, on the routes 
and types of trafficking, and ultimately on the prices for ATS and the profits that can be 
made in ATS trafficking and importation. High degrees of border control and law 
enforcement seizures warrant more sophisticated modi operandi to disguise the illicit 
substances and may necessitate the re-routing of shipments via less stringent transit  
points, thus making the operation more costly and increasing wholesale and retail prices 
(Pietschmann 1997: 278).
Drug seizures and arrests of persons involved in supply and delivery may also disrupt  
and, at times, destroy supply chains. Seizures and other losses reduce the availability  
of ATS in the illicit market. If, despite these losses and disruptions, levels of demand remain 
unchanged, prices for ATS increase thus raising profit margins further. ATS become more 
expensive if ‘it is highly risky to bring them to the market. The high prices they can fetch, 
however, create vast profits’ (Block 1993: 693). It has been argued that law enforcement 
activities that target the trafficking stage of the illicit ATS trade result in greater profits for 
criminal organisations as they factor ‘a “risk premium”, ie a compensation for the additional 
risks’ into their prices (Pietschmann 1997: 278).
As noted earlier, cross-border trafficking in and importation of ATS in Oceania largely 
involves more potent forms of ATS such as ecstasy and crystal methylamphetamine,  
while the local production in Australia for the most part involves ATS of lower quality, lesser 
purity and potency, and lower price. In simple terms, the domestic ATS production and  
trade involve substances of lower value in comparison to the international ATS trade.  
The domestic ATS production also frequently involves amateur operators with limited  
skills operating in small clandestine laboratories. International ATS trafficking, in contrast,  
is more commonly associated with large, sophisticated criminal enterprises. This pattern is 
unsurprising as transnational organised crime is more likely to engage in operations which 
involve products of greater value even though these products are more likely to be the focus 
of law enforcement activities. In this context, Block has argued that the degree of law 
enforcement activities also determines the quality of the products in the illicit market:
[T]he more severely [prohibition] is administered, the stronger will be the 
potency of the ensuing drugs. A smuggler would rather risk transporting a 
suitcase full of cocaine than marijuana because of its greater value. […] This, 
too, is the explanation for the most recent generation of chemical substitutes: 
crack, ice, PCP, etc. (Block 1993: 692).
Others have argued that profit margins are greater if levels of law enforcement and the 
associated risks of seizures are arrests are low. For example, it has been held that ‘the risks 
associated with manufacture and trafficking of [ATS] are definitely not larger than those 
associated with cocaine or heroin where several borders have to be crossed and law 
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enforcement authorities have developed skills in detection’. Consequently, an illicit drug 
market, such as that for ATS other than ecstasy, in which production, supply, and sale are 
confined to one jurisdiction, is seen by some as less vulnerable and thus more profitable.  
‘It is particularly this additional profitability’ of ATS, argues Pietschmann, ‘that goes beyond 
that of heroin or cocaine, which represents a special danger for fuelling further expansion  
in the future’ (1997: 275).
In 2005, UNODC made some model calculations about the income generated by trafficking 
in ecstasy and other ATS in Oceania. This calculation, shown in Table 18 below, takes into 
account the total amount (in weight) of ATS intended for sale and consumption in the region, 
the total of substances lost through seizures and otherwise, the total amount of ATS 
available for consumption, and the wholesale price.
Table 18: Income for ATS and ecstasy wholesale, Oceania
ATS (excl. ecstasy) Ecstasy
Total intended for consumption 9,286 kg 5,940 kg
Total seized/lost 569 kg 748 kg
Total available for consumption 8,718 kg 5,192 kg
Wholesale price per pure gram US$63 US$143
Wholesaler income US$550 million US$741 million
Source: UNODC 2005: 140
According to UNODC figures, approximately 9,286 kg of ATS other than ecstasy were 
intended for consumption in Oceania. Only 569 kg or approximately 6.1 percent of the  
total were lost or seized by law enforcement agencies, leaving 8,718 kg available for 
consumption. In other words, losses of ATS between production and wholesale are quite 
small. As much of the production of ATS is carried out locally in great quantities, and as  
law enforcement seizures only marginally reduce the quantity available for consumption, the 
wholesale price for ATS other than ecstasy is estimated to be comparatively low; ‘the closer 
the manufacturing site, the cheaper the product’ (UNODC 2003a: 7). According to UNODC 
data, the wholesale price in Oceania for ATS other than ecstasy is as low as US$63 per  
pure gram. This represents an increase of US$56 or 800 percent compared with the price  
at production level (c US$7 per gram; see Table 8 above).
UNODC estimated that the amount of ecstasy intended for consumption in Oceania was 
5,940 kg. It is suggested that 12.6 percent of that amount (749 kg) is lost in seizures or 
otherwise, leaving 5,192 kg of ecstasy available for consumption. As ecstasy is, for the  
most part, imported into the region and as greater quantities are lost to law enforcement 
agencies, the price for ecstasy increases greatly at the wholesale stage. UNODC estimated 
that the wholesale price for ecstasy was US$143 per gram; that is US$97 (or 300%) higher 
than the price at production level, resulting in a total income of US$741 million for ecstasy 
wholesalers.
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The data displayed in Table 18 confirm that profit margins at the trafficking stage are higher 
for ecstasy than for other ATS. Three principal reasons can be identified:
the amount of ecstasy intended for consumption in Oceania is smaller than the amount •	
of other ATS
unlike other ATS, ecstasy is almost exclusively imported into the region and often •	
trafficked across long distances
greater amounts of ecstasy (absolute and relative) are seized and otherwise lost  •	
in Oceania.
These three reasons were factored into the calculation of wholesale prices and resulted in 
greater profits for ecstasy trafficking; ‘[a]t each trafficking step the mark-up is still greater’ 
(UNODC 2003a: 7). This confirms earlier suggestions that profit margins for ecstasy 
traffickers and importers are remarkably higher although the illicit trade in ecstasy in  
Oceania is smaller in size than the trade in other ATS. Similar observations have been  
made in studies undertaken in the United States, United Kingdom, Germany, and Norway  
in the early 1990s where it was found that
[c]alculations of total gross profitability (total gross profits from both 
manufacturing and trafficking as a percent of initial costs of raw material) 
suggest that MDMA [ecstasy] may be the economically most attractive 
substance to manufacture and distribute, followed by methamphetamine and 
methcathinone (Pietschmann 1997: 282, 285 with reference to Saunders 
1994: 137).
ATS wholesale prices (excluding ecstasy)
Price and profitability for ATS wholesale vary between substances and also on the purity  
of the substances on offer. Table 19 shows price estimates for methylamphetamine at 
wholesale level in Australia and New Zealand in recent years. According to these figures,  
the wholesale price in Australia in 2004 averaged US$84,500 per kilogram of 
methylamphetamine (US$84.50 per gram). Actual wholesale prices depend on the  
purity of the substance involved which can vary between 3.7 percent and 77 percent. 
Accordingly, one kilogram of methylamphetamine may be as cheap as US$ 44,313, while 
purer and more potent forms of methylamphetamine sell for as much as US$118,168.
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Wholesale prices for methylamphetamine in New Zealand are much higher than those in 
Australia. This can be explained by the country’s more distant location, greater difficulties  
of obtaining precursor chemicals, and tighter border and law enforcement controls. It is 
estimated that the typical wholesale price for one kilogram of methylamphetamine was 
US$253,550 in 2004. Table 19 also shows that ‘typical’ wholesale prices in New Zealand 
increased by almost 29 percent between 2002 and 2003 and by a further 13 percent from 
2003 to 2004. This increase is surprising, given that local production and demand also rose 
at the same time, but it may be reflective of more methylamphetamine seizures and tighter 
law enforcement during that period.
Table 19: Wholesale price estimates, methylamphetamine, Australia and 
New Zealand, 2002–04
2002 2003 2004 
US$ / kg US$ / kg US$ / kg
Australia
Typical price/purity ($ / %) n.a. n.a. 84,500 / 38
Price range ($) n.a. n.a. 44,313 – 118,168
Purity range (%) n.a. n.a. 3.7 – 77
New Zealand
Typical price ($)  176,741  224,810  253,605
Price range ($) 160,670 – 192,810 204,370 – 245,250 230,550 – 276,660
Source: UNODC 2004: 381; 2005: 357–358; 2006: 378
Ecstasy wholesale prices
Table 20 shows ecstasy wholesale price estimates for Australia and New Zealand. From  
the limited data available, it seems that, as with other ATS, wholesale prices vary greatly 
depending on the purity of the substances on offer. Wholesale prices in New Zealand are 
again higher than those in Australia. It has been estimated that the typical wholesale price 
for ecstasy in Australia in 2004 was US$16,851 per 1,000 units (or US$16.51 per unit). In 
comparison, the typical price in New Zealand in 2003 was US$26,070 (or US$26.7 per unit). 
The price difference can be attributed to the greater distances and difficulties associated 
with importations into New Zealand.
64
Table 20: Wholesale price estimates, ecstasy, Australia and New Zealand, 
1999–2004
1999 2000 2001 2002 2003 2004
UNODC
US$/ 
1000 
units
US$/ 
1000 
units
US$/ 
1000 
units
US$/ 
1000 
units
US$/ 
1000 
units
US$/ 
1000 
units
Australia
Typical price/purity ($ / %) 12,735 n.a. n.a. n.a. n.a. 6,851 / 46
Price range ($) 9,590 –  
15,980
n.a. n.a. n.a. n.a. 11,078 –  
30,000
Purity range (%) n.a. n.a. n.a. n.a. n.a. 3.7 – 77.1
New Zealand
Typical price ($) 26,413 n.a. 23,854 25,050 26,070 n.a.
Price range ($) 21,130 –  
31,696
n.a. 16,913 –  
29,598
18,330 –  
31,880
17,380 –  
37,760
n.a.
Source: UNODCCP 2002: 209; 2003: 333; 2004: 385; 2005: 357; 2006: 380
Observations
The clandestine nature of trafficking in and importation of ATS into the countries of Oceania 
means that the available information about this aspect of the ATS trade is very limited. 
Existing knowledge stems largely from ATS seizures and little is known about the extent  
and nature of operations that remain undetected. Consequently, the available, open source 
information may not adequately reflect the true levels and patterns of ATS trafficking in  
the region.
On the basis of the existing data and research the following general observation about  
ATS trafficking in Oceania can be made:
ATS seizures in Australia and New Zealand have increased since the 1990s, although  •	
the number of seizures and the amount of ATS seized varies greatly between individual 
years.
Ecstasy seizures have increased rapidly and steadily in Australia and New Zealand. •	
Annual seizures of ecstasy in Australia are among the highest in the world. Ecstasy in 
Oceania is for the most part imported from Europe and increasingly from southeast Asia. 
Smaller amounts are also imported from north America.
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There is ample evidence that the Pacific Islands have been used for ATS trafficking and •	
that many island nations have been used as transit points for trafficking operations. The 
lack of comprehensive law enforcement and border control in the Pacific Islands means 
that the true levels of ATS trafficking are not known. There is some importation of crystal 
methylamphetamine into the former US territories in the region including Palau, the 
Northern Marianas, and Guam.
Patterns and levels of ATS trafficking in Oceania do not always reflect global trends. •	
Much of the illicit ATS trade is interregional and remains unaffected by developments 
elsewhere. This is different for ecstasy, where the trade is closely linked to Europe and 
southeast Asia.
Trafficking in and importation of ATS into Australia is largely done through cargo and •	
postal shipments. The use of drug mules and couriers or smuggling in personal luggage 
seems rare. Importation of crystal methylamphetamine into Micronesia, in contrast, is 
often done by drug couriers.
Most seizures of ATS are of medium size (trafficable quantities), though seizures of large, •	
commercial shipments of ATS are not uncommon. Ecstasy, particularly, is frequently 
imported into Australia in very large consignments.
Organised crime involvement in ATS trafficking in Oceania is not well documented  •	
and currently not well understood. There is evidence that the more sophisticated 
cross-border operations involving large quantities of ATS are facilitated by transnational 
criminal organisations while some of the purely domestic trade is carried out by 
amateurs, including locals. European syndicates, sometimes with the help of Asian 
groups, seem to dominate the illicit ecstasy trade. Outlaw motorcycle gangs have been 
and continue to be involved in the importation of other ATS, especially in Queensland, 
Western Australia, South Australia, and New Zealand.
Profit margins for ATS trafficking are greater for the more difficult operations  •	
which involve higher risks of detection and arrests. Patterns of trafficking are more 
sophisticated for potent ATS such as ecstasy and crystal methylamphetamine. 
Consequently, the profits made at the trafficking stage of these substances are  
also higher in comparison with ATS of lower potency and purity.
The increase in ATS seizures does not seem to have impacted noticeably on availability •	
and wholesale prices for ATS.
Chapter 4: 
Demand
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Against global trends, the use of ATS, including ecstasy, has grown substantially in Australia, 
New Zealand, and other parts of the region in recent years. Since 1988, ATS have been, 
after cannabis, the second most popular illicit drug in Australia and New Zealand (Hall & 
Hando 1993: 61; Hando & Hall 1997: 84; Yoshida 1997: 14). Ecstasy has become the third 
most popular substance. Especially among young people, abuse of ATS and ecstasy is 
much higher than of cocaine and heroin (UNODC 2003a: 2). At least since 1993, ATS use  
in Australia has been described as ‘epidemic’ (Hall & Hando 1993: 53–54), although use 
appears to have stabilised in the past few years.
According to estimates by UNODC, 25 million people worldwide, or 0.6 percent  
of the population, aged between 15 and 64 used ATS (excluding ecstasy) in 2005  
(UNODC 2007: 150). In addition, it is estimated that approximately 9 million people,  
or 0.2 percent, of the global population between 15 and 64 years used ecstasy during  
that period (UNODC 2007: 161). Other estimates made by WHO in 1997 suggested  
that more than 35 million people worldwide were regular users of amphetamine and 
methylamphetamine (Anglin et al. 2000: 139).
Levels of ATS and ecstasy abuse in Oceania are higher than anywhere else in the world. 
UNODC has consistently held that ‘the prevalence of [ATS] use is highest in the Oceania 
region’ (UNODC 2005: 112). UNODC estimates that 620,000 people or three percent of  
the population aged 15–64 years in Oceania used ATS in 2005. A further three percent  
(or 627,000 people) are said to have used ecstasy in that period (UNODC 2007: 151, 161). 
The problem of ATS and ecstasy abuse is particularly concentrated in Australia which 
continues to report the highest level of ATS and ecstasy abuse of any country in the world. 
Methylamphetamine and ecstasy are the second most prevalent drugs in Australia, after 
cannabis (UNODC 2003a: 58, 107; UNDCP 1996: 114; INCB 2006: para 640). Ecstasy 
abuse in Australia, too, has increased steadily since the beginning of data collection in 1985 
(UNDCP 1996: 114). In New Zealand, levels of abuse of these substances are lower than  
in Australia but are still above global averages. The following sections explore the levels  
of ATS consumption in Australia, New Zealand, and the Pacific Islands more closely and 
analyse the retail market for ATS in the region.
As with other data used in this study, the availability of statistics about consumption and 
demand is very limited, and these statistics are particularly prone to inaccuracy. UNODC 
collects and releases information about illicit drug abuse in its annual World drug report.  
The contents of this report and the quality of the data contained therein are dependent on 
information supplied by individual countries. It is the only international data collection of this 
kind. Many countries, however, do not provide information about levels of abuse to UNODC 
or to other international agencies. Frequently, the data are not collected annually or are not 
collected at all. Some countries are reluctant to disclose information about the levels of drug 
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consumption and other countries simply do not see ATS and other drug abuse as a problem 
worth investigating. But even if statistics about ATS consumption are kept, methodologies 
used to collect that data differ between countries. UNODC remarked that:
[a]ssessing the extent of drug abuse (the number of abusers) is a particularly 
difficult undertaking because it involves measuring the size of a hidden 
population. Margins of error are considerable, and tend to multiply as the 
scale of estimation is raised, from local to national, regional and global levels. 
Despite some improvements in recent years, estimates provided by member 
states to UNODC are still very heterogeneous in terms of quality and  
reliability. […]
One key problem in currently available prevalence estimates from countries is 
still the level of accuracy, which varies strongly from country to country. While 
a number of estimates are based on sound epidemiological surveys, some 
are obviously the result of guesswork (UNODC 2006: 403, 404, cf 403–416).
Thus, it is difficult, if not impossible, to compare the absolute numbers of drugs users 
between any two or more countries. It is more useful to look at developments within one 
country over a period of time and also compare the relative levels of abuse between different 
countries. With these limitations in mind, the following trends can be observed in relation to 
ATS consumption in Oceania.
ATS consumption in Australia and New Zealand
ATS (excluding ecstasy)
Amphetamine use in Australia has historically been quite high. Early amphetamine 
‘epidemics’ date back to the 1960s and 70s when medical practitioners frequently 
prescribed amphetamine in the belief its use was safe (see further Hall & Hando 1993: 59). 
Once the negative effects of ATS were understood, chemists, medical practitioners, and 
users stayed away from amphetamine. Once the adverse health and psychological effects  
of frequent amphetamine use became more popularly known, restrictions were introduced 
to prohibit availability and prescriptions of amphetamine, causing a decrease in licit 
consumption levels (Hando & Hall 1997: 82–83).
Research on the early emergence, levels, and patterns of illicit ATS consumption in Australia 
and New Zealand in the 1960s, 70s, and 80s is extremely limited. During that time, much  
of the concern of law enforcement activity and scholarly research was with opium, cocaine, 
and – periodically – with LSD abuse, and many researchers considered the ATS problem  
as negligible in comparison (Hall & Hando 1993: 61; cf McAllister, Moore & Makkai 1991). 
There is some evidence that the prohibition of ATS triggered a change in the composition 
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and characteristics of ATS users. When ATS were available legally over the counter or by 
prescription, the substances were mostly used orally by middle-aged, middle class women. 
The closure of licit avenues to obtain ATS was followed by the development of an illicit market 
for ATS production, distribution, and consumption, and subsequently ATS use shifted to 
mainly younger men who administered ATS by injection or otherwise (Hall & Hando 1993: 
60). It has been argued that the illicit use of amphetamine initially emerged among people 
who worked long hours or night shifts, truck drivers, and among students who consumed 
ATS to manage the pressures of academic demands. An article published in 1974 stated:
They are the plague of industrialised states, the premier drug of students, the 
middle class, and the military. They include the tranquilisers and stimulants 
upon which much of society relies in order to cope with the pressures of 
urban survival (Lessem 1974: 127–128).
ATS, and later ecstasy, also became very popular in nightclubs and at parties. It is for this 
reason that ATS are often associated with economic development, income growth, and 
urbanisation (Gordon 2001: 18) and are frequently referred to as party drugs, a term which 
disguises the illicit nature and harmful effects of the substances. To that end, the image  
and perception of ATS among consumers and among parts of the wider population are 
fundamentally different from that of many other illicit drugs such as heroin. This image  
of ATS and the description of these substances as recreational or party drugs assist 
significantly in the marketing of these substances and are an important tool to facilitate  
the sale of ATS by criminal organisations to new and young users.
Comprehensive statistics on the levels and patterns of ATS consumption in Australia and 
New Zealand are available from the mid 1990s onwards. Table 21 illustrates the prevalence 
of ATS use in Australia, and in New Zealand between 1996 and 2004. Data for the years not 
shown here are currently not available.
Table 21: Annual amphetamine use, population aged 15–64 years, 
Australia and New Zealand, 1996–2004 (percent)
1996 1997 1998 1999 2000 2001 2002 2003 2004
Australia 2.0 n.a. 3.6 n.a. 2.8a 4.0 n.a. n.a. 3.8
New Zealand n.a. n.a. 2.0 n.a. n.a. 3.4 n.a. n.a. n.a.
a: Figure for 2000–01 UNODC 2003a: 63
Source: UNODCCP 2002: 268; UNODC 2004: 401; 2005: 371–372; UNODC 2003b: 107; 2006: vol 2: 389
The data displayed in Table 21, although fragmentary, show a growth in the levels of 
amphetamine consumption in Australia over the past decade. The annual prevalence of 
amphetamine use among persons aged between 15 and 64 years doubled within a period 
of five years, between 1996 and 2001. From the limited information available, it appears that 
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there has been no further growth in the annual prevalence of abuse since 2001 and UNODC 
suggests that ‘use of amphetamines have shown significant declines over the past four 
years’ (UNODC 2006: 148) although only a slight decrease can be seen between 2001 and 
2004. New Zealand has equally, if somewhat belatedly, witnessed relatively high levels of 
amphetamine abuse. According to UNODC, 3.4 percent of persons aged 15–64 years used 
ATS in New Zealand in 2001; other studies show that approximately 10 percent of New 
Zealanders aged 18–29 (or 100,000 people) used ATS in that year (Wilkins et al. 2005).
Table 22: Annual ATS use, population aged 13–45 years, New Zealand, 
1998–2004 (percent)
1998 2001 2004
New Zealand 2.9 5.0 6.0
Source: Wilkins 2002; Wilkins et al. 2005
Research conducted in New Zealand confirms the trends identified by UNODC. Table 22 
shows that studies from New Zealand estimated the annual prevalence of ATS consumption 
in 2004 among persons aged 13 to 45 years to be 6 percent or 114,000 people. Further, it 
was found that the majority of consumers (90,000 people or 5% of the population in that 
age group) had used amphetamine (including methylamphetamine); three percent (62,000 
people) had consumed ecstasy, and one percent (16,000) crystal methylamphetamine 
(Wilkins et al. 2005; Wilkins et al. 2004b).
While the annual prevalence of abuse appears to be higher in New Zealand than in Australia, 
some research suggests that the lifetime prevalence is higher Australia. In 2001, 17 percent 
of Australians aged 15–45 were said to have tried an ATS during their lifetime in comparison 
with 12 percent of New Zealanders of that age group (Wilkins et al. 2004b: 49). With 
consumer rates in New Zealand growing in recent years, lifetime prevalence there has  
also increased since 2001.
The patterns and consequences of ATS consumption and the treatment of ATS users  
are beyond the scope of this study. A number of characteristics of ATS use in Oceania  
are relevant to determine the market for ATS, however, and the involvement of criminal 
organisations in that market. These characteristics include:
ATS have become the second most popular illicit drug in Australia and New Zealand •	
(after cannabis; Wilkins, Bhatta & Casswell 2002)
many amphetamine users show a pattern of poly-drug use (Wilkins et al. 2005;  •	
Hando & Hall 1997: 91; Wilkins et al. 2004b: 31; Mouzos et al. 2007)
levels of ATS use in Australia and New Zealand are especially high among young people •	
in their 20s (Hando & Hall 1997: 84; Wilkins et al. 2004b: 39; cf Mouzos et al. 2007)
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levels of amphetamine use are higher among men than women (Hando & Hall 1997:  •	
84, 85; Wilkins et al. 2004b: 24, 38; cf Mouzos et al. 2007)
ATS use is more common among tertiary students and people in full-time employment •	
than in other parts of society (Wilkins et al. 2004b: 41)
methylamphetamine is frequently consumed at nightclubs, dance parties and raves,  •	
and in private circles (NDARC 2005: 50, 54)
ATS purchases are most frequently made in private homes (approximately 58%) and in •	
streets and alleys (around 28%). Purchases in public buildings or by home delivery are 
less common (AIC 2000–07: Q17c)
ATS are often perceived by consumers as safe and non-addictive (Wilkins et al. 2005).•	
Ecstasy
In comparison with amphetamine and methylamphetamine, MDMA and other ecstasy-type 
stimulants have a much shorter history of abuse in Oceania. Surveys conducted as recently 
as 1988 suggested that MDMA use in Australia was too low to be reliably measured (Hall & 
Hando 1993: 63). Ecstasy abuse started to spread from very low levels in the early 1990s. 
At that time some Australian researchers predicted
that MDMA use was self-limiting. The euphoric effects which were usually 
experienced during the first few occasions of use soon disappeared, perhaps 
because of a rapid development of tolerance to the drug. When larger doses 
were taken in an attempt to regain the euphoric effects, the unpleasant 
side-effects overwhelmed the positive effects (Hall & Hando 1993: 64).
One additional difficulty in assessing the levels and patterns of ecstasy abuse stems from 
the fact that frequently substances are sold as ecstasy even though they are not MDMA, 
MDA or MDEA, and many users are not aware of this fact. This means that some users  
may falsely report the use of ecstasy (Degenhardt et al. 2004: 194; McGregor & Makkai 
2003; Mouzos et al. 2007: 11).
In 2007, UNODC estimated that 627,000 people or three percent of the population aged 
15–64 years in Oceania consumed ecstasy annually in 2005. This is the highest annual 
prevalence of ecstasy use of any region in the world (UNODC 2007: 161). In recent years, 
consumption rates for ecstasy have exceeded those for other ATS, demonstrating its 
growing popularity. The limited data available (shown in Table 23 Figure 10 below) illustrate 
the steady increase in levels of ecstasy consumption in Australia and New Zealand between 
1996 and 2004.
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Table 23: Annual ecstasy use, population aged 15–64, Australia and  
New Zealand, 1996–2004 (percent)
1996 1997 1998 1999 2000 2001 2002 2003 2004
Australia 1.0 n.a. 2.4 n.a. n.a. 3.4a n.a. n.a. 4.0
New Zealand n.a. n.a. 1.0 n.a. n.a. 2.2 n.a. n.a. n.a.
a: A survey published in 2004 reported that 2.9% of Australians aged 14 and older used ecstasy in 2001  
(Degenhardt et al. 2004: 189)
Source: UNODCCP 2002: 268; UNODC 2003b: 107; 2004: 401; 2005: 371–2; 2006: 390. Similar data can be found 
in NDARC 2006: 24
Figure 10: Annual ecstasy use, population aged 15–64, Australia and  
New Zealand, 1996–2004 (percent)
Source: UNODCCP 2002: 268; UNODC 2003b: 107; 2004: 401; 2005: 371–2; 2006: 390. Similar data can be found 
in NDARC 2006: 24
The increase in ecstasy use between 1996 and 2004 is particularly significant in Australia, 
which is said to have the highest consumption rate of ecstasy in the world. While data from 
New Zealand are limited, that country also reports very high levels of ecstasy prevalence. 
This is confirmed by other research undertaken in New Zealand which suggests that the 
annual prevalence of abuse as a percentage of the population aged 13–45 years increased 
from 1.5 percent in 1998 to 3.4 percent in 2001 (Wilkins 2002; Wilkins et al. 2005). The 
majority of sources anticipate a further increase in MDMA consumption in Australia and  
New Zealand in coming years, especially if supply from Asia continues to grow (NSW Police 
2006: 9).
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The magnitude of the ecstasy abuse problem in the region, especially in Australia, has 
triggered a number of inquiries into the user population of ecstasy, the circumstances that 
lead to ecstasy abuse, general patterns of abuse, and treatment of users. NDARC, for 
instance, has published a plethora of research on the consumer aspects of the illicit ATS 
trade. Table 24 illustrates some of the demographics of regular ecstasy users in Australia  
in 2003, 2004, and 2005.
Table 24: Demographic dataa of regular ecstasy users, Australia, 2003–05
2003 2004 2005
Mean age (years) 25 24 24
First use of ecstasy (median age, years) 18 18 19
Mean years of school education 12 12 12
Tertiary education (%) 46 50 50
Full-time employment (%) 30 37 35
Full-time students (%) 22 21 24
a: national average
Source: NDARC 2004: 10; NDARC 2006: 21
A number of characteristics of ecstasy consumption emerge from NDARC surveys and 
other research. These characteristics include, inter alia:
Ecstasy use is more common among young people, especially those aged 20–29 years. •	
According to Australian data, the highest levels of abuse are among persons aged 
20–29 years, followed by 14–19 year-olds. A survey published in 2004 found that  
10.4 percent (or 273,000) of persons aged 20–29 years and 5.0 percent (86,000)  
of persons aged 14–19 years used ecstasy in 2001 (Degenhardt et al. 2004: 189; 
NDARC 2006: 15–16). Equally in New Zealand, ecstasy use is most common among 
persons aged 20–29 years (Wilkins et al. 2004b: 39).
Ecstasy users are often of middle class background, caucasian, slightly more likely  •	
to be male, and frequently have tertiary qualifications or are studying towards them 
(Degenhardt et al. 2004: 188, 193; Wilkins et al. 2004b: 25, 38, 41). As a result the 
image of ecstasy is often associated with affluence and success (Wilkins et al. 2005).
Ecstasy consumption frequently occurs at nightclubs, raves and dance parties, pubs,  •	
or in private circles (NDARC 2006: 21; Webb 2003: 82–83).
As with other ATS, poly-drug use is common among (experienced) ecstasy users; •	
‘ecstasy users can rarely be considered users of this drug only’ (Degenhardt et al. 2004: 
193; NDARC 2006: 15–16; Wilkins et al. 2004b: 30).
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Crystal methylamphetamine
In recent years there has been growing concern in the region about increasing evidence  
of widespread abuse of crystal (crystalline) methylamphetamine, also referred to as ice,  
or as P (New Zealand), shabu (Philippines), syabu (Malaysia), and philopon (Korea). Crystal 
methylamphetamine is of much higher purity (up to 80%) than other methylamphetamine 
sold on the illicit market (which usually ranges between 1% and 40% purity) (Caldicott et al. 
2005: 158). Crystal methylamphetamine is most commonly used by way of inhalation using 
a glass pipe, although smoking, snorting, oral administration and injection also occur (Topp 
et al. 2002: 346).
The consumption of crystal methylamphetamine has been relatively common in some  
parts of east and southeast Asia (Gordon 2001: 18) for some time and has also emerged  
as a major problem in some parts of the Pacific, especially in Hawai’i and the former  
US territories of Palau and Northern Marianas. In Japan, Philippines, Brunei Darussalam, 
Singapore, and Malaysia, crystal methylamphetamine has become the main type of ATS 
used. Indonesia, too, is experiencing growing levels of crystal methylamphetamine 
consumption (UNODC Regional Centre for East Asia 2004: 7, 11–12).
Despite growing concern and increased media attention, the demand for, and abuse of, 
crystal methylamphetamine in Australia and New Zealand are not well documented and  
not well researched or understood. The situation is complicated by the fact that many 
studies do not isolate the information on crystal methylamphetamine from other ATS and 
that frequently, unknown to consumers, low purity methylamphetamine is marketed as ice. 
The limited research on crystal methylamphetamine suggests that the substance made  
a first, albeit very limited, appearance on the Australian illicit drug market in 1998. By 2001, 
availability and use had increased markedly, especially in Sydney (Topp et al. 2002: 342, 
346). Today, every state and territory in Australia reports anecdotally of increases in  
crystal methylamphetamine availability and use (Pieper 2006: 19). The increase of crystal 
methylamphetamine availability is also documented in increased seizures of ice imports by 
ACS (see chapter 3). It appears that crystal methylamphetamine consumption was initially 
more common in private homes and private circles (NDARC 2006: 57). More recently, there 
have been a growing number of reports of increased crystal methylamphetamine use among 
‘party drug users’ in public places such as nightclubs, raves, and pubs (SA Police 2006), 
and among police detainees (Mouzos et al. 2007: 16).
Research conducted in New Zealand has shown an increase in use of crystal 
methylamphetamine starting in the late 1990s. Between 1998 and 2001, annual 
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prevalence of crystal methylamphetamine abuse among persons aged 15 to 45 years 
increased from 0.1 percent to 0.9 percent (Wilkins, Bhatta & Casswell 2002: 258).
There is, to date, no comprehensive study of the user population of crystal 
methylamphetamine in Australia and New Zealand. From the limited research and some 
media reports it seems that there are two main clusters of crystal methylamphetamine users:
in the nightclub and party scene (who usually inhale the substance)•	
among people (often without employment) with a history of drug addiction, especially •	
heroin (who usually inject crystal methylamphetamine).
As with other ATS, consumption is more common among young people and among men, 
and poly-drug consumption is also common (Wilkins et al. 2005; Wilkins et al. 2004b: 32, 
41–42; The ice age 2006).
ATS consumption in the Pacific Islands
Data and other information about illicit drug use in the Pacific Islands are extremely  
limited. There are no formal drug abuse monitoring systems in place and many reports  
are anecdotal, not supported by evidence, and usually only relate to single incidents and 
countries. There is no comprehensive knowledge on the levels of illicit drug use in the island 
nations and the countries have not contributed any data to UNODC’s annual World drug 
report on this point.
The market for amphetamines and methylamphetamines in the Pacific Islands is very limited 
given the availability of, tolerance towards, and relative low cost of other locally produced 
substances. Historically, drug abuse in the Pacific has revolved around substances such as 
cannabis, and also kava and betelnut in the Melanesian islands (Devaney, Reid & Baldwin 
2006b: 15, 300; Halvaksz 2006: 56–58). UNODC has pointed out that ‘[t]here is little 
indication of any significant import of drugs to the Pacific Islands’ (UNODC Regional Centre 
for East Asia 2003: 10). As a result, abuse of opium or coca based substances is extremely 
rare. Equally, the use of ATS is not widespread among the populations in the Pacific Islands 
(UNODC Regional Centre for East Asia 2003: 16; Devaney, Reid & Baldwin 2006b: 82). The 
buying power of the local populations is very low and the great majority of people simply 
cannot afford expensive, imported illicit drugs (Devaney, Reid & Baldwin 2006b: 16, 301). 
There have so far only been anecdotal reports about ecstasy being sold among tourists  
in Nadi, Fiji (PIF, pers comm. 3 July 2006), and Papua New Guinea has witnessed some 
isolated cases of ecstasy abuse (UNODC Regional Centre for East Asia 2003: 16).
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An exception to the general view that ATS are not widespread in the Pacific Islands exists  
in the former US jurisdictions of Palau and Northern Marianas, and also in Guam and 
Hawai’i. In these territories there is significant evidence of methylamphetamine consumption, 
especially in the form of crystal methylamphetamine. Consumption started in about  
1990 when the substance was first introduced from Korea and the Philippines (Devaney, 
Reid & Baldwin 2006b: 301, 305, 307; Feizkah 2004: 54; INCB 2005: paras 622, 638; 
UNDCP Regional Centre for East Asia and the Pacific 2003: 18; UNODC Regional Centre  
for East Asia and the Pacific 2003: 16). According to some sources, the consumption in the 
Northern Marianas is concentrated among elite parts of society. The drug situation in the 
Marianas has been described as ‘endemic’ and has led to increased levels of violent and 
other crime in the capital Saipan (Crocombe 2001: 86, 370). There have also been some 
suggestions that consumption of crystal methylamphetamine among Pacific Islanders on  
the US west coast and in Hawai’i explains the relatively higher levels of use among ethnic 
Polynesian and Micronesian groups in New Zealand (Wilkins et al. 2005; Wilkins et al. 
2004b: 40; see further Joe 1995). One recent report stated that methylamphetamine 
consumption can also be found in French Polynesia (Devaney, Reid & Baldwin 2006b: 301), 
but there is currently no further evidence to support this claim.
The principal problems with ATS in the Pacific, as has been shown in previous chapters,  
are trafficking in ATS through the region and some evidence of local production. There is 
growing concern that the production and trafficking of these substances in the region may 
ultimately result in growing consumption of ATS by local populations (Devaney, Reid & 
Baldwin 2006b: 16, 304; UNODC Regional Centre for East Asia 2003: 10). For example, 
Gordon suggested that ‘history shows that where any country is used as a conduit for drug 
smuggling, inevitably some of the product seeps into the local populace’ (Gordon c2003). 
Equally, Shibuya and Smith have argued:
[w]hile it was once true, due to economic constraints such a low incomes, 
that there was no viable market for drugs in most island states this is now 
changing. States that act as transit zones eventually become consumers of 
these same drugs – a pattern that has emerged in other parts of the world 
(Shibuya & Smith 2002).
ATS retailing in Oceania
The size and continuing growth of the illicit ATS market in Oceania are direct results of the 
very high demand for these substances. The level of demand is the most significant factor  
in determining the size of the market and the profits that can be made in this market. The 
following sections examine the retail market of ATS and the retail prices of ATS in Oceania.
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Retail market
The size of the retail market for ATS and the profits that can be achieved in that market  
are determined by a variety of factors. Production and supply of ATS, which have been 
discussed in chapters 2 and 3 of this study, have an important impact on the size of the 
demand for ATS. Greater availability of ATS and improved trafficking and supply networks 
contribute directly to a rise in the level of demand and are thus important for market growth 
(Pietschmann 1997: 279). Furthermore, the nature and level of competition in that market – 
competition between different suppliers and with other illicit drugs – impact on the size and 
profits of the retail market. The marketing and image of the substances sold, the health risks 
associated with drug consumption, and any risks of arrest and seizure are further factors 
that determine the demand for and use of ATS (Pietschmann 1997: 276).
It has been estimated that the total illicit drug market in Oceania amounted to about  
US$16 billion in 2005. This estimate is based only on data from Australia and New Zealand. 
In relation to the population in the region, this means that the average per capita spending 
on illicit drugs in Oceania is US$502 or 2.6 percent of GDP (2003). This figure is 10 times 
higher than the global average of US$51 per capita (0.9% of GDP, 2003). UNODC confirms 
‘that the highest expenditures on drugs per year are found in the Oceania region […]. 
Expressed as a percentage of GDP, drug sales (at the retail level) seem to be most important 
in the Oceania region’ (UNODC 2005: 139). It is said that Australia has the highest level of 
spending on illicit drugs of any country in the world (Calvani 2006: 10). Similar observations 
have been made about New Zealand. Here, research has shown that ATS users spend on 
average approximately NZ$1,085 per year on amphetamine. Ecstasy users in New Zealand 
are said to spend on average NZ$592 per year on ecstasy (Wilkins et al. 2004b: 63).
ATS including ecstasy make up about 25 percent of the illicit drug retail market in Oceania. 
UNODC estimates that the total retailer income for ATS in Oceania amounts to almost  
US$4 billion, including approximately US$2.3 billion for ATS sales and US$1.55 billion  
for ecstasy sales (Table 25). Other research published in New Zealand estimated that the 
domestic retail market for amphetamine in New Zealand was NZ$122.5 million and, for 
ecstasy, NZ$45.8 million (Wilkins et al. 2004b: 63).
ATS sales in Oceania represent approximately 8 percent of the global ATS retail market 
(excluding ecstasy). In comparison, the ATS retail market in Europe only accounts for 
approximately US$2 billion or seven percent of global sales (UNODC 2005: 141). Ecstasy 
sales in Oceania make up approximately 10 percent of the global market (UNODC 2005: 
143); a very significant margin relative to the small population of the region.
78
Table 25: ATS and ecstasy supply and demand in Oceania
ATS (excl. ecstasy) Ecstasy
Estimated user population 794,000 519,000
Estimated actual annual consumption 7,846 kg 5,192 kg
Implied consumption per user 10 g 10 g
Average retail price per pure gm US$293 US$298
Retailer income US$2,296 million US$1,549 million
Source: UNODC 2005: 140
ATS other than ecstasy
Table 25 and Figure 11 show that profit margins for ATS supply are particularly high at the 
final retail stage, especially for ATS other than ecstasy. UNODC estimates that the retail price 
per pure gram of ATS (not including ecstasy) in Oceania is US$293, US$230 more than the 
wholesale price per gram (see chapter 3 above). Other reports confirm ‘that the mark-up 
between the wholesale and retail value of ATS’ can be extremely high (Cherney, O’Reilly & 
Grabosky 2005: 7). In comparison, profit margins for ATS producers and traffickers are 
significantly lower than for ATS retailers.
Figure 11: Prices for ATS and ecstasy at production, wholesale, and retail 
stages, Oceania (US$)
Source: UNODC 2005: 140, 142
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The significant difference between wholesale prices and retail prices for ATS may reflect  
the greater risks of detection, arrest, and seizure associated with ATS sales. These risks are 
said to translate into a surcharge for retail sales. It has to be noted, however, that, as was 
mentioned earlier, the production of ATS other than ecstasy is usually carried out in close 
geographic proximity to end users. Consequently, the persons selling the substances to end 
users may be closely associated with (or may even be identical to) the persons supplying 
and producing the substances. As a result, ATS retail profits, wholesale profits, and 
manufacturing profits may all remain with a closely associated group of people.
The distance between place of production and place of final sale has an obvious bearing  
on the pricing of, and profit margins for, ATS (UNODC 2003a: 8, 44). The significant 
difference between wholesale, and retail prices for ATS other than ecstasy has been 
attributed by UNODC:
low costs, high profits, easily camouflaged labs and manufacturing close to 
retailing are incentives for organised crime’s involvement in ATS. Small capital 
investment, ease of manufacturing, low costs for precursors and equipment, 
and high volumes make the ATS business extremely lucrative, despite the low 
(unit) prices. Similar economic incentives are unavailable to the producers of 
cocaine and heroin, for example (UNODC 2003a: 5).
Ecstasy
A slightly different picture emerges for the retail market for ecstasy in Oceania where the 
profit margin for retailers is relatively smaller. UNODC estimates that retailer income per  
gram of ecstasy is US$298. That is US$143 or approximately 200 percent more than the 
wholesale income (chapter 3). Thus, in comparison with other ATS, profit margins in the illicit 
ecstasy trade are equally high and are more evenly spread between wholesale and retail 
levels (see Figure 11). This may be explained by the fact that production, wholesale,  
and retail places for ecstasy are geographically distant and that every stage between 
manufacturing and final sale involves additional expenses and dangers that are factored  
into the wholesale and retail prices.
Retail prices
As with goods and services available on the legal market, retail prices for ATS are 
determined by the demand for and supply of these substances. Profit margins for criminal 
organisations involved in the ATS trade are high as long as there is a significant demand, 
and supply is readily available. To ensure high levels of demand it is necessary to keep retail 
prices relatively low, otherwise substances may be seen by some users as a prohibitively 
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expensive, thus deterring some of the demand (Pietschmann 1997: 276). In general, higher 
prices tend to result in lower demand for drugs. Financial restraints bar the majority of a 
consumer population from purchasing expensive drugs, especially if illicit drugs with similar 
pharmacological effects are available more cheaply. Only a small segment of consumers, 
especially those who are heavily drug dependent, may have recourse to criminal activities  
to overcome the financial restraints to purchase illicit drugs (Pietschmann 1997: 278).
Retail prices for ATS do not automatically reflect the actual costs associated with their 
production and distribution. Retail prices are also influenced by many other factors, some  
of which cannot be quantified. For example, ATS sales prices are also determined by the 
availability of and competition from similar drugs and the competition between different 
producers and suppliers. A number of studies have shown that illicit drugs with similar 
pharmacological properties compete in the marketplace and that the retail price for these 
drugs determines consumer behaviour (Pietschmann 1997: 277). Contributing to the 
competition between ATS and other illicit drugs such as LSD and cannabis is the fact that 
these substances can be offered more cheaply than ATS and, in the case of cannabis,  
also pose fewer health risks than ATS (Wilkins, Bhatta & Casswell 2002: 260–261). Other 
research has shown that the hazardous health and psychological effects of amphetamine 
use are a significant deterrent to existing and potential users (Hando & Hall 1997: 83).
To compete with other drugs in the illicit market, retail prices for illicit drugs, may, at times, 
be deliberately deflated to increase demand. For example, there appears to be some 
interaction between the retail prices for the various ATS and cocaine, which is chemically 
different from ATS, but shares some pharmacological similarities (except that its effects last 
for a shorter time than those of ATS; see Chesher 1993: 19–20). It has been observed that 
ATS sales, which are generally cheaper than cocaine, benefited from high cocaine prices 
(Pietschmann 1997: 279). There have recently been some allegations that low ATS retail 
prices forced Colombian drug cartels to reduce the retail price for cocaine, sometimes 
below wholesale price, to compete with ATS and create interest in and demand for cocaine.
Despite the competition with other illicit drugs, the emergence and growth of the illicit ATS 
market in Oceania has not substituted the market for other illicit drugs, and will not do so.  
It has been found that the ATS market emerged alongside existing illicit drug markets; it did 
not replace them. The illicit ATS trade is closely linked to the trade in other illicit drugs and 
criminal organisations, especially those that engage in cross-border trade, frequently supply 
and sell more than one drug and use trafficking and supply channels for a variety of illicit 
drugs (Gordon 2001: 20).
It was noted earlier that domestically produced drugs are relatively cheaper and have high 
profit margins at the retail level. In comparison, imported drugs are more expensive and 
have lower profit margins at the retail level, but higher profit margins at production and 
wholesale stages. Similar observations have been made by UNODC which confirm that the 
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distance to the manufacturing site has a direct impact on the retail price. Even locally within 
one country, there is a clear connection between retail prices and the proximity of the 
manufacturing site. Concentration of ATS production in one part of the country may result  
in lower retail prices in that geographical area. This is illustrated in southeast Queensland 
where concentration of illicit ATS production is particularly high and prices are comparatively 
low. UNODC observed that in ‘2001 prices in Queensland (a major source of 
methylamphetamine) were 1/3 less than those in neighbouring New South Wales,  
and significantly less than in Victoria or Northern Territory’ (UNODC 2003a: 8, 44).
In New Zealand, in contrast, domestic production has only recently been established, which 
meant that retail prices were comparatively high. As local production continues to grow, it is 
anticipated that retail prices will decrease in New Zealand (Wilkins, Bhatta & Casswell 2002: 
260). Wilkins and his research team (2005) remarked that lower prices in New Zealand 
indicate that conditions for supply have improved and that supply is becoming less costly.
Information regarding the prices paid for ATS in Australia, New Zealand, and the Pacific 
Islands is limited and, at times, conflicting. The clandestine nature of the sales transactions 
and the unwillingness of consumers and suppliers to disclose any information mean that 
many estimates remain speculative and are frequently based on very small samples.
A further difficulty in establishing and comparing retail prices arises from the lack of 
information on the quality and purity of the substances sold. As was shown earlier, ATS 
prices vary significantly depending on the type and purity of the substance of offer (see 
Section 2 above). Many consumers – and sometimes suppliers, too – do not know the 
quality of their products and have no opportunity to examine the substances. It has also 
been observed that ATS sales frequently involve fraudulent and overpriced drugs (Wilkins, 
Bhatta & Casswell 2002: 261). For example, a common pattern observed in the ecstasy 
supply in Australia and New Zealand, is that many tablets sold as ecstasy to consumers do 
not actually contain MDMA. Unknown to the buyer, tablets containing methylamphetamine, 
sometimes in combination with ketamine, are sold as ecstasy to reap the generally higher 
prices paid for MDMA (NDARC 2006: 15; Wilkins et al. 2005; Mouzos et al. 2007).
Estimates and surveys of ATS retail prices are only available for Australia and New Zealand 
and not for the Pacific Islands. Data are currently collected by three main sources: UNODC, 
the ACC and NDARC. UNODC publishes retail price estimates in its annual World drug 
report. These data are useful to draw comparisons between different years and, more so, 
between different countries. UNODC, however, relies on the accuracy of data provided  
to it by countries, and many countries do not provide that information or do not provide  
it every year. As a result, UNODC information about retail prices has many gaps. More 
comprehensive datasets are generated annually by the ACC. ACC data are limited to 
information provided by law enforcement agencies in Australia and cannot be compared 
with information collected abroad. Starting in 2003, NDARC also began to publish annual 
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surveys about price estimates for ATS and other illicit drugs. This information is available  
for all eight Australian jurisdictions but NDARC does not calculate a national average price. 
Figures are only available for the years 2003, 2004, and 2005 and it has to be noted that  
the NDARC data are based on very small, non-random samples which may not adequately 
reflect actual prices and price margins. Given the differences in which the information  
about retail prices is sourced, processed, and categorised, it is impossible to draw direct 
comparisons between the UNODC, ACC, and NDARC reports. Furthermore, the data are 
released in different measuring units and different currencies. However, some common 
trends and patterns can be observed in all three reports.
ATS (excluding ecstasy)
UNODC data on retail prices for ATS are particularly fragmentary and only available for 
Australia for the years 1999 and 2003. According to these reports, the per gram street price 
for amphetamine in Australia dropped from US$118.40 in 1999 to US$95.80 in 2003.
Retail price estimates for ATS published by the ACC show different trends for the six 
Australian states and there appears to be no common or national trend among them.  
The variation of retail prices within one jurisdiction in any one year is also very great and 
average prices are not available.
Table 26: Retail price estimates, ATS, Australia, 1998–2006
1998 1999 2000 2001 2002 2003 2004 2005 2006
UNODCa US$/g US$/g US$/g US$/g US$/g US$/g US$/g US$/g US$/g
Australia n.a. 118 n.a. n.a. n.a. 96 n.a. n.a. n.a.
1997–
98
1998–
99
1999–
2000
2000–
01
2001–
02
2002–
03
2003–
04
2004–
05
2005–
06
ACC AU$/g AU$/g AU$/g AU$/g AU$/g AU$/g AU$/g AU$/g AU$/g
NSW 100 19–120 40–150 90–120 n.a. 500 90–500 90–500 100–500
Qld n.a. n.a. 370 70–90 n.a. 200–250 200–250 200–300 250–350
SA n.a. n.a. 50 n.a. n.a. 200 n.a. 40–250 30–500
Tas 100–120 70–80 70–80 60–70 60–70 400 200–400 n.a. n.a.
Vic n.a. n.a. 50–100 300 200 200–250 200–250 230–280 180–230
WA 100 n.a. 150–300 n.a. 250 250–500 200–400 450 250–600
a: Price refers to typical retail price irrespective of range and purity
Source: UNODCCP 2002: 209, 211; UNODC 2004: 385; 2005: 357; ACC and ABCI 1998–2007
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In summary, the available information on ATS retail prices in Australia, shown in Table 26, 
does not show any significant change or trend in the 1997–2006 period. ACC figures seem 
to indicate that the maximum prices paid for ATS have increased in some parts of Australia 
but there is no clear indication that average street prices have increased. UNODC data  
show a modest drop in ATS retail prices between 1999 and 2003. The lack of any significant 
change in ATS retail prices in recent years is remarkable as the period between 1997 and 
2006 saw significant seizures of ATS (see chapter 3). These seizures, however, have been 
outweighed by growing ATS production during the same period, thus retail prices remained 
relatively stable.
In examining Australia’s three biggest jurisdictions (NSW, Vic and Qld), it appears that  
in NSW, prices for ATS increased between 1997–98 and 2002–03 and remained stable 
between 2003–04 and 2005–06. ATS price estimates for NSW show an increasingly great 
variation between highest and lowest prices paid. This may reflect different purities available 
on the illicit drug market in that state.
Figure 12: ATS price estimates, NSW, 1997–98 to 2005–06
Source: ABCI and ACC 1998–2007
In Victoria, retail prices for ATS have been more stable in recent years and there is only little 
variation between maximum and minimum prices. Average prices for ATS are very similar to 
those reported in NSW, averaging approximately $250 per pure gram.
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Figure 13: ATS price estimates, Victoria, 1999–2000 to 2005–06
Source: ABCI and ACC 2000–07
Retail prices in Queensland appear to be at the same level as prices in New South Wales 
and Victoria. In contrast to the southern states, prices dropped after 1999–2000 and have 
since risen, albeit very slowly (see Figure 14).
Figure 14: ATS price estimates, Queensland, 1999–2000 to 2005–06
Source: ABCI and ACC 2000–07
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Retail prices for ATS in New Zealand are not well documented and UNODC reports  
contain no information on ATS retail prices in New Zealand. Other research estimated  
that the average price per gram of pure amphetamine in New Zealand was approximately 
NZ$80–200, averaging about NZ$142 per gram in 2001 (Wilkins et al. 2004b: 34, 63).
Ecstasy
UNODC data on retail prices for ecstasy in Australia are only available for the years 1999, 
2001, 2003, and 2004. From the limited information available (Table 27), it appears that retail 
prices have remained stable, averaging approximately US$30 in most years. As with other 
ATS, retail prices vary depending on the purity of the substances sold. The figures for 2004 
showed that ecstasy of low purity was as cheap as US$18 per gram while more pure 
varieties could be as expensive as US$60.
Data by the ACC for the six Australian states also do not show any significant changes  
in the street price for ecstasy in recent years (Table 27). Data collected by NDARC (which 
relates to prices per tablet rather than per gram) in the years 2003–05 also do not show any 
noticeable changes in retail prices and largely confirm the information provided by UNODC 
and the ACC. Prices remained stable in all jurisdictions and there was no great difference  
in retail prices around Australia. The significant seizures of ecstasy in recent years did not 
translate into higher retail prices in the illicit drug market. Greater and more effective law 
enforcement measures adopted in recent years did not disrupt or otherwise affect the 
ecstasy retail market as levels of demand also continued to be high in recent years. This 
suggests that seizures and other losses have been offset by greater levels of ecstasy 
importation and possibly by domestic production.
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Table 27: Retail price estimatesa, ecstasy 1998–2006
1998 1999 2000 2001 2002 2003 2004 2005 2006
UNODC US$/g US$/g US$/g US$/g US$/g US$/g US$/g US$/g US$/g
NZ n.a. n.a. n.a. n.a. n.a. 41 Av: $49 
($40–59)
n.a. n.a.
Australia n.a. 30 n.a. 29 n.a. 17b Av: $32 (31%)
($18–60)
1.5–90.6% 
purity)
n.a. n.a.
1997–
98
1998–
99
1999–
2000
2000–
01
2001–
02
2002–
03
2003– 
04
2004–
05
2005–
06
ACC AU$/t AU$/t AU$/t AU$/g AU$/g AU$/g AU$/g AU$/g AU$/g
NSW 50 20–70 20–70 20–70 20–70 60–70 30–70 30–70 30–60
Qld 30–50 35–50 40–60 40–50 35–50 35–60 35–60 – 40
SA n.a. 50–70 25–50 35–80 25–40 30–80 35 20–50 25–40
Tas 70–80 12–25 12–25 50–60 50–70 30–70 30–70 40–50 25–40
Vic 80 60 40–60 30–50 35 25–35 25–35 – 21–40
WA 40–70 – 25–60 50 35–60 45–50 35–50 40–50 40–50
1998 1999 2000 2001 2002 2003 2004 2005 2006
NDARCc AU$/t AU$/t AU$/t AU$/t AU$/t AU$/t AU$/t AU$/t AU$/t
Nat’l av. 
range
n.a. n.a. n.a. n.a. n.a. n.a. 35
(15–80)
35 n.a.
ACT n.a. n.a. n.a. n.a. n.a. 35 35 35 35
NSW n.a. n.a. n.a. n.a. n.a. 35 35 30 30
NT n.a. n.a. n.a. n.a. n.a. 50 50 50 50
Qld n.a. n.a. n.a. n.a. n.a. 35 35 32 30
SA n.a. n.a. n.a. n.a. n.a. 35 35 30 30
Tas n.a. n.a. n.a. n.a. n.a. 50 40 45 40
Vic n.a. n.a. n.a. n.a. n.a. 30 30 30 30
WA n.a. n.a. n.a. n.a. n.a. 40 50 40 40
a: Price refers to typical retail price irrespective of range and purity
b: Oceania, price per gram, UNODC 2003a: 7
c: Median price per tablet, irrespective of range. NDARC 2006: 25; 2007: 28
Source: UNODCCP 2002: 209, 211; UNODC 2004: 385; 2005: 357; 2006: 380; ABCI and ACC 1998 to 2007
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Figures 15 and 16 illustrate that, according to ACC figures, between the 1997–98 and 
2005–06 financial years, retail prices for ecstasy remained largely steady in New South 
Wales and Queensland. Victoria, in contrast, witnessed a slight drop in ecstasy retail prices 
during that time (Figure 17).
Figure 15: Ecstasy price estimates, NSW, 1997–98 to 2005–06
Source: ABCI and ACC 1998 to 2007
Figure 16: Ecstasy price estimates, Queensland, 1997–98 to 2005–06
Source: ABCI and ACC 1998 to 2007
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Figure 17: Ecstasy price estimates, Victoria,1997–98 to 2005–06
Source: ABCI and ACC 1998 to 2007
Statistics on ecstasy street prices in New Zealand are limited and UNODC reports only 
contain information for the years 2003 and 2004 when retail prices averaged approximately 
US$45.00. In New Zealand’s 2001 national drug survey, respondents reported that the 
average price per ecstasy tablet in New Zealand was approximately NZ$40–80. Other 
research published in New Zealand in 2004 found the average price per ecstasy tablet  
to be NZ$71.90 (Wilkins et al. 2004b: 63). According to these figures, ecstasy is more 
expensive in New Zealand than in Australia. This may reflect the smaller market and the 
additional expenses associated with trafficking to New Zealand but it has also been 
attributed to more effective border control mechanisms in New Zealand. The data are, 
however, too fragmentary to make any conclusive findings.
Methylamphetamine
UNODC and the NDARC provide some additional, albeit fragmentary, data on the retail 
prices for methylamphetamine and crystal methylamphetamine (see Table 28 below). 
According to UNODC figures the average retail price for methylamphetamine in Australia  
in 2004 was US$188.80, although prices varied greatly depending on the purity of the 
substance sold.
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Methylamphetamine is significantly more expensive in New Zealand than in Australia. 
UNODC reported a price of US$550.40 per (pure) gram of methylamphetamine for  
2003 and US$424.40 in 2004. Data released by local researchers show a decline in 
methylamphetamine street prices from NZ$250–300 per gram in 1998 to NZ$100–180  
in 2001. It has been reported elsewhere that in mid-2002, methylamphetamine was selling  
on New Zealand streets for about NZ$100–180 per gram (Bellamy & McNab 2003: 8).  
Much higher prices have been reported for sales of crystal methylamphetamine, referred  
to as P in New Zealand. It has been estimated that crystal methylamphetamine was  
selling for NZ$1,000 per gram in New Zealand in 2002 (Bellamy & McNab 2003: 8).
Table 28: Price estimates, methylamphetamine, Australia and  
New Zealand, 1998–2004
1998 1999 2000 2001 2002 2003 2004
$/g $/g $/g $/g $/g $/g $/g
Australia n.a. n.a. n.a. n.a. n.a. n.a. Av: US$189 
(US$66–295; 
0.3–88% purity)
NZ NZ$250–300a n.a. n.a. NZ$100–180b n.a. US$550c Av: US$424 
(US$65–784)
a: Wilkins 2002: 14
b: Wilkins 2002: 14; Wilkins et al. 2002: 260
c: Price refers to ‘typical retail price’ irrespective of range and purity
Source: UNODC 2006: 378
NDARC surveys differentiate retail prices for methylamphetamine between ice, speed, and 
methylamphetamine base (Table 29). According to these surveys, street prices for crystal 
methylamphetamine (or ice) have been stable in most Australian states and territories in  
the 2003–05 period. New South Wales and Queensland reported slight increases between 
2004 and 2005. The price per 0.1 gram unit of crystal methylamphetamine (referred to as 
point (pt)) averages approximately $40–50 in most parts of Australia. This is supported by 
other research which placed the average price for a point of crystal methylamphetamine in 
Sydney at $50 (Topp et al. 2002: 346).
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Table 29: Price estimatesa, methylamphetamine type, 2003–05
Crystal 
methylamphetamine Methylamphetamine
Methylamphetamine 
base
2003 2004 2005 2003 2004 2005 2003 2004 2005
$/pt $/pt $/pt $/g $/g $/g $/pt $/pt $/pt
ACT 45 48 35 175 80 80 40 40 40
NSW 50 40 50 55 60 60 40 38 30
NT 65 50 80 60 100 200 50 50 75
Qld 40 40 50 200 180 180 25 28 25
SA 25 25 25 40 50 65 25 25 25
Tas 50 50 50 200 300 325 50 50 50
Vic 40 40 40 180 180 180 33 29 23
WA 50 50 50 200 300 300 50 50 50
a: Median price per point or gram, irrespective of range. Note that these figures are based on very small samples
Source: NDARC 2006: 61
Retail prices for methylamphetamine are measured in grams, not points. Methylamphetamine 
is cheaper than crystal methylamphetamine because it is of lesser quality and lower purity. 
Street prices for methylamphetamine are subject to very great variations which may reflect 
market availability but could also be reflective of the very small sample base and the lack of 
reliability of the surveys. According to NDARC data, prices for methylamphetamine rose in 
recent years in all Australian jurisdictions expect the ACT.
In contrast, prices for methylamphetamine base, measured in points (units of 0.1 gram)  
fell in most parts of Australia in recent years. NDARC surveys show remarkable price drops 
in New South Wales and Victoria between 2003 and 2005.
Observations
In comparison to other aspects of the illicit ATS trade, levels and patterns of ATS 
consumption in Oceania are quite well documented and researched, especially in  
Australia and New Zealand. The available information also identifies very similar trends  
and developments; the existing literature is, perhaps surprisingly, very consistent on most 
aspects of ATS consumption in Oceania. The key issues that crystallise include:
Levels of ATS consumption are very high in Oceania. Australia and New Zealand  •	
report among the highest rates of ATS use in the world. Consumption of ATS other  
than ecstasy seems to have levelled off in recent years while levels of ecstasy 
consumption continue to rise. There are some indications that consumption of  
crystal methylamphetamine is increasing in Australia and some Pacific Islands  
such as the Northern Marianas.
91
The number of ATS consumers in Oceania is very large relative to the small population  •	
of the region. This means that the region provides a very big customer base for ATS 
suppliers. Further, research has shown that per capita spending on illicit drugs in 
Oceania is higher than in any other region of the world.
For locally produced ATS, such as methylamphetamine, profit margins are particularly •	
high at the retail stage, particularly in comparison with profits at production and 
wholesale levels. For ecstasy, a substance that is mostly imported into the region,  
profit margins at wholesale and retail levels are more equal.
The retail market for ATS including ecstasy increased significantly in Oceania in recent •	
years. Production, supply and demand of most ATS and especially of ecstasy and 
crystal methylamphetamine continue to grow. This illicit drug market has emerged 
alongside existing drug markets; it has not substituted the markets for heroin, cocaine, 
cannabis and other narcotic drugs.
Retail prices for ATS in Australia are low compared with other parts of the  •	
region. Substances of greater quality and purity, such as ecstasy and crystal 
methylamphetamine are more expensive, also because they are more frequently 
imported. Locally produced ATS of low purity are cheaper. Retail prices for ATS have 
largely been stable in recent years. Increased seizures of ATS in Australia have not 
disrupted ATS supplies and have not caused any noticeable increase in retail prices.
Retail prices for ATS in New Zealand are slightly higher than in Australia because the  •	
size of illicit drug market is smaller and the market is more reliant on imports. The greater 
geographical distances and tighter border controls also explain the higher street prices  
in New Zealand.
There is currently no information on retail prices of ATS or any other drug in the Pacific •	
Islands. Levels of ATS consumption in the Pacific Islands are also insufficiently 
researched.
In combination, high levels of demand, stable retail prices, high levels of supply, and •	
significant expenditure on illicit drugs provide a profitable setting for ATS sales in the 
region and explain the significant and growing involvement of criminal elements in this 
market. Even local producers of small quantities of ATS can sell their substances 
profitably, which explains the significant number of so called boxed labs in Australia  
and New Zealand. Imported ATS, such as ecstasy and crystal methylamphetamine  
are equally profitable at wholesale and retail levels. Given the greater level of 
sophistication required for the importation of illicit drugs, the supply and distribution  
of these substances is more closely associated with large, transnational criminal 
organisations. There is, to date, no systematic study of the profile of ATS suppliers  
at the point of final sale.
Chapter 5: 
Legal frameworks
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International frameworks
ATS and their precursors were placed under international control by the 1971 Convention  
on Psychotropic Substances (1019 UNTS 75) and the 1988 Convention against Illicit Traffic 
in Narcotic Drugs and Psychotropic Substances (1696 UNTS 449). These documents 
criminalise a range of activities related to the production, trafficking, and possession of ATS 
and establish a comprehensive framework for law enforcement and judicial cooperation, and 
for mutual legal assistance. A number of provisions address specific issues associated with 
the involvement of criminal organisations in the illicit ATS trade. The following sections briefly 
outline the concept and core contents of the two conventions and then explore relevant 
offences relating to ATS production, trafficking, and consumption, and analyse provisions 
relating to ATS precursor control.
1971 Convention on Psychotropic Substances
The purpose of the Convention on Psychotropic Substances is to restrict the use of 
psychotropic substances to medical and scientific purposes and prevent and combat their 
abuse and the illicit traffic in these substances (Preamble). The convention was opened for 
signature in Vienna on 21 February 1971 and entered into force on 16 August 1976, 90 
days after 40 states had signed it, as required by Article 26 of the convention. Today, 179 
states are parties to it. Table 30 shows a list of state parties to the convention in Oceania.
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Table 30: 1971 Convention on Psychotropic Substances, signatories, 
Oceaniaa 
Country
Signature/
accession
Entry into force/
ratification/accession
Australia 21 Dec 1971 17 Aug 1982
Cook Islands see New Zealand ..
Fiji 25 Mar 1993 ..
France (incl. French Polynesia, New Caledonia, 
Wallis and Futuna)
17 Dec 1971 28 Jan 1975
FSM 29 Apr 1991 ..
Kiribati .. ..
Marshall Islands 9 Aug 1991 ..
Nauru .. ..
New Zealand 13 Sep 1971 7 June 1990
Niue .. ..
Northern Marianas .. ..
Palau 19 Aug 1998 ..
PNG 20 Nov 1981 ..
Samoa .. ..
Solomon Islands .. ..
Tokelau see New Zealand ..
Tonga 20 Oct 1975 ..
Tuvalu .. ..
United States (incl. Guam, American Samoa) 21 Feb 1971 16 Apr 1980
Vanuatu .. ..
..=not applicable
a: as at 9 September 2006
The development of the 1971 convention was a response to growing concern in the 1960s 
over the spread of illicit production and abuse of synthetic drugs in various parts of the world 
and over the diversion of substances such as amphetamine and LSD onto the illicit market. 
The convention is, for the most part, modelled after the 1961 Convention on Narcotic Drugs 
(520 UNTS 151). This convention established a comprehensive control and penalisation 
system and a framework for international cooperation but the scope is limited to narcotic 
drugs such as opium, coca, and cannabis and does not cover synthetic substances 
(Chatterjee 1981: 457). As the abuse of pharmaceutical and synthetic drugs became more 
prominent in the 1960s, the UN Commission on Narcotic Drugs responded by developing  
a comprehensive control and monitoring regime modelled after the 1961 Single Convention 
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on Narcotic Drugs which resulted in the 1971 Convention on Psychotropic Substances 
(Yoshida 1997: 8; Bassiouni & Thony 1996: 921). 
The 1971 Convention on Psychotropic Substances initially placed 32 synthetic drugs under 
international control. The current number of internationally controlled substances under this 
convention is 105. Substances can be added to the schedules of the convention subject to 
the requirements and procedure set out in Article 2. These substances are divided into four 
schedules, designed to reflect the heterogeneity of psychotropic drugs and the different 
risks and hazards associated with their abuse (Lessem 1974: 144). Substances listed in 
Schedule I are considered the most dangerous and placed under the most stringent control. 
These substances are prohibited unless their possession, use, etc is specifically approved 
for medical and scientific purposes by governments (Articles 5(1) and 7). Substances under 
the remaining three schedules are less stringently controlled. These substances were seen 
as less dangerous and state parties are free to limit the use of these substances ‘by such 
measures as they consider appropriate’ (Article 5(2)). MDMA, amphetamine, and 
methylamphetamine are listed in Schedules II and IV of the 1971 convention. The 
classification of ATS is said to reflect the medical use and risks of abuse of these substances 
and it has been argued that the substances listed in Schedules II–IV ought to be controlled 
less stringently so that important research is not inhibited (Cabranes 1973: 768). The 
classification of some substances, however, does not seem to follow this system and does 
not reflect contemporary patterns of abuse (Bassiouni & Thony 1996: 923–924). 
In summary, the 1971 convention requires licensing systems for the manufacturing, trade, 
and distribution of ATS and other psychotropic substances (Article 8). Further provisions 
relating to international trade, export and import of psychotropic substances are contained 
in Articles 12 and 13. Supply and use of ATS is limited to medical prescription (Article 9). 
Unauthorised manufacturing, trading, and distribution of ATS and other psychotropic 
substances is criminalised under Article 22(1). Signatories are further required to penalise 
conspiracies and participation in these offences by Article 22(2)(a)(ii) (see further Boister 
2001: 95–96; Chatterjee 1981: 483). To ensure that offenders cannot escape prosecution, 
countries in which offenders are found are obliged by Article 22(2)(iv)to prosecute offences 
under the convention or extradite the offender (see further Boister 2001: 224–229). Article 
21 calls upon signatories to collaborate in preventing and suppressing the illicit traffic in 
psychotropic substances (see further Boister 2001: 293–299). Lastly, state parties to the 
convention are required to report annually to the INCB on their control and enforcement 
efforts and provide information about changes to domestic law and about major drug cases 
(Article 16; see further Boister 2001: 476–477).
It was noted earlier that the provisions under the 1971 Convention on Psychotropic 
Substances are modelled, for the most part, after the Single Convention on Narcotic Drugs, 
written 10 years earlier. The separation of narcotic drugs from psychotropic substances has 
frequently been criticised and many have argued for the combination of both types of illicit 
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drugs under the same control regime in a single convention. This was, however, prevented 
by industrialised nations, due to strong lobbying by the pharmaceutical industry in these 
countries. Unlike narcotic drugs, which are mostly cultivated in developing nations, 
psychotropic substances generally involve chemicals produced in industrialised nations. 
Countries with large chemical and pharmaceutical industries were unwilling to accept the 
stringent control regime imposed over the cultivation of narcotic drugs. A further reason 
associated with the distinction between narcotic drug and psychotropic substance control 
relates to the patterns of consumption and the heterogeneity of these drugs. Use of 
pharmaceutical drugs has become a part of everyday life in most parts of the world, 
especially in western, developed nations. In contrast to the consumption of narcotic drugs, 
pill taking is a widely accepted habit which makes social and legal control more difficult 
(Bassiouni & Thony 1996: 915).
As a result, the regime instituted under the 1971 convention is less stringent than the Single 
Convention on Narcotic Drugs and provides more loopholes for countries that produce and 
trade psychotropic substances. Boister observed that because the 1971 convention ‘was 
aimed at drug manufacturing states rather than agricultural states, its provisions are not  
as rigorous as those of the 1961 Convention’ (Boister 2001:47). Still, many industrialised 
nations initially refused to ratify the 1971 convention, to protect their pharmaceutical 
industries and some of the major synthetic drug producing states continued to resist 
accession to the convention until very recently (Bassiouni & Thony 1996: 915–915). 
1988 Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances
The 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances  
is aimed at combating the involvement of criminal organisations in the illicit drug trade 
(Preamble, para 3) and has been described as ‘the most comprehensive international drug 
policy to date’ (Gardner 1993: 288). During the 1970s and 80s it became obvious that the 
existing international drug control regime could not reduce the demand for and supply of 
illicit drugs and that the criminal elements engaged in the illicit drug market had become 
more and more sophisticated in disguising and organising their illicit trade and circumventing 
the international control measures which were increasingly seen as ‘insufficiently robust’ 
(Gilmore 1996: 2; cf Bassiouni & Thony 1996: 921–922). 
Concern over the rise, spread, influence, and economic power of criminal organisations  
led to the development of the Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, initiated by the Government of Venezuela in 1984 (Roucherau 
1988: 601). The convention is the first international legal instrument to recognise the 
economic dimension and high profitability of the illicit drug trade. As its title suggests, the 
convention is aimed predominantly at suppressing illicit drug trafficking and, to that end, 
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focuses specifically on law enforcement, controlled delivery, tracing and forfeiture of 
proceeds of drug trafficking. The convention was opened for signature in Vienna on 20 
December 1988 and entered into force two years later on 11 November 1990, 90 days after 
the 20th country acceded (Article 29(1)). Today, the convention has 180 parties around the 
world. Table 31 sets out the state parties to the convention in Oceania.
Table 31: 1988 Convention on against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, signatories, Oceaniaa 
Country
Signature/
accession
Entry into force/
ratification
Australia 14 Feb 1989 14 Feb 1993
Cook Islands see New Zealand ..
Fiji 25 Mar 1993 ..
France (incl. French Polynesia, New Caledonia, 
Wallis and Futuna)
13 Feb 1989 31 Dec 1990
FSM 6 July 2004 ..
Kiribati .. ..
Marshall Islands .. ..
Nauru .. ..
New Zealand 18 Dec 1989 16 Dec 1998
Niue .. ..
Northern Marianas .. ..
Palau .. ..
PNG .. ..
Samoa 19 Aug 2000 ..
Solomon Islands .. ..
Tokelau see New Zealand ..
Tonga 29 Apr 1996 ..
Tuvalu .. ..
United States (incl. Guam, American Samoa) 20 Dec 1989 20 Feb 1990
Vanuatu January 2006 ..
..=not applicable
a: as at 9 September 2006
The principal purpose of the 1988 Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances, as stated in Article 2(1), is ‘to promote cooperation among the 
Parties so that they address more effectively the various aspects of illicit traffic in narcotic 
drugs and psychotropic substances having an international dimension’. To that end, Article 
3 requires signatories to comprehensively criminalise a range of activities associated with the 
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production, trafficking, supply, and possession of illicit drugs, criminalise the laundering of 
proceeds deriving from these activities, and equally penalise any incitement, conspiracy, and 
participation in these activities. Article 3 represents ‘a major extension and elaboration of 
drug related crimes beyond the limited provisions of the […] 1971 Convention’ (Boister 
2001: 98). The requirement to criminalise the conduct identified in Article 3 is an absolute 
one; failure by signatories to enact adequate domestic offences constitutes noncompliance 
under the convention.
The 1988 convention applies to all those illicit narcotic drugs and psychotropic substances 
listed in the schedules of the 1961 Single Convention on Narcotic Drugs (Article 1(n) 1988 
Convention) and the 1971 Convention on Psychotropic Substances (Article 1(r)). In addition, 
its application also extends to a range of precursor chemicals listed in the annex of the 
convention. The annex consists of two tables which include many of the key ingredients 
used in ATS and ecstasy production, including ephedrine, lysergic acid, 1P2P, and 
pseudoephedrine. Article 12 of the 1988 convention calls upon state parties to prevent  
the diversion of precursor chemicals ‘used for the purpose of illicit manufacture of narcotic 
drugs or psychotropic substances, and [to] cooperate with one another to that end’. The 
convention specifically criminalises the possession of these substances ‘knowing that they 
are being or are able to be used in or for the illicit cultivation, production or manufacture of 
narcotic drugs or psychotropic substances’ (Article 3(1)(c)(ii)).
The 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
further contains extensive measures relating to the laundering of proceeds of drug crimes 
and for the interdiction and forfeiture of these assets (see further Gardner 1993: 297). 
Articles 6–10 seek to strengthen international cooperation by providing a range of 
mechanisms for extradition (see further Boister 2001: 252–274; Sproule & St-Denis 1989: 
277–280), controlled delivery (see further Sproule & St-Denis 1989: 287–288), mutual legal 
assistance, and other forms of law enforcement and judicial cooperation (see further Boister 
2001: 299–344; Sproule & St-Denis 1989: 285–287). Articles 15–19 contain specific 
measures relating to the transportation of illicit drugs by commercial carriers, by sea,  
through ports, and by use of mail. The remaining articles are largely concerned with 
reporting requirements, and with the administration and implementation of the convention 
(Gurulé 1998–99: 80–84).
ATS production
The 1971 Convention on Psychotropic Substances, unlike the 1988 convention, does not 
itself criminalise particular activities. Instead, Article 22 renders any conduct illegal that is  
not lawful in terms of the convention. It is left to state parties to specify particular forms of 
criminal conduct. While the 1971 convention does not enumerate specific offences, Article 
22 is generally understood as criminalising ‘illicit traffic’ in psychotropic substances. This 
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term is further defined in Article 1(j) and explicitly includes the manufacturing of psychotropic 
substances (Boister 2001: 91–92). The 1971 convention, however, does not limit the 
cultivation of plants, such as ephedra, from which ATS and other psychotropic substances 
are made (Boister 2001: 46).
With regard to ATS production, the 1988 convention requires state parties to criminalise  
‘the production, manufacture, extraction, [and] preparation’ of psychotropic substances 
contrary to the provisions of the 1971 convention, Article 3(1)(a)(i). It further prohibits the 
possession or purchase of psychotropic substances for the purpose of manufacturing, etc. 
(Article 3(1)(a)(iii)). The 1988 Convention on Illicit Drugs and Psychotropic Substances also 
places restrictions on equipment and other material used in the manufacturing of ATS.  
This includes, for example, precursor chemicals and machines used for the encapsulation  
of tablets (Article 3(1)(a)(iv), (c)(ii)). Article 12 regulates the diversion of precursors and  
Article 13 the trade and diversion of other equipment and material to the illicit traffic. 
The financing of ATS production and the concealment and conversion (or laundering) of 
funds deriving from ATS production are criminalised under Article 3(1)(a)(v), (b)(i), (ii) (Boister 
2001: 107–121). In order to adequately target the involvement of criminal organisations in 
the illicit drug trade, criminal responsibility is expanded under Article 3(1)(a)(v) to include 
organisers, managers, and financiers (Boister 2001: 106–107). This ‘facilitates the 
identification and arrest of the principals in the criminal scheme in question rather than 
merely those with a lower level of involvement’ (Gilmore 1996: 7; Roucherau 1988: 604). 
Liability for all convention offences extends to attempts, participation, incitement, and 
conspiracy (Article 3(1)(c)(iii), (iv)) (Boister 2001: 121–123). Under Article 3(5) the convention 
further requires state parties to provide aggravated offences or more severe penalties for 
crimes that involve criminal organisations, offenders who are engaged in other international 
organised crime activities, that involve the use of violence, or offences that are committed  
to facilitate other criminal acts (Bassiouni & Thony 1996: 928–929).
To further dismantle the illicit production of ATS and other illicit drugs, Article 13 of the  
1988 convention requires state parties ‘to prevent trade in and the diversion of materials  
and equipment for illicit production or manufacture of narcotic drugs and psychotropic 
substances’. This provision seeks to ensure that equipment such as laboratory materials, 
glassware, tanks, and encapsulating machines, which are commonly used in the licit  
drug industry, are not purchased for or diverted to clandestine drug laboratories (Gardner 
1993: 296).
ATS trafficking
As mentioned in the previous section, Article 22 of the 1971 convention is generally 
understood as criminalising the illicit trafficking in psychotropic substances. This includes  
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all forms of unauthorised trade and distribution (Boister 2001: 92). In relation to ATS 
trafficking, the 1988 convention requires state parties to criminalise the ‘offering, offering for 
sale, distribution, sale, delivery on any terms whatsoever, brokerage, dispatch, dispatch in 
transit, transportation, importation or exportation’ of psychotropic substances contrary to 
the provisions of the 1971 convention (Article 3(1)(a)(i)). It further prohibits the possession or 
purchase of psychotropic substances for the purpose of trafficking (Article 3(1)(a)(iii)). The 
financing of ATS trafficking and the concealment and conversion of funds deriving from ATS 
production are criminalised under Article 3(1)(a)(v), (b)(i), (ii). Liability for all of these offences 
extends to attempts, participation, incitement, and conspiracy (Article 3(1)(c)(iii), (iv)). Higher 
penalties or special offences apply to cases of trafficking that involve criminal organisations, 
offenders who are engaged in other international organised crime activities, that involve the 
use of violence, or offenders who hold a public office (Bassiouni & Thony 1996: 928–929).
ATS consumption
The ambiguity arising from the lack of any specific conduct prohibited in the 1971 
convention is particularly evident in relation to abuse and consumption of psychotropic 
substances, including ATS. In essence, it is unclear whether the convention criminalises 
possession of psychotropic substances, especially if the possession is only intended for 
personal use. There appears to be general consensus that there is no obligation for state 
parties to criminalise possession of substances set out in Schedules II–IV, which includes 
ATS and ecstasy. Only substances listed in Schedule I are placed under more stringent 
control, and possession of Schedule 1 substances without ‘special licence or prior 
authorisation’, including possession for personal use, is said to be unlawful, Article 7(b)  
1971 convention. There is no obligation to make possession of Schedule II, III and IV 
substances unlawful, although the convention notes in Article 8 that it would be ‘desirable’ 
to do so (Lessem 1974: 144–145; Boister 2001: 93–95).
The initial drafts of the 1988 convention did not include offences for personal possession for 
purchase for personal consumption as these offences were considered ‘unconnected to the 
main target of the Convention, the illicit traffic’ (Boister 2001: 101; Sproule & St-Denis 1989: 
269). The preamble of the 1988 convention now states in paragraph 7 that the convention, 
inter alia, seeks ‘to eliminate the root causes of the problem of abuse of narcotic drugs and 
psychotropic substances, including the illicit demand for such drugs and substances and 
the enormous profits derived from illicit traffic’. Further, Article 14(4) of the 1988 convention 
calls upon state parties to ‘adopt appropriate measures aimed at eliminating or reducing 
illicit demand for narcotic drugs and psychotropic substances, with a view to reducing 
human suffering and eliminating financial incentives for illicit traffic’. The 1988 convention 
differentiates between possession for commercial and for personal use. Possession for the 
purpose of production, manufacturing etc. is an offence under Article 3(1)(a)(iii) (Boister 
2001: 104). Possession of illicit drugs for personal consumption, in contrast, is not included 
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in the list of criminal offences in Article 3(1). Instead, Article 3(2) of the 1988 convention 
requires state parties ‘to establish as a criminal offence under its domestic law, when 
committed intentionally, the possession […] of psychotropic substances for personal 
consumption’. Personal consumption of illicit drugs, such as ATS, is seen as less serious 
than possession for commercial purposes and the offence under paragraph (2) is not 
subject to the same extensions and aggravations as the offences relating to production  
and trafficking set out in paragraph (1) (Boister 2001: 123–130). 
Precursors
In contrast to plant-based narcotic drugs such as heroin, cannabis, and cocaine, ATS are 
based on chemical ingredients. In the case of narcotic drugs, the 1961 Single Convention 
on Narcotic Drugs provides the same control regime for plants, raw materials, intermediates, 
and end products. For example, the convention criminalises the cultivation and possession 
of coca bush in the same way as it criminalises the possession and sale of the end product 
cocaine. For ATS and many other synthetic drugs the key ingredients or precursors are, 
however, not regulated in the same way as the end product. 
Until recently, precursors were not subject to any control at all. International law also did not 
address the issue of precursor control until 1988. The provisions of the 1971 Convention of 
Psychotropic Substances, for instance, 
do not list substances which have been included because they are capable  
of conversion into psychotropic substances, but only those which have the 
defined dangerous properties themselves. The […] Convention also does  
not explicitly confer upon the Commission the authority to place under 
international control substances which are ‘convertible’ into psychotropic 
substances (Commentary 1976: 32).
The institution of stringent control regimes over ‘finished’ ATS and other psychotropic 
substances beginning in the 1970s triggered a shift in trafficking patterns. Rather than 
trafficking the end product, criminal organisations shifted to trafficking the precursor 
substances which were subject to lesser, if any, control. 
Precursor control is based on the ‘assumption that, by exercising better controls over the 
movement of precursors from the stage of production to disposal by the end-user, it will be 
possible to restrict access to them by illicit drug manufacturers, thus reducing the quantity  
of illicit drugs manufactured’ (Jayasuriya 1998: 272). The control of specific ATS precursors 
was first introduced in 1955 in Japan which experienced high rates of methylamphetamine 
abuse at that time. A number of other countries introduced precursor control in the 1970s. 
The United States followed in 1980. 
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In international law, precursor chemicals used in ATS production were largely legal and their 
trade uncontrolled until the late 1980s. The initial proposals by Latin American nations to 
control the trade in precursor substances were met by fierce resistance from the main 
producers of these chemicals China, Japan, and Europe (Roucherau 1988: 610). After years 
of negotiation, the 1988 convention introduced a monitoring, control, and prohibition system 
for precursors used in the illicit manufacture of ATS and other synthetic drugs in order to 
‘limit the access of traffickers to the indispensable materials of their industry and enable 
authorities to detect, track, and identify the precursors when traffickers are trying to obtain 
them’ (Bassiouni & Thony 1996: 927). Although the convention is much weaker and more 
selective than earlier proposals for precursor control, the inclusion of precursors into the 
international drug control regime marks an important shift in international law as the 
criminalisation of the illicit precursor trade impacts particularly on industrialised nations  
with large chemical industries. The convention attempts 
to strike an appropriate balance between the desire of the law enforcement 
community to exploit an obvious area of relative vulnerability for the trafficker 
with the real commercial needs of the chemical and pharmaceutical industries 
and other private sector participants (Gilmore 1996: 4, 10; cf Roucherau 
1996: 610–611).
In relation to precursor chemicals, the main concern of the convention is with the prevention 
of the diversion of these substances from the legitimate into the illegitimate trade. The 
convention intends to criminalise the supply of essential chemicals used to produce 
psychotropic substances and Article 12 regulates the diversion of precursors if (and only if) 
they are used for the cultivation, production or manufacture of illicit drugs. State parties  
are further obligated to monitor suspicious shipments, provide proper labelling and 
documentation for lawful export shipments, maintain adequate records, and give advance 
notification of international shipments for certain chemicals (Cherney, O’Reilly & Grabosky 
2005: 14–15; Gardner 1993: 296; Gilmore 1996: 8–10; Jayasuriya 1998: 272–273). 
The precursor control under the 1988 convention extends to 22 substances, including eight 
ATS precursors. Individual countries have placed additional precursors under the control 
regime. In some countries the regulations that apply to the finished ATS also extend to 
precursors; in others, precursors are regulated separately. As a result, there is a significant 
discrepancy between jurisdictions and in some countries, between end product and 
precursors (UNDCP 1996: 53–54; Bassiouni & Thony 1996: 922, 927). To ensure greater 
uniformity in precursor control, the UNDCP in 1993 issued Guidelines for use by national 
authorities in preventing the diversion of precursor and essential chemicals which were 
endorsed by the UN Economic and Social Council in the same year (Gilmore 1996: 13), but 
this initiative did not have the desired effects and precursor control remains very diverse 
around the world and throughout the Oceania region.
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Ephedrine, for example, is a substance that has widespread pharmaceutical use but is also 
abused as a stimulant and as a precursor of methylamphetamine. Ephedrine supply is only 
controlled as a precursor under the 1988 Convention against Illicit Traffic in Narcotic Drugs 
and Psychotropic Substances. The more stringent 1971 Convention on Psychotropic 
Substances does not regulate the manufacturing and distribution of ephedrine (UNDCP 
1996: 41, 53). 
Research has also shown that illicit manufacturers of ATS frequently shift between 
precursors and substitute precursors in response to availability, control, regulation, 
enforcement, price, and demand. In particular, UNDCP observed ‘the use of alternates not 
yet under international control […] in the manufacture of structurally related new drugs’ 
(UNDCP 1996: 65).
In addition to the obligations under international law, a further initiative to control the supply 
and availability of ATS precursors was launched by the INCB in 2003 under the name 
Project Prism. This worldwide project aims to prevent the diversion of ATS precursors 
specifically by launching backtracking investigations into interceptions and seizures of ATS 
precursors and manufacturing equipment and into the use of the internet for precursor 
trading. Further, the project seeks to obtain an overview of the production and trade of 
safrole and safrole-rich oils used in illicit ecstasy production and to enhance supply of and 
response to pre-export notifications (INCB 2005: Annex X; Cherney, O’Reilly & Grabosky 
2005: 15–16).
Observations
In combination, the 1971 Convention on Psychotropic Substances and the 1988 
Convention on Illicit Traffic in Narcotic Drugs and Psychotropic Substances provide  
a comprehensive regime for the international control of ATS and their precursors. The 
conventions establish a range of criminal offences for activities associated with ATS 
production, trafficking, importation, and consumption, including specific provisions directed 
against the involvement of criminal organisations in this trade and the laundering of proceeds 
of such crime.
The illicit drug trade is a global problem which requires global solutions. ‘The 
internationalisation of crime’ argues Roucherau, ‘requires concerted international 
suppression but more so it requires a conscious effort to fight the consumption as well as 
the production’ of illicit drugs (Roucherau 1988: 602). The current regime of international 
drug conventions has frequently been criticised for overburdening those countries in which 
illicit drugs are produced and, in return, for being unfairly lenient towards the main consumer 
countries. 
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As many producer nations of illicit drugs are developing countries, this imbalance is often 
perceived as a manifestation of imperialistic attitudes of industrialised nations that are the 
principal consumer countries (Sproule & St-Denis 1989: 266–267). The separation between 
developing producer states on the one hand, and developed consumer states on the other 
is less significant in the contemporary illicit ATS trade, as many ATS are manufactured in the 
country of consumption or originate from other industrialised countries. But the principal 
focus of many obligations under the international drug conventions remains on the 
production and supply of ATS and not on the demand for these substances. This is 
reflected, for example, in the 1988 convention, which does not criminalise possession for 
personal use in the same stringent manner it penalises production and distribution of illicit 
drugs (Sproule & St-Denis 1989: 269–270). It is, however, the demand for ATS and other 
illicit drugs which is fuelling this trade and which is seen by many as the root cause of the 
problem (Roucherau 1988: 612).
The principal weakness of the existing international drug conventions is their reliance  
on the voluntary cooperation of the state parties, which is often less than forthcoming.  
In many instances, countries have been unable, reluctant, or simply unwilling to comply  
with the obligations under the conventions. Many authors see the emphasis on domestic 
criminalisation and enforcement as the principal failure of the international drug conventions 
(see, for example, Gurulé 1998: 78; Lessem 1974: 143). It allows countries to construe 
criminal offences according to their own needs and political agendas. The loose terminology 
of many provisions in the international drug conventions inhibits uniformity at the domestic 
level (Boister 2001: 132). There has been criticism of the international drug conventions for 
failing to provide appropriate and clear guidance in respect of the suppression of the illicit 
drug problem. Instead, many view the drug conventions as mere regulatory frameworks for 
a highly profitable, licit drug industry, rather than as measures against the illicit trade (Boister 
2001: 543).
A further problem of the existing system is the lack of any obligation to prevent the 
overproduction of drugs for medical and scientific use and the oversupply of precursors. 
There is currently no set production quota, no estimate system, and the conventions do  
not prohibit the production of substances and quantities that are medically and scientifically 
unnecessary (Bassiouni & Thony 1996: 917, 920; Cabranes 1973: 768; Lessem 1974: 145; 
cf Gardner 1993: 297–299).
The current system also lacks appropriate mechanisms to ensure State Parties live up to 
their obligations. Sproule and St-Denis note that ‘[t]he insertion of safeguard clauses in many 
articles and the weakness of monitoring and supervisory mechanisms will allow recalcitrant 
parties to avoid their Convention obligations with relative impunity’ (1989: 291). The INCB 
may create some peer pressure by identifying those countries with particular drug problems, 
but neither the Commission nor the INCB have any coercive powers to enforce the 
conventions in countries that fail to live up to their obligations (see further Sproule & St-Denis 
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1989: 288–290). To close this gap in international drug control, some authors have called for 
the institution of penalties ‘for non-compliance by participating states. Since, as a practical 
matter, nations seem unwilling to enforce an embargo, perhaps a system of fines, levied by 
the Commission with appeals to the Council and the International Court of Justice (ICJ), 
would serve the same purpose’ (Cabranes 1973: 768).
As with most other UN conventions, the ICJ is the final arbiter for disputes between 
signatories to the 1971 and 1988 conventions. Article 31(2) of the Convention on 
Psychotropic Substances and Article 32(2) of the Convention on Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances specifically provide that disputes over convention 
obligations may be referred to the ICJ if they cannot be resolved by way of negotiation, 
mediation etc. In theory, this allows state parties to ask the ICJ to take legal action against 
signatories that violate or ignore convention obligations, for example, by allowing major drug 
production or by turning a blind eye to large scale trafficking, money laundering, or other 
organised crime activities. The ICJ may then issue a declaratory judgment confirming 
noncompliance, which may create some pressure on the country to act appropriately. 
Otherwise, failure to adhere to an ICJ judgment constitutes a violation of Article 94 of the 
Charter of the United Nations and may be referred to the UN Security Council. Some 
authors have argued that
in extreme cases, where government officials have not only failed to comply 
with the express terms of the Convention, but also have actually facilitated or 
condoned narcotics trafficking and money laundering within their territory, the 
complainant-party might seek recourse with the UN Security Council. The 
authority of the Security Council could be brought to bear on the offending 
nation to force compliance [and] the non-complying party could suffer 
Security Council sanctions (Gurulé 1998: 115).
Political and economic considerations have so far prevented any country from referring to 
the ICJ any case in which signatories did not live up to convention obligations or in which 
governments were collaborating with drug cartels. Some countries reject the jurisdiction  
of the ICJ altogether, thus preventing the court from seeking convention adherence. In 
addition, Article 32(3) of the 1971 convention and Article 32(3) of the 1988 convention 
specifically allow a country to ‘declare that it does not consider itself bound by’ the ICJ 
jurisdiction over convention obligations. Among the countries in Oceania, France, and Papua 
New Guinea have declared their reservation to Article 32(1) of the 1971 convention. France 
and the United States have filed their declaration that they do not consider themselves 
bound by Article 32(2) of the 1988 convention (Gurulé 1998: 116–117). The presence of 
escape and safeguard clauses in almost every article of the drug conventions, remarks 
Boister (2001: 68), ‘indicates that states are still wary about international drug control and 
jealous of their sovereignty’ (see also Sproule & St-Denis 1989: 290–291).
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Domestic laws
Australia
Australia is a signatory to the 1971 Convention on Psychotropic Substances (1982 AuTS 14) 
and the 1988 Convention on Illicit Traffic in Narcotic Drugs and Psychotropic Substances 
(1993 AuTS 4). Both conventions have been ratified and implemented into domestic law, in 
the Psychotropic Substances Act 1976 (Cth) and Crimes (Trafficking in Narcotic Drugs and 
Psychotropic Substances) Act 1990 (Cth). In Australia, relevant drug offences can be found 
in federal criminal law and in the criminal laws of Australia’s six states and two territories  
(see Bronitt & McSherry 2005: 809–830; Brown et al. 2006: 935–966; Schloenhardt 2006: 
269–304).
Federal offences
Federal drug offences in Australia are, for the most part, concerned with conduct that  
relates to the import and export of illicit drugs. Until 2005, the offences could be found in  
the Customs Act 1901 (Cth) and the Crimes (Trafficking in Narcotic Drugs and Psychotropic 
Substances) Act 1990 (Cth). The most significant federal drug offences were in Section 
233B(1) of the Customs Act 1901 (Cth) which included offences such as importing 
prohibited imports in para (b) and possessing prohibited imports in para (c). 
In 2005, federal drug offences underwent a major reform with the Law and Justice 
Legislation Amendment (Serious Drug Offences and Other Measures) Act 2005. The 
purpose of this reform was to bring all federal drug offences together in the federal Criminal 
Code in a new Part 9.1 entitled Serious drug offences (new Sections 300.1–314.5). This 
new part was specifically designed ‘to create offences relating to drug trafficking and to  
give effect to the United Nations Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances’ (s 300.1(1)). The new drug offences under the Criminal Code 
include:
Division 302: trafficking controlled drugs•	
Division 303: commercial cultivation of controlled drugs•	
Division 304: selling controlled drugs•	
Division 305: commercial manufacture of controlled drugs•	
Division 306: pre-trafficking controlled precursors•	
Division 307: import-export offences•	
Division 308: possession offences•	
Divisions 309, 310: drug offences involving or harming children.•	
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The new federal drug offences mark a significant expansion of federal jurisdiction. While  
the offences coexist with state and territory drug laws, the new legislation allows federal 
agencies to engage in purely local investigations and prosecutions (Brown et al. 2006: 956). 
The enactment must also be seen as a significant step towards harmonisation and 
uniformity between the drug laws at federal and state levels (Norberry 2005: 2).
The seriousness of and penalties for drug offences under federal criminal law are determined 
by the quantity of illicit drugs involved. The offences provide different penalties for offences 
involving commercial quantities (life imprisonment or 7,500 penalty units or both), marketable 
quantities (imprisonment for 25 years/5,000 penalty units), and for offences that do not 
specify a minimum quantity (imprisonment for 10 years/2,000 penalty units). There are no 
aggravating elements for offences committed by criminal organisations, but some special 
provisions exist if certain offences are committed ‘for a commercial purpose’.
In federal drug laws, narcotic drugs and psychotropic substances are listed in different 
schedules and are differentiated depending on their natural or chemical ingredients and/or 
their ‘seriousness’ (Section 300.2 Criminal Code). The new Criminal Code offences use the 
terms ‘controlled drug’, ‘controlled plant’, ‘border controlled plant’, and ‘border controlled 
drug’. The terms are defined in Section 300.2. The new legislation also makes specific 
reference to precursors. The lists of controlled drugs are set out in Section 314.1 and 
include amphetamine, methylamphetamine, MDA, and MDMA. The precursors listed in 
Section 314.3 include all the relevant ATS and ecstasy precursors: ephedrine, ergometrine, 
ergotamine, isosafrole, lysergic acid, 3,4-methylenedioxyphenylacetic acid, 3,4-
methylenedioxyphenylacetic-2-propanone, phenylacetic acid, phenyl-2-propanone, 
piperonal, pseudoephedrine, and safrole.
ATS producTion
The federal Criminal Code contains a number of offences relating to the manufacturing  
of ATS and other drugs and also contains specific offences to prohibit the illicit trade in 
precursors.
Division 305 contains three offences relating to the manufacture of controlled drugs.  
These include: 
manufacturing commercial quantities of controlled drugs (Section 305.3) •	
manufacturing marketable quantities of controlled plants (Section 305.4) •	
manufacturing controlled drugs (Section 305.5). •	
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These offences have been specifically designed to suppress commercial ATS production in 
Australia; their purpose
is to target the illicit commercial manufacture of controlled drugs. Although 
occasional instances of the manufacture of heroin and other narcotics are 
reported, the majority of offences falling under this [new] Division will involve 
synthetic drugs, such as legitimate uses in industry (Norberry 2005: 32).
The terms ‘manufacturing’ and ‘manufacturing a substance’ are defined in Section 305.1. 
The application of the offence is limited to manufacturing ‘for a commercial purpose’. In 
simple terms, it is an offence to manufacture ATS for the purpose of selling or distributing 
these substances (Section 305.2). The requisite intention to manufacture for a commercial 
purpose is deemed to exist when the offence involves trafficable quantities (Section 305.6; 
Brown et al. 2006: 962–963). Manufacturing for other purposes, especially for personal 
consumption, is not criminalised under federal law, but liability may arise under relevant 
offences in state or territorial drug laws. 
ATS imporTATion And TrAfficking
The new drug offences under the Criminal Code (Cth) contain a range of ‘import–export 
offences’ in Division 307 (see further Brown et al. 2006: 964–965). These offences are 
differentiated depending on the quantity involved. They include: 
importing and exporting commercial quantities of border-controlled drugs or border-•	
controlled plants (Section 307.1) 
importing and exporting marketable quantities of border-controlled drugs or border-•	
controlled plants (Section 307.2)
importing and exporting border-controlled drugs or border-controlled plants (Sections •	
307.3, 307.4). 
Under new Section 300.2, ‘importing includes bringing into Australia’. Importation is, 
depending on the quantity involved, an offence under Sections 307.1, 307.2 or 307.3. 
Importing precursors is criminalised in Sections 307.11 – 307.13.
Until 2005, trafficking offences stemming from the 1988 Convention against Illicit Traffic  
in Narcotic Drugs and Psychotropic Substances were included in the Crimes (Traffic in 
Narcotic Drugs and Psychotropic Substances) Act 1990 (Cth) (see further Schloenhardt 
2006: 287–288). The 2005 reform of federal drug offences substituted these offences with 
new provisions under Division 302 Criminal Code entitled ‘trafficking controlled drugs’.  
A new comprehensive definition of the term ‘trafficking’ is set out in Section 302.1 (see
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further Norberry 2005: 21–22; Brown et al. 2006: 959). The explanatory memorandum  
to the legislation states:
[t]he trafficking offences target dealings in controlled drugs. The range of 
conduct covered by the exhaustive definition of trafficking is broad: the 
trafficking offences are proposed to extend beyond sale to the ancillary 
activities of transport and delivery, as well as preparatory conduct such  
as preparation for supply, packaging and possession with intention to sell  
a drug (Norberry 2005: 20).
The new offences include: 
trafficking commercial quantities of controlled drugs (Section 302.2) •	
trafficking marketable quantities of controlled drugs (Section 302.3) •	
trafficking controlled drugs (Section 302.4). •	
ATS conSumpTion
Federal drug laws in Australia do not have separate offences for the consumption or use of 
ATS or other illicit drugs. Instead, the Criminal Code contains a comprehensive regime of 
possession offences in Division 307 and 308 (see further Brown et al. 2006: 963–966). The 
offences penalise the possession of natural and manufactured drugs, as well as possession 
of plants, equipment and precursors. For offences in Division 308 it is irrelevant whether the 
drug or plant has been imported into Australia or whether it was manufactured locally. Under 
Division 308 it is an offence to:
possess a controlled drugs (Section 308.1)•	
possess a controlled precursor ( Section 308.2)•	
possess plants, material, equipment, or instructions for commercial cultivation of •	
controlled plants (Section 308.3)
possess substances, equipment, or instruction for commercial manufacture of controlled •	
drugs (Section 308.4).
The offences in Sections 307.5 – 307.10 of the Criminal Code relate specifically to the 
possession of drugs or plants that have been unlawfully imported into Australia or that are 
reasonably suspected of having been unlawfully imported. The offences and penalties vary 
depending on the quantity involved. They include:
possessing commercial quantities of unlawfully imported border-controlled drugs or •	
border-controlled plants (Section 307.5)
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possessing marketable quantities of unlawfully imported border-controlled drugs or •	
border-controlled plants (Section 307.6)
possessing unlawfully imported border-controlled drugs or border-controlled plants •	
(Section 307.7)
possessing commercial quantities of border-controlled drugs or border-controlled plants •	
reasonably suspected of having been unlawfully imported (Section 307.8)
possessing marketable quantities of border-controlled drugs or border-controlled plants •	
reasonably suspected of having been unlawfully imported (Section 307.9)
possessing border-controlled drugs or border-controlled plants reasonably suspected of •	
having been unlawfully imported (Section 307.10).
precurSorS
Division 306 Criminal Code (Cth) contains three ‘new federal offences targeting illicit dealings 
in precursor chemicals for the purpose of manufacturing controlled drugs’ (Australia 2005: 
37). The offences include pre-trafficking commercial quantities of controlled precursors 
(Section 306.2); pre-trafficking marketable quantities of controlled precursors (Section 
306.3); and pre-trafficking controlled precursors (Section 306.4). 
The new offences introduce the 
central concept of pre-trafficking which covers a range of conduct involving 
precursors. The term pre-trafficking reflects the fact that the precursor 
offences target conduct that is preparatory to the actual trafficking of a 
controlled drug (Norberry 2005: 37).
Under Section 306.1(b) and (c) pre-trafficking includes the manufacture of precursors with 
intention to use them to manufacture drugs, to sell them to a manufacturer, or to sell them 
believing another person will use them to manufacture drugs. Importing precursors is a 
separate offence under Sections 307.11 – 307.13.
State and territory drug laws
The Australian states and territories, pursuant to their constitutional power over criminal law, 
have enacted a variety of offences relating to cultivating or manufacturing, selling, supplying, 
and possessing illicit drugs. The offences, their scope and penalties vary remarkably 
between the eight different jurisdictions. The following section highlights the most relevant 
provisions relating to the illicit production, trafficking, and possession of ATS and their 
precursors.
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The substances covered by the drug offences in the various states and territories are, for  
the most part, identical throughout Australia. Narcotic drugs and psychotropic substances 
are listed in different schedules of the relevant drug laws and are differentiated depending  
on their natural or chemical ingredients and/or their seriousness. The terminology used to 
describe banned substances varies between jurisdictions (for example, prohibited drug 
(NSW, WA); controlled drug (NT, Tas); dangerous drugs (Qld); or drug of dependence (SA, 
Vic)). All Australian jurisdictions have included ATS in their lists of illicit drugs: Schedule 1 
Criminal Code (ACT); sch 1 Drugs Misuse and Trafficking Act 1985 (NSW); sch 2 Misuse  
of Drugs Act 1990 (NT); sch 1, 2 Drugs Misuse Regulations 1987 (Qld); sch 1 Controlled 
Substances (Prohibited Substances) Regulations 2000 (SA); sch 1, pt 2 Misuse of Drugs Act 
2001 (Tas) [Note: MDEA is not included in the Tasmanian legislation]; sch 11, pt 3 Drugs, 
Poisons and Controlled Substances Act 1981 (Vic); s 6(2) Misuse of Drugs Act 1981 (WA).
ATS producTion
The production and manufacturing of ATS and other illicit drugs is penalised in all Australian 
jurisdictions: ss 607, 609 Criminal Code (ACT); s 24 Drugs Misuse and Trafficking Act 1985 
(NSW); s 8(1) Misuse of Drugs Act 1990 (NT); s 8 Drugs Misuse Act 1986 (Qld); s 32(1) 
Controlled Substances Act 1984 (SA); ss 6, 21 Misuse of Drugs Act 2001 (Tas); s 6(1)(b) 
Misuse of Drugs Act 1981 (WA). In Victoria manufacturing is included in the definition of 
trafficking, ss 71(1), 71AA–71AC Drugs, Poisons and Controlled Substances Act 1981.
In addition to the production offences, all Australian jurisdictions criminalise the possession 
of equipment used in the manufacturing of ATS and other drugs: ss 613, 614 Criminal Code 
(ACT); ss 8B(1), 8C(1) Misuse of Drugs Act 2001 (NT); s 9A Drugs Misuse Act 1986 (Qld);  
s 31(1)(c) Controlled Substances Act 1984 (SA); Misuse of Drugs Act 2001 (Tas); s 71A 
Drugs, Poisons and Controlled Substances Act 1981 (Vic); s 6(2) Misuse of Drugs Act 1981 
(WA). Some jurisdictions include extensive lists of controlled equipment in their drug laws. 
For example, Schedule 8B Drugs Misuse Regulations 1987 (Qld), introduced in 2006, 
includes equipment such as condensers, distillation heads, heating mantles, pill presses, 
rotary evaporators, reaction vessels, and splash heads.
ATS TrAfficking
Supplying ATS and other illicit drugs is an offence in all jurisdictions: ss 603, 628–630 
Criminal Code (ACT); s 25 Drug Misuse and Trafficking Act 1985 (NSW); s 5(1) Misuse of 
Drugs Act 1990 (NT); s 6 Drugs Misuse Act 1986 (Qld); s 32(1)(c)–(e) Controlled Substances 
Act 1984 (SA); ss 12, 14, 26, 27A Misuse of Drugs Act 2001 (Tas); ss 71–71B Drugs, 
Poisons and Controlled Substances Act 1981 (Vic); ss 6, 7 Misuse of Drugs Act 1981 (WA). 
These offences are generally kept quite broad in their application, to penalise any type of 
distribution, sale, and transportation of illicit drugs, including ATS. The offences also extend 
to preparatory acts such as possession for the purpose of selling or otherwise supplying 
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illicit drugs (cf s 3 Drug Misuse and Trafficking Act 1985 (NSW); s 4 Drug Misuse Act 1986 
(Qld)). Purchase for mere personal use, however, is usually not enough to establish supply  
or trafficking (R v Quaille [1988] 2 Qd R 103 at 113, 116).
Some jurisdictions, such as Queensland and New South Wales, have additional offences  
for trafficking. These refer to commercial supply of illicit drugs, not to cross-border 
operations: s 29 Drug Misuse and Trafficking Act 1985 (NSW); s 5 Drugs Misuse Act 1986 
(Qld) (R v Quaille [1988] 2 Qd R 103 at 113; Colvin et al. 2005: para 8.15; Schloenhardt 
2006: 282–284). New South Wales has a further offence for supplying a prohibited drug  
on an ongoing basis, s 25A Drug Misuse and Trafficking Act 1985 (NSW; see further  
Brown et al. 2006: 953; Boyden 2001: 34–35). 
poSSeSSion of ATS
Unlawful possession of ATS is criminalised in all Australian jurisdictions: s 169 Drugs of 
Dependency Act 1989 (ACT); s 9(1) Misuse of Drugs Act 1990 (NT); ss 10, 26 Drug Misuse 
and Trafficking Act 1985 (NSW); s 9 Drugs Misuse Act 1986 (Qld); s 31(1)(a) Controlled 
Substances Act 1984 (SA); s 24(a) Misuse of Drugs Act 2001 (Tas) s 73 Drugs, Poisons  
and Controlled Substances Act 1981 (Vic); s 6(2) Misuse of Drugs Act 1981 (WA). Liability 
for possession arises for any person who has illicit drugs, including ATS, under his or her 
control; the offence is not limited to consumers. Some jurisdictions have a separate offence 
for the self-administration of illicit drugs and for administration of drugs to or by another 
person (for example, ss 12–14 Drugs Misuse and Trafficking Act 1985 (NSW)).
precurSorS
Precursor chemicals necessary for the production of ATS and other illicit drugs are covered 
by the drug laws in all Australian jurisdictions. Controlled precursors are set out in the 
relevant acts or subordinate legislation: sch 3 Criminal Code Regulations 2005 (ACT);  
Drugs Misuse and Trafficking Regulations 2000 (NSW; see further Brown et al. 2006: 945); 
sch 2 Misuse of Drugs Act 1990 (NT); sch 6 Drugs Misuse Regulations 1987 (Qld); s 33,  
sch B Controlled Substances (Poisons) Regulations 1996 (SA); sch 1, pt 4 Misuse of Drugs 
Act 2001 (Tas); sch 11 Drugs, Poisons and Controlled Substances Act 1981 (Vic); sch 3, 4 
Misuse of Drugs Regulations 1982 (WA). Minor variations aside, the lists of controlled 
precursor substances in each state and territory are largely identical and include all the 
principal chemical ingredients used in ATS production. Victoria and Western Australia have 
particularly comprehensive lists of controlled precursors, while the lists in Tasmania and the 
ACT are comparatively short (Caldicott et al. 2005: 157).
All states and territories criminalise the possession and/or storage of ATS precursors: ss 
610–612 Criminal Code (ACT); s 24A Drug Misuse and Trafficking Act 1985 (NSW); ss 8A(1), 
8D(1) Misuse of Drugs Act 1990 (NT); ss 9A, 10B Drugs Misuse Act 1986 (Qld); s 31(1)(a) 
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Controlled Substances Act 1984 (SA); ss 32–34 Controlled Substances Regulations 1996 
(SA); ss 10,11, 20 Misuse of Drugs Act 2001 (Tas); s 71A Drugs, Poisons and Controlled 
Substances Act 1981 (Vic); s 14 Misuse of Drugs Act 1981 (WA). Queensland has an 
additional, aggravated offence for possession of certain combinations of precursor 
substances, s 10B Drugs Misuse Act 1986 (Qld), schedule 8C Drugs Misuse Regulations 
1987 (Qld). Western Australia has special offences in ss 15, 17 Misuse of Drugs Act 1981 
for the sale and supply of precursors.
In an attempt to further limit the availability of ATS precursors and curb the sale of otherwise 
legitimate substances through pharmacies and other outlets (sometimes referred to as 
pseudo-runs, see chapter 2), some states have introduced regulations to monitor and 
restrict the control of medicines containing pseudoephedrine: s 23 Poisons and Therapeutic 
Goods Regulation 2002 (NSW); ss 277, 285A Health (Drugs and Poisons) Regulation 1996 
(Qld); s 33(1), (3) Controlled Substances (Poisons) Regulations 1996 (SA). The introduction 
of these measures is the result of Project STOP, an initiative of the Pharmacy Guild of 
Australia and the Australian Government, which created an electronic database to monitor, 
inter alia, purchases of cold and cough medicines containing pseudoephedrine and to 
prevent people from obtaining excessive amounts (Cherney, O’Reilly & Grabosky 2005: 17). 
It is anticipated that jurisdictions that have not already done so, will soon introduce similar 
regulations.
Observations
In summary, Australian drug laws at federal and state/territory level comprehensively 
criminalise a broad range of activities associated with the production, trafficking, and 
consumption of ATS. Further offences exist for the possession of equipment commonly 
used in the manufacturing of illicit drugs. 
In recent years, additional legislation has been introduced to target more specifically the illicit 
trade in precursors, including the purchase of legitimate substances through pharmacies 
and other outlets. Some jurisdictions, such as Queensland, introduced these measures as 
recently as 2006 (for example, Drug Legislation Amendment Act 2006 (Qld), Drugs Misuse 
Amendment Regulation (No 1) 2006 (Qld), No 71 of 2006), so the effect of the new 
provisions remains to be seen. Other states, such as New South Wales, have criminalised 
the precursors trade for several years (Crimes Legislation Further Amendment Act 2000), but 
the figures shown earlier demonstrate that penalisation of the precursor trade has done little 
to stem the production and flow of ATS or to raise the retail price for these substances. 
The main emphasis of Australian drug offences, especially at the federal level, is on 
commercial producers and suppliers of illicit drugs, including ATS. The harshest penalties 
are reserved for individuals and organisations who manufacture, traffic, import, or supply 
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illicit drugs in great quantities or who do so on a continuing basis. In contrast, the 
consumption and the possession of illicit drugs for personal use do not attract very high 
penalties. Australian drug laws are particularly concerned with manufacturing and trafficking 
stages of the illicit drug trade. The demand for and consumption of illicit drugs are not 
criminalised equally.
A particular feature of illicit drug control and enforcement in Australia is the division of drug 
laws into eight separate criminal jurisdictions in addition to federal laws. While the differences 
between the jurisdictions in suppressing the illicit ATS trade may only be subtle, they add to 
the impression that some jurisdictions are ‘soft’ or ‘tough’ on drugs. The division may also 
be seen as unnecessarily confusing and bureaucratic for a country of only 21 million people. 
For some time, there has been academic debate about the development of a single national 
criminal law to remove the existing differences. A single, uniform drug law would indeed be  
a powerful mechanism in the war on drugs, but this proposal is at present unrealistic and 
opposed by too many states and territories. Instead, it is hoped that the recent introduction 
of new federal drug offences, which place much greater emphasis on controlling the 
precursor trade and criminalise individuals and criminal organisations who engage in the 
drug trade for commercial purposes more heavily, will eventually lead to a harmonisation  
of drug offences around Australia and set a new, higher standard for the prevention and 
suppression of the illicit ATS trade and of the organised crime elements involved in it. The 
governments of the Australian territories and states have expressed their commitment to 
follow the model of new Commonwealth Criminal Code offences, although reform at the 
state and territory level has been slow in forthcoming in the first year since their introduction 
(Norberry 2005: 2; Brown et al. 2006: 966).
New Zealand
New Zealand has signed the 1971 and 1988 conventions. In New Zealand, drug offences 
are consolidated in the Misuse of Drugs Act 1975. Drugs are classified ‘based on the risk  
of harm the drug poses to individuals, or to society, by its misuse’ (s 3a, as introduced by 
Misuse of Drugs Amendment Act 2000). ATS such as methylamphetamine and MDA are 
seen as posing a very high risk of harm and are listed as Class A Controlled Drugs in 
Schedule 1 of the Act (s 3A(a)). Amphetamine and MDMA are seen as posing a high risk  
of harm (s 3A(b)) and are classified as Class B Controlled Drugs under Schedule 2. 
Amphetamine analogues such as MDEA are classified as Class D drugs (Wilkins 2002). 
Precursors were placed under control in 1998 with the Misuse of Drugs Amendment Act 
1998. Today, all major ATS precursors are included in Schedule 4 of the Misuse of Drugs  
Act 1975.
Relevant drug offences are included in Misuse of Drugs Act 1975, s 6 under the heading 
‘dealing with controlled drugs’. The section criminalises production and manufacture of any 
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controlled drug (s 6(1)(b)), the import and export of controlled drugs (s 6(1)(a)), and the 
supply and administration, including offer to supply or administer, any Class A or Class B 
controlled drug (s 6(1)(c)). Under subsection (6) the Act establishes a ‘presumption of supply’ 
in cases in which an accused is found in possession of 56 g or more amphetamine, or 5 g 
or 100 doses of MDMA, MDEA, and MDA. This presumption reverses the burden of proof to 
the accused, who has to demonstrate that they were not intending to sell substances found 
in their possession (Wilkins 2002). 
An additional offence for drug possession and consumption is contained in s 7(1)(a) of the 
Act. Supply, production and manufacturing of equipment, material, and precursors capable 
of being used in the production of illicit drugs are offences under s 12A. Separate offences 
exist for importing and exporting precursors under ss 12AB, 12AC.
Pacific Islands
The ATS control system and the criminalisation of activities associated with illicit ATS 
production, trafficking, and consumption are less developed in the Pacific Island nations 
than in Australia and New Zealand. Many countries in the region lack comprehensive and 
up-to-date drug laws and do not have adequate laws addressing the involvement of criminal 
organisations in the illicit ATS trade. Among the principal reasons for this situation are the 
lack of accession and adherence to international drug treaties and the fact that many 
domestic drugs laws are out of date, as they have not been adequately updated to 
criminalise contemporary patterns of the illicit ATS trade in the region.
Pacific Islands and international law
Many countries in the region have not signed the 1971 or 1988 conventions (see Figures 
Tables 30 and 31 above) and, as a result, have not implemented relevant criminal offences 
and enforcement measures at domestic levels. Only three Pacific Island nations, Fiji, 
Federated State of Micronesia, and Tonga have acceded to or signed both conventions.  
The two conventions also apply in the French territories New Caledonia, French Polynesia, 
and Wallis and Futuna, and in the US territories of Guam, Northern Marianas, and American 
Samoa. New Zealand’s signature to the conventions extends to Cook Islands and Niue, both 
self governing territories in free association with New Zealand, which retains foreign affairs 
powers, and Tokelau, a self administering territory of New Zealand. Kiribati, Nauru, Solomon 
Islands, and Tuvalu have not signed either convention. The Marshall Islands, Palau, and 
Papua New Guinea signed the 1971 convention, but had not signed the 1988 convention  
by September 2006 (INCB 2006: paras 624–626). 
116
Domestic laws in Pacific Island nations
The lack of comprehensive drug laws in many countries along with weaknesses in the 
regulation of the financial markets make the Pacific Islands particularly vulnerable to ATS 
trafficking and to the laundering of proceeds of ATS and other drug-related crime. This 
problem is well illustrated in the prosecution and trial that followed the seizure of the 
clandestine mega-lab in Suva, Fiji in 2004. Despite the magnitude of this operation and the 
available evidence against the defendants, the maximum penalty available for these criminal 
activities at that time was only eight years imprisonment, as Fijian drug laws did not contain 
specific provisions to criminalise large scale ATS production and the possession of 
precursors (State v Yuen Yei Ha [2005] FJHC 165; cf former reg 3 Dangerous Drugs 
Regulations, Dangerous Drugs Act 1985, s 41(1)). Fijian drug laws have since been  
repealed with the introduction of a new Illicit Drugs Control Act in 2004.
A primary problem is the fact that some countries currently do not include ATS and ecstasy 
in their lists of controlled and prohibited drugs, either adequately or at all. ATS are, for 
example, not covered by the drug laws of Solomon Islands (Dangerous Drugs Act 1997: 
under this Act the Minister may provide for the inclusion of ATS as a dangerous drug, but  
as yet ATS have not been included), Vanuatu (Dangerous Drugs Act 1988), and Kiribati 
(Dangerous Drugs Ordinance1980). Amphetamine is not explicitly included in the list of 
narcotic substances in s 902(e)(iii) Narcotic Drugs under the Marshall Islands Code (Code of 
the Republic of the Marshall Islands 2004, Title 7: Narcotic Drugs), and ecstasy and ecstasy-
like substances are not currently covered by Samoa’s Narcotics Act 1967. Elsewhere,  
ATS and ecstasy are included in the relevant lists of controlled drugs (State Code 1999 
(Micronesia), Title 11: Controlled Substances s 1121(3); Illicit Drugs Control Act 2004 (Fiji) 
sch 1, pts 2, 5; Misuse of Drugs Act 1998 (Niue) sch 1, 2; Dangerous Drugs Act 1952 
(PNG); Crimes, Procedure and Evidence Rules 2003 (Tokelau) s 49(1)(ii); Illicit Drugs Control 
Act 2003 (Tonga) sch 1. Current legislation from Cook Islands, Northern Marianas, Nauru, 
and Palau were unavailable at the time of writing.
Precursor control and regulation in the Pacific Islands is, for the most part, nonexistent. 
Currently, only four jurisdictions, Federated States of Micronesia, Fiji (Illicit Drugs Control Act 
2004 sch 2 and s 6(a), (b)), Niue (Misuse of Drugs Act 1998 (Niue) sch 5. Sections 12(2)(a), 
(2)(b), 12AB, and 12 AC of the Act provide offences for the possession etc of precursors), 
and Tonga (Illicit Drugs Control Act 2003 sch 2 and s 5(a), (b)), have included precursors in 
their drug laws. The FSM list of precursors is limited to substances relating to narcotic drugs 
and does not include any of the major ATS precursors (State Code, Title 11: Crimes, ch 11: 
Controlled Substances s 1112). All four countries are state parties to the 1988 convention 
and thus obliged to control precursors accordingly. Samoa and Tokelau, although parties  
to the convention, have not yet extended their legislation to include precursor control. 
Countries in Oceania that have not signed the 1988 convention do not currently control  
and criminalise the illicit trade in ATS and other precursors.
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All Pacific Island jurisdictions criminalise the production of illicit drugs: Commonwealth of  
the Northern Mariana Islands Code (6) s 2141(a)(1) [production is included in the definition  
of trafficking]; State Code 1999 (Micronesia) Title 11: Crimes, Chapter 11: Controlled 
Substances s 1141(1)(a), [production is included in the definition of trafficking]; Illicit Drugs 
Control Act 2004 (Fiji) s 5(a); Dangerous Drugs Ordinance 1980 (Kiribati) s 17 and 
Dangerous Drugs Regulations (Kiribati) s 3; Code of the Republic of the Marshall Islands 
2004, Title 7: Public Health, Safety and Welfare; Chapter 9: Narcotic Drugs s 903(a), (d); 
Misuse of Drugs Act 1998 (Niue) s 6(1)(b); Dangerous Drugs Act 1952 (PNG) s 3(1)(b); 
Narcotics Act 1967 (Samoa) s 18(2)(a) [production is included in the definition of dealing 
under s 2]; Laws of the Solomon Islands 1997, Chapter 98: Dangerous Drugs s 15(1);  
Illicit Drugs Control Act 2003 (Tonga) s 4(a). Current provisions from Cook Islands, Nauru, 
Tokelau, Tuvalu, and Vanuatu were unavailable at the time of writing. The offence extends  
to the manufacturing of ATS and ecstasy, except in Kiribati, Solomon Islands, and Vanuatu 
where ATS are not included in the list of controlled substances. Fiji, Niue, and Tonga, all 
signatories to the 1988 convention, also have special offences for the possession of 
equipment relating to illicit drug production (Illicit Drugs Control Act 2004 (Fiji) s 6(a), (b); 
Misuse of Drugs Act 1998 (Niue) ss 12A(1)(a), (2)(b); Illicit Drugs Control Act 2003 (Tonga) 
sch 3 and s 5(a), (b)). Supply of and trafficking in illicit drugs are offences throughout the 
region (Commonwealth of the Northern Mariana Islands Code (6) s 2141(a)(1); State Code 
1999 (FSM), Title 11: Crimes, ch 11: Controlled Substances s 1141(1)(a); Illicit Drugs Control 
Act 2004 (Fiji) ss 4(a), 5(a), (b); Dangerous Drugs Ordinance 1980 (Kiribati) s 17 and 
Dangerous Drugs Regulations (Kiribati) s 5(1); Code of the Republic of the Marshall Islands 
2004, Title 7: Public Health, Safety and Welfare s 903(b); Misuse of Drugs Act 1998 (Niue) 
ch 9: Narcotic Drugs; Narcotics Act 1967 (Samoa) ss 6(1)(a), (c), (d), 7(1)(b); Laws of the 
Solomon Islands 1997, ch 98: Dangerous Drugs s 18(2)(b); s 15(1); Crimes, Procedure and 
Evidence Rules 2003 (Tokelau) s 49(2)(i); Illicit Drugs Control Act 2003 (Tonga) ss 3, 4(a), (b); 
Laws of the Republic of Vanuatu 1988, ch 12: Dangerous Drugs s 2). Papua New Guinea 
criminalises the importation of drugs (s 3(1)(c) Dangerous Drugs Act 1952) but the Act has 
no separate offence for supply or trafficking. Current provisions from Cook Islands, Nauru, 
and Tuvalu were unavailable at the time of writing. 
The possession of illicit drugs is penalised in every jurisdiction (Commonwealth of the 
Northern Mariana Islands Code s 2141(a)(1); State Code 1999 (Micronesia), Title 11:  
Crimes, ch 11: Controlled Substances s 1141(1); Illicit Drugs Control Act 2004 (Fiji) s 5(a); 
Dangerous Drugs Ordinance (Kiribati) s 17 and Dangerous Drugs Regulations (Kiribati)  
s 6(1); Code of the Republic of the Marshall Islands 2004, Title 7: Public Health, Safety  
and Welfare s 903(a); Misuse of Drugs Act 1998 (Niue) ch 9: Narcotic Drugs; ss 6(1)(f),  
7(1)(a); Dangerous Drugs Act 1952 (PNG) ss 3(1)(d), 4(3)(d); Narcotics Act 1967 (Samoa)  
ss 7, 18(2)(a); Laws of the Solomon Islands 1997, Chapter 98: Dangerous Drugs s 15(1); 
Crimes, Procedure and Evidence Rules 2003 (Tokelau) s 49(2)(ii); Illicit Drugs Control Act 
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2003 (Tonga) s 4(a); Laws of the Republic of Vanuatu 1988, ch 12: Dangerous Drugs s 2). 
Current provisions from Cook Islands, Nauru, and Tuvalu were unavailable at the time of 
writing). 
In summary, there are great discrepancies between the countries of the Pacific Islands in the 
regulation and criminalisation of the illicit ATS and precursor trade. Fiji and Tonga, as well as 
the French, US, and New Zealand territories in the region have the most up-to-date laws, 
and comprehensively control and penalise all aspects of the illicit ATS market. In contrast, 
the laws of the Solomon Islands and Vanuatu are particularly outdated. In Papua New 
Guinea the current drug laws were enacted in 1952, 33 years before PNG’s independence, 
and the laws do not adequately address many aspects of the contemporary illicit drug trade. 
In 1997, the PNG Government proposed the introduction of a new Controlled Substances 
Bill to increase penalties and criminalise drug trafficking more appropriately (PNG 
Parliamentarian … 1997; cf UNODC Regional Centre for East Asia and the Pacific 2003). 
Significant loopholes also remain in the drug laws of Kiribati. In addition to gaps in the 
criminalisation of ATS and ATS-related offences, many jurisdictions do not have adequate 
laws to authorise law enforcement officials to carry out sophisticated, high level 
investigations into drug trafficking cases (UNODC Regional Centre for East Asia 2003: 7).
In general, the principal reason for inadequate and out-of-date legislation in some countries 
appears to be the lack of accession and adherence to international drug conventions. Those 
countries that are state parties to the 1971 and 1988 conventions have more appropriate 
laws to prevent and suppress the illicit trade in ATS and their precursors. Those that have 
not signed the relevant treaties lag in their criminalisation and enforcement efforts and may 
be seen as easy staging posts for the operations of transnational drug trafficking rings. 
But while the countries with the weaker drug control laws may be seen as more vulnerable 
to organised crime, there is, to date, little evidence to support the view that these countries 
are actually and deliberately targeted by criminal organisations in the Pacific Islands. The 
case of the Fijian ATS laboratory, however, has shown that if and when large scale cases  
of ATS production or supply are detected, countries with outdated laws lack the ability to 
adequately investigate, prosecute, and sentence offenders. In the absence of international 
treaties, some countries also lack the ability to appropriately engage in bilateral and 
multilateral law enforcement and judicial cooperation, thus further hampering the 
effectiveness of the criminal justice system.
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Observations
The illicit trade in ATS in Oceania is not regulated evenly throughout the region. Many 
countries have not signed relevant international treaties and, accordingly, their domestic  
laws do not prevent and suppress the illicit production, trafficking, and use of ATS 
adequately, if at all. Major discrepancies exist in the ways different countries criminalise the 
illicit ATS trade and enforce their laws. On the one hand, Australia, Fiji, New Zealand, Niue, 
and the US and French territories in Oceania have very comprehensive and up-to-date 
legislation, criminalising every aspect of ATS production, trafficking, consumption, precursor 
trading, and the laundering of proceeds of ATS and other drug-related crime. On the other 
hand, the laws in Papua New Guinea, Solomon Islands, and Vanuatu are particularly out-of 
date and ill-suited to deal with large scale operations of transnational criminal enterprises. 
The Pacific Islands Forum recently addressed this issue by developing a range of model 
laws on transnational organised crime for adoption by Forum member countries. Among 
these model laws is an Illicit Drugs Control Bill 2002 which, it is understood, formed the 
basis for the reform of drug laws in Fiji in 2004 (PIF 2002; cf Spillane 2006). These model 
laws, however, are best practice guidelines and the Forum has no power to force countries 
to adopt them. 
At the international level, the 1971 Convention on Psychotropic Substances and the 1988 
Convention against Illicit Traffic in Narcotic Drugs on Psychotropic Substances provide  
a comprehensive set of rules to control the licit trade in ATS and suppress the illicit ATS 
industry. The regime established by the international conventions is not without flaws, but it 
is currently the best available and most universal weapon in the war on illicit drugs, including 
ATS. Thus, it is desirable that more countries in Oceania sign up to this body of law and 
bring their domestic laws into line with international obligations.
While greater acceptance of the international drug control regime in the region is desirable 
and necessary to fight the activities of transnational organised crime more effectively, it will 
not make the ATS problem completely go away. It should be noted that the countries with 
the most comprehensive drug laws in the region, notably Australia and New Zealand, also 
have the greatest incidence of ATS production, trafficking, and abuse. Greater suppression 
of the ATS trade and tighter law enforcement in the region may displace some of the 
industry and temporarily change some of the patterns of the illicit trade, but will not alter  
one of the key contributors to the problem: the seemingly insatiable demand for ATS in  
the industrialised parts of the region.
Chapter 6: 
Conclusions
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This study demonstrates that the economic incentives for involvement in the illicit market  
for ATS in Oceania are considerable at the production, trafficking, and retail levels. The 
manufacture, trafficking, and sale of ATS are financially extremely lucrative and tend to be 
more profitable than the markets for narcotic substances such as heroin or cocaine. Given 
the high profitability of the ATS trade in Australia, New Zealand, and the Pacific Islands, 
further expansion of the market can be expected. It is anticipated that more criminal 
entrepreneurs, whether small and isolated, or large and ongoing, will try to exploit this 
lucrative market, resulting in greater production and availability of ATS in the region.  
Some parts of the illicit ATS production and trade are already dominated by large criminal 
organisations. Organised crime is also moving into other aspects of the illicit ATS trade,  
such as precursor production, diversion, and trafficking, and is increasingly spreading  
the ATS industry into the smaller and more remote markets of the Pacific Islands.
ATS production, trafficking, and consumption
At the production level, the illicit manufacturing of ATS is particularly lucrative given the ease 
with which most ATS can be produced, the availability of many precursor substances, the 
flexibility with which ingredients and manufacturing processes can be changed, and the  
low level of skill and expertise required to produce the basic varieties of ATS. This study  
has shown that ATS production ranges from low scale, local laboratories, to large scale 
operations with international links. Organised crime features more prominently in the more 
sophisticated types of ATS production and there is growing evidence that the production  
of ATS such as ecstasy and crystal methylamphetamine, which are more difficult to 
manufacture, is slowly but steadily being shifted towards and into the region.
Contributing to the high levels of ATS production in the region are the availability and 
diversion of ATS precursors. While some countries have recently introduced measures to 
suppress the illegal precursor trade, it remains largely uncontrolled in many others. Further, 
some jurisdictions only control and prohibit some, but not all principal ATS precursors. 
Although ATS and precursor control have become tighter in many parts of the region, this 
has not been followed by any significant reduction in ATS availability and supply. Even in 
places where precursors are comprehensively regulated, ever changing patterns of ATS 
production with different ingredients pose a challenge to legislators and law enforcement 
agencies who are generally slow in catching up with new methods of ATS production  
and supply.
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Criminal organisations have responded to more comprehensive control by making the 
trafficking of ATS more sophisticated so that it becomes more difficult to intercept and 
eliminate with traditional enforcement techniques. There is general consensus that
[i]ncreased arrests, prosecutions, and penalties have had little deterrent value 
in the wake of the vast profits that derive from drug trafficking. While the 
prosecution of drug lords certainly captures headlines as victories in the war 
on drugs, these traffickers are quickly replaced by others in order to meet the 
seemingly insatiable demand for drugs (Bassiouni & Thony 1996: 947).
In reviewing the available evidence on the nature and the scale of the illicit ATS trade in 
Oceania, it becomes apparent that the existence and magnitude of the problem is, for the 
most part, caused by the extremely high demand for ATS, especially in Australia and New 
Zealand. The demand for ATS is further fuelled by their retail prices, which are relatively low 
in Australia and New Zealand compared with most other illicit drugs of similar pharmacology. 
This creates economic incentives for consumers to choose ATS over other illicit drugs. If, as 
anticipated, the supply of ATS continues to grow in the region, retail prices can be expected 
to decline further, thus attracting new users and causing existing users of other drugs to 
switch to cheaper ATS. Research has shown that the illicit ATS market has developed 
alongside existing illicit drug markets and has not completely substituted the demand for 
other narcotic and synthetic drugs. It has also been observed that poly-drug use is 
particularly common among ATS consumers, especially those using crystal 
methylamphetamine. Consequently any strategy to reduce the illicit ATS trade must go hand 
in hand with measures suppressing the illicit market for other drugs (Wilkins et al. 2005).
Essential to any strategy against ATS trafficking and organised crime is the emphasis on 
attacking the economic aspects and market factors of the ATS trade at production, supply, 
and, in particular, at the demand level (cf Gurulé 1998: 120). The ‘immense production of 
drugs is a direct result of the tremendous demand. Until demand is eliminated, ingenious 
traffickers will continue to find innovative methods to infiltrate borders’ (Bassiouni & Thony 
1996: 947). Demand reduction for ATS, however, does not feature prominently in existing 
international drug conventions, which are more concerned with regulating the licit trade in 
psychotropic substances and suppressing the illicit industry. Equally, the focus of domestic 
laws, especially in the main consumer countries, is on ATS production and supply, and not 
on consumption and abuse. Consequently, many scholars have called for the ‘development 
of guiding principles on demand reduction’ and for ‘commitment by all states to implement 
an approach which is balanced more adequately between suppression of illicit suppliers and 
reduction of demand for ATS’ (Bassiouni & Thony 1996: 947).
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Precursors
Recent initiatives to reduce the illicit production and supply of ATS focus specifically on the 
control of precursor chemicals and on the diversion of substances from the licit market for 
use in illicit ATS manufacturing. The control of precursor chemicals and equipment used in 
ATS production has arguably been ignored for a long time. This is in part because of the 
difficulties of separating the legal industry from the illicit trade. Since the introduction of the 
1988 Convention against Illicit Trafficking in Narcotic Drugs and Psychotropic Substances,  
a greater number of countries have regulated ATS precursors and have criminalised illicit 
precursor supply and sale, but many countries in the region have not yet addressed this 
issue comprehensively.
The increasing control and criminalisation of ATS precursors was followed consistently by 
alterations in illicit ATS production. Chemicals that were placed under control were simply 
substituted by new ingredients. Precursor control has not led to a significant decline in illicit 
ATS production, even in those countries where precursors are regulated comprehensively. 
Moreover, a new trade in pre-precursor chemicals has emerged and some manufacturers 
have been found attempting to produce their own precursors (Cherney, O’Reilly & Grabosky 
2005: 17–18; Wardlaw 1993: 97). In this context, Wardlaw remarked as early as 1993 that:
As with other supply reduction strategies, authorities should be careful not to 
expect precursor control schemes to do more than limit the uncontrolled 
expansion of chemical drug manufacture. It is important, too, to monitor the 
impact of such schemes to ensure that their negative consequences do not 
outweigh their positive attributes. For example, production of more dangerous 
drugs using alternative chemicals, the manufacturing of amphetamines 
containing dangerous impurities as a result of new chemical processes or 
combinations, and an increase in theft of precursors (some of which would 
almost certainly involve violence and corruption) could well produce an overall 
situation which is as bad or worse than that which now faces us (Wardlaw 
1993: 98).
Legislation and enforcement
Despite the fact that over 150 countries participate in the 1971 and 1988 conventions, 
international drug control efforts appear to be lagging behind the phenomena of increased 
ATS production, trafficking, and consumption. The international instruments and their 
enforcement have had little effect in stemming the flow of ATS in the face of increased 
demand and supply (Bassiouni & Thony 1996: 905). ‘[T]he strategy to extinguish the illicit 
drug problem, at least thus far, failed’ (Boister 2001: 69).
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According to Gardner:
[t]he prosperity of an international drug control policy will primarily depend on 
three factors: whether party states to an international convention have 
incentives to follow the treaty’s provision; whether adequate enforcement 
mechanisms exist to ensure that parties are meeting their treaty obligations; 
and whether the terms of the treaty do not impose an unfair burden on party 
states (Gardner 1993: 308).
One of the difficulties in regulating the illicit ATS trade is that domestic laws and international 
conventions dealing with ATS are trying to achieve two competing goals. One is to regulate 
and enable the licit supply of ATS by the pharmaceutical industry. The second goal is to 
suppress the illicit supply by criminal organisations. Boister remarked that:
These goals may be irreconcilable and it may be that the system has served 
more to keep drug companies in business than to put illicit traffickers out of 
business. Enactment of severe laws and tighter law enforcement has always 
tended to be followed by a surge in the illicit traffic and a rise in illicit drug 
prices (Boister 2001: 69).
Although domestic and international drug regulations may not always achieve their stated 
objectives, there is ample evidence and general consensus that without strict control of 
narcotic drugs and psychotropic substances under international and domestic laws, drug 
production, trafficking, and consumption would rise and pose a far greater menace than it 
does already (Boister 2001: 69). Consequently, the international drug regime is the best 
available and most universal tool to fight the illicit ATS trade and the criminal organisations 
engaged in that trade.
Many countries in Oceania have not yet signed the relevant international drug conventions 
because the obligations under international law pose significant challenges to small island 
nations. Many, if not most countries will need to amend their laws, including drug laws, penal 
codes, and procedural legislation. The criminal justice and law enforcement systems of 
some countries also require adjustment to put in place the provisions under the international 
instruments.
In addition to the legislative requirements to meet obligations under the conventions, many 
of the international measures require substantial financial, material, and human resources. 
This creates particular difficulties for smaller and economically less developed nations.  
Many countries in Oceania simply do not have the resources to commit themselves to  
the international drug control regime. The costs associated with the control, monitoring,  
and enforcement of international drug laws add ‘less and less to the benefits achieved  
and more and more to the cost to society. Ultimately, the costs outweigh the benefits’ 
(Gardner 1993: 308).
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International conventions and drug policies are frequently seen as unduly harsh on 
agricultural, producer, developing countries and unduly favourable to developed, consumer 
countries. The earlier analysis showed that international drug control focuses more heavily 
on production and trafficking and much less on the problem of consumption. However, the 
problem of ATS use is one shared by Australia, New Zealand, other parts of the Pacific 
region, and indeed most parts of the world. Consequently, adjustments to the international 
drug control regime are needed to address the issues of demand and consumption and 
their role in the illicit ATS trade more appropriately. Many studies confirm that policies 
directed at reducing the demand for illicit drugs are more cost-effective than those aimed  
at supply reduction. It is thus not surprising that some authors see ‘the development of an 
international convention that focuses on the social and psychological realities that underpin 
drug use’ as ‘the next appropriate step’ for international law to take (Boister 2001: 545).
To enable greater recognition of the international drug control regime, argues Lessem (1974: 
147), ‘the agreement must be acceptable to as many states as possible. If it is too restrictive 
or if it demands too much, then it will fail to attract the general support necessary for 
successful implementation.’ The danger inherent in this argument is, however, that the 
common denominator acceptable to a majority of states is of such a low standard that  
it fails to equip the international community with adequate tools to fight the activities of 
sophisticated criminal enterprises. Thus, international agreements must combine the desire 
to find universal acceptance with a clear determination to prevent and suppress the illicit 
ATS trade rigorously and vehemently.
The way ahead
Although the growth of the illicit ATS market in Oceania ‘seems to be only a question of 
time’ (Pietschmann 1997: 288), the speed and level of this expansion can, to some extent, 
be determined by the level of law enforcement and the effectiveness of legislative and  
policy mechanisms at domestic, regional, and international levels. This study shows  
that comprehensive legislative and enforcement strategies to prevent and suppress the 
production, trafficking, and sale of ATS do have a direct impact on this illicit trade. These 
strategies may never completely eradicate the illicit trade in ATS but, in combination with 
policies to address the demand aspect of ATS, can significantly reduce the profitability  
and thus the size of the illicit ATS market.
The single most important obstacle to more effective suppression of the illicit ATS trade  
is the reluctance by many, if not most countries, to openly engage in mutual cooperation. 
Bassiouni and Thony note that a ‘global problem requires global solutions in which 
international solidarity must supersede national interests. However, if this postulate is 
correct, then the expectations of success are dim because states are not likely to rise above 
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selfish national interests’ (Bassiouni & Thony 1996: 948). Gurulé remarks that ‘[e]mphasis  
on domestic investigations and prosecutions at the expense of international cooperative 
efforts is a prescription for failure and will ensure the continued growth and proliferation  
of international drug trafficking and organised crime’ (Gurulé 1998: 78).
The international drug control regime has frequently been criticised as ineffective  
because success is not always immediate. As a result, some countries have bypassed  
the international system and declared their own ‘war on drugs’. Immediate success, total 
suppression of the ATS trade, and total eradication of crops are, however, unrealistic goals. 
‘Accordingly’, argues Gardner ‘drug policy goals must reflect realistic expectations’ (Gardner 
1993: 292).
In the short and medium term, it is desirable that the international conventions addressing 
the trafficking in narcotic drugs and psychotropic substances including ATS obtain more 
recognition, further support, and greater enforceability. It is crucial that more countries in 
Oceania ratify the existing conventions and amend their domestic laws accordingly, thus 
ensuring greater uniformity among law and law enforcement in the region.
In the long term, the international community should work together to address the 
shortcomings of the existing drug control regime and alleviate the burden of developing 
countries in acceding to and enforcing this body of law. Escape and safeguard clauses in 
the existing system need to be removed and the role of supervisory bodies, international  
and regional forums in this field need to be strengthened to make their work more effective 
and, as far as possible, enforceable. The harmonisation of criminal law and criminal justice 
systems should go hand in hand with closer judicial and law enforcement cooperation as 
well as with greater recognition of the root causes of drug abuse.
As Gardner noted (1993: 317)
[a]s the world is realising, overnight success is neither a guarantee nor a 
reality. Consistency, persistence, and optimism towards the testing of new 
drug control approaches are the only arsenal against slick international drug 
networks that are often too slippery to catch.
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Oceania is believed to account for around 10 percent of the global ATS market,  
a disproportionately large share in relation to the population of the area. This illicit 
trade is of concern to contemporary criminal justice and poses a challenge to law 
enforcement agencies, governments and communities. This report explores patterns 
of ATS production, trafficking and demand in the region, analyses the involvement  
of organised crime, and reviews international and domestic legislative frameworks  
to control and penalise these activities.
